<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006458.pub4" GROUP_ID="ARI" ID="771206050301155538" MERGED_FROM="" MODIFIED="2017-12-05 22:45:39 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A129" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0"><COVER_SHEET MODIFIED="2017-12-05 22:45:35 +0000" MODIFIED_BY="Liz Dooley"><TITLE MODIFIED="2013-04-23 00:02:27 -0300" MODIFIED_BY="[Empty name]">Nebulised hypertonic saline solution for acute bronchiolitis in infants</TITLE><CONTACT MODIFIED="2017-12-05 22:45:35 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="BCFE36B982E26AA2007834EBE1DEA3AC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linjie</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>lzhang@furg.br</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 53 32258394</PHONE_1><FAX_1>+55 53 32258394</FAX_1></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2017-12-05 22:45:35 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="BCFE36B982E26AA2007834EBE1DEA3AC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linjie</FIRST_NAME><LAST_NAME>Zhang</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>lzhang@furg.br</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 53 32258394</PHONE_1><FAX_1>+55 53 32258394</FAX_1></ADDRESS></PERSON><PERSON ID="61CD83C582E26AA200383EFA99689668" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Raúl</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Mendoza-Sassi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>rmend@vetorial.net</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>Federal University of Rio Grande</ORGANISATION><ADDRESS_1>Rua Visconde Paranaguá 102</ADDRESS_1><ADDRESS_2>Centro</ADDRESS_2><CITY>Rio Grande</CITY><ZIP>96201-900</ZIP><REGION>RS</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 5332311869</PHONE_1><FAX_1>+55 5332311869</FAX_1></ADDRESS></PERSON><PERSON ID="34AEF69782E26AA200C1C7C4BCC46F8E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Claire</FIRST_NAME><LAST_NAME>Wainwright</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>claire_wainwright@health.qld.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory Medicine</DEPARTMENT><ORGANISATION>Royal Children's Hospital</ORGANISATION><ADDRESS_1>Herston Road</ADDRESS_1><ADDRESS_2>Herston</ADDRESS_2><CITY>Brisbane</CITY><ZIP>4029</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 36361932</PHONE_1><FAX_1>+61 7 36361958</FAX_1></ADDRESS></PERSON><PERSON ID="5344" ROLE="AUTHOR"><FIRST_NAME>Terry</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Klassen</LAST_NAME><SUFFIX>MD, MSc, FRCPC</SUFFIX><POSITION>Director</POSITION><EMAIL_1>tklassen@mich.ca</EMAIL_1><URL>http://www.mich.ca</URL><MOBILE_PHONE>+1 780 970 3615</MOBILE_PHONE><ADDRESS><ORGANISATION>Manitoba Institute of Child Health</ORGANISATION><ADDRESS_1>513-715 McDermot Avenue</ADDRESS_1><CITY>Winnipeg</CITY><ZIP>R3E 3P4</ZIP><REGION>MB</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 204 789 3754</PHONE_1></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2017-09-15 09:23:23 -0300" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="11" MONTH="8" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="11" MONTH="8" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="11" MONTH="8" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/><REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/><LAST_CITATION_ISSUE ISSUE="12" YEAR="2017"/></DATES><WHATS_NEW MODIFIED="2017-12-05 19:44:39 -0200" MODIFIED_BY="Liz Dooley"><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-12-05 19:44:39 -0200" MODIFIED_BY="Liz Dooley"><DATE DAY="11" MONTH="8" YEAR="2017"/><DESCRIPTION><P>We conducted updated searching and new analyses. We created and examined a funnel plot to explore possible small-study effects and publication bias. We revised the review text. We included 17 new trials in this updated review (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). We excluded nine new trials (<LINK REF="STD-Al_x002d_bahadily-2017" TYPE="STUDY">Al-bahadily 2017</LINK>; <LINK REF="STD-Bagus-2012" TYPE="STUDY">Bagus 2012</LINK>; <LINK REF="STD-Bueno-Campa_x00f1_a-2014" TYPE="STUDY">Bueno Campaña 2014</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2015" TYPE="STUDY">Flores-González 2015</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2016" TYPE="STUDY">Flores-González 2016</LINK>; <LINK REF="STD-Gupta-2016" TYPE="STUDY">Gupta 2016</LINK>; <LINK REF="STD-Malik-2015" TYPE="STUDY">Malik 2015</LINK>; <LINK REF="STD-Nenna-2014" TYPE="STUDY">Nenna 2014</LINK>; <LINK REF="STD-Silver-2015" TYPE="STUDY">Silver 2015</LINK>). Nine studies await classification (<LINK REF="STD-CTRI_x002f_2010_x002f_091_x002f_003065" TYPE="STUDY">CTRI/2010/091/003065</LINK>; <LINK REF="STD-EudraCT2009_x002d_014758_x002d_14" TYPE="STUDY">EudraCT2009-014758-14</LINK>; <LINK REF="STD-NCT00677729" TYPE="STUDY">NCT00677729</LINK>; <LINK REF="STD-NCT01777347" TYPE="STUDY">NCT01777347</LINK>; <LINK REF="STD-NCT01834820" TYPE="STUDY">NCT01834820</LINK>; <LINK REF="STD-NCT02029040" TYPE="STUDY">NCT02029040</LINK>; <LINK REF="STD-NCT02045238" TYPE="STUDY">NCT02045238</LINK>; <LINK REF="STD-NCT02233985" TYPE="STUDY">NCT02233985</LINK>; <LINK REF="STD-NCT02834819" TYPE="STUDY">NCT02834819</LINK>). We conducted additional post hoc subgroup, sensitivity, and meta-regression analyses.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-11-21 04:19:33 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="11" MONTH="8" YEAR="2017"/><DESCRIPTION><P>Nebulised hypertonic saline may modestly reduce the length of hospital stay among infants hospitalised with acute bronchiolitis and improve clinical severity score. Nebulised hypertonic saline may also reduce the risk of hospitalisation among outpatients and emergency department patients.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2017-12-05 03:47:19 -0200" MODIFIED_BY="Liz Dooley"><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-18 04:10:23 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="8" MONTH="5" YEAR="2013"/><DESCRIPTION><P>Searches conducted. We included four new trials and performed new analyses (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>). Our conclusions remain unchanged.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-18 04:10:35 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="7" MONTH="6" YEAR="2010"/><DESCRIPTION><P>Searches conducted. We included three new trials and conducted new analyses (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>). The conclusions remain unchanged.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-18 04:11:18 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="10" MONTH="5" YEAR="2010"/><DESCRIPTION><P>Searches conducted. We included three new trials and performed new analyses (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>). Our conclusions remain unchanged.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-18 04:11:30 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="13" MONTH="5" YEAR="2009"/><DESCRIPTION><P>No changes; republished to fix technical problem.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-11-18 04:11:37 -0200" MODIFIED_BY="[Empty name]"><DATE DAY="18" MONTH="2" YEAR="2008"/><DESCRIPTION><P>Converted to new review format.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-13 11:07:23 -0300" MODIFIED_BY="Paolo Rosati"><DATE DAY="13" MONTH="11" YEAR="2007"/><DESCRIPTION><P>Searches conducted.</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2017-11-21 03:19:01 -0200" MODIFIED_BY="[Empty name]"><INTERNAL_SOURCES MODIFIED="2013-03-31 21:26:06 -0300" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2013-03-31 21:26:06 -0300" MODIFIED_BY="[Empty name]"><NAME>Faculty of Medicine, Universidade Federal do Rio Grande</NAME><COUNTRY CODE="BR">Brazil</COUNTRY><DESCRIPTION/></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES MODIFIED="2017-11-21 03:19:01 -0200" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2017-11-21 03:19:01 -0200" MODIFIED_BY="[Empty name]"><NAME>National Council for Scientific and Technological Development (CNPq)</NAME><COUNTRY CODE="BR">Brazil</COUNTRY><DESCRIPTION><P>Fellowship of research productivity (PQ) </P></DESCRIPTION></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2017-12-05 19:45:18 -0200" MODIFIED_BY="Liz Dooley"><SUMMARY MODIFIED="2017-12-01 11:13:49 -0200" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2017-05-11 02:32:42 -0300" MODIFIED_BY="[Empty name]">Is hypertonic saline solution via nebuliser effective and safe for infants with acute bronchiolitis?</TITLE><SUMMARY_BODY MODIFIED="2017-12-01 11:13:49 -0200" MODIFIED_BY="[Empty name]"><P><B>Review question</B></P><P>Is hypertonic saline solution via nebuliser effective and safe for the treatment of infants with acute bronchiolitis, compared to normal saline solution?</P><P><B>Background</B></P><P>Acute bronchiolitis is the most common lower respiratory tract infection in children aged up to two years. Bronchiolitis occurs when small structures (bronchioles) leading to the lungs become infected, causing inflammation, swelling, and mucus production. This makes breathing difficult, especially in very young children, who develop coughs and wheezing.</P><P>Because bronchiolitis is usually caused by a virus, drug treatment is usually not effective. Hypertonic saline (sterile salt water solution) breathed in as a fine mist using a nebuliser may help relieve wheezing and breathing difficulty.</P><P>We compared nebulised hypertonic (&#8805; 3%) saline solution with nebulised normal (0.9%) saline for infants with acute bronchiolitis.</P><P>This is an update of a review previously published in 2008, 2010, and 2013.</P><P><B>Search date</B></P><P>11 August 2017</P><P><B>Study characteristics</B></P><P>We identified 26 new studies in this update, of which 9 await assessment and 17 trials (N = 3105) were added. We included a total of 28 trials involving 4195 infants with acute bronchiolitis.</P><P><B>Key results</B></P><P>Nebulised hypertonic saline may reduce hospital stay by 10 hours in comparison to normal saline for infants admitted with acute bronchiolitis. We found that 'clinical severity scores', which are used by doctors to assess patient health, for children treated as outpatients or in hospital improved when administered nebulised hypertonic saline compared to normal saline. Nebulised hypertonic saline may also reduce the risk of hospitalisation by 14% among children treated as outpatients or in the emergency department. We found only minor and spontaneously resolved adverse effects from the use of nebulised hypertonic saline when given with treatment to relax airways (bronchodilators).</P><P>Reductions in hospital stay were smaller than previously thought. However, an average reduction of 10 hours in the length of hospital stay for infants is significant because bronchiolitis usually has a short duration. Nebulised hypertonic saline appears to be safe and widely available at low cost.</P><P><B>Quality of evidence</B></P><P>The quality of the evidence was low to moderate: there were inconsistencies in results among trials and risk of bias in some trials. Future large trials are therefore needed to confirm the benefits of nebulised hypertonic saline for children with bronchiolitis treated as outpatients and in hospital.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-12-05 19:35:57 -0200" MODIFIED_BY="Liz Dooley"><ABS_BACKGROUND MODIFIED="2017-09-03 22:15:09 -0300" MODIFIED_BY="[Empty name]"><P>Airway oedema (swelling) and mucus plugging are the principal pathological features in infants with acute viral bronchiolitis. Nebulised hypertonic saline solution (&#8805; 3%) may reduce these pathological changes and decrease airway obstruction. This is an update of a review first published in 2008, and previously updated in 2010 and 2013.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2017-09-29 13:19:15 -0300" MODIFIED_BY="[Empty name]"><P>To assess the effects of nebulised hypertonic (&#8805; 3%) saline solution in infants with acute bronchiolitis.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-11-18 04:13:35 -0200" MODIFIED_BY="[Empty name]"><P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE Daily, Embase, CINAHL, LILACS, and Web of Science on 11 August 2017. We also searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 8 April 2017.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2017-12-01 09:22:38 -0200" MODIFIED_BY="[Empty name]"><P>We included randomised controlled trials and quasi-randomised controlled trials using nebulised hypertonic saline alone or in conjunction with bronchodilators as an active intervention and nebulised 0.9% saline, or standard treatment as a comparator in children under 24 months with acute bronchiolitis. The primary outcome for inpatient trials was length of hospital stay, and the primary outcome for outpatients or emergency department trials was rate of hospitalisation.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2017-11-18 04:16:20 -0200" MODIFIED_BY="[Empty name]"><P>Two review authors independently performed study selection, data extraction, and assessment of risk of bias in included studies. We conducted random-effects model meta-analyses using Review Manager 5. We used mean difference (MD), risk ratio (RR), and their 95% confidence intervals (CI) as effect size metrics.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2017-12-05 19:35:57 -0200" MODIFIED_BY="Liz Dooley"><P>We identified 26 new trials in this update, of which 9 await classification due to insufficient data for eligibility assessment, and 17 trials (N = 3105) met the inclusion criteria. We included a total of 28 trials involving 4195 infants with acute bronchiolitis, of whom 2222 infants received hypertonic saline.</P><P>Hospitalised infants treated with nebulised hypertonic saline had a statistically significant shorter mean length of hospital stay compared to those treated with nebulised 0.9% saline (MD -0.41 days, 95% CI -0.75 to -0.07; P = 0.02, I² = 79%; 17 trials; 1867 infants) (GRADE quality of evidence: low). Infants who received hypertonic saline also had statistically significant lower post-inhalation clinical scores than infants who received 0.9% saline in the first three days of treatment (day 1: MD -0.77, 95% CI -1.18 to -0.36, P &lt; 0.001; day 2: MD -1.28, 95% CI -1.91 to -0.65, P &lt; 0.001; day 3: MD -1.43, 95% CI -1.82 to -1.04, P &lt; 0.001) (GRADE quality of evidence: low).</P><P>Nebulised hypertonic saline reduced the risk of hospitalisation by 14% compared with nebulised 0.9% saline among infants who were outpatients and those treated in the emergency department (RR 0.86, 95% CI 0.76 to 0.98; P = 0.02, I² = 7%; 8 trials; 1723 infants) (GRADE quality of evidence: moderate).</P><P>Twenty-four trials presented safety data: 13 trials (1363 infants, 703 treated with hypertonic saline) did not report any adverse events, and 11 trials (2360 infants, 1265 treated with hypertonic saline) reported at least one adverse event, most of which were mild and resolved spontaneously.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2017-11-18 04:25:46 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised hypertonic saline may modestly reduce length of stay among infants hospitalised with acute bronchiolitis and improve clinical severity score. Treatment with nebulised hypertonic saline may also reduce the risk of hospitalisation among outpatients and emergency department patients. However, we assessed the quality of the evidence as low to moderate.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2017-12-05 19:45:18 -0200" MODIFIED_BY="Liz Dooley"><BACKGROUND MODIFIED="2017-12-05 03:50:44 -0200" MODIFIED_BY="Liz Dooley"><CONDITION MODIFIED="2017-12-05 03:50:44 -0200" MODIFIED_BY="Liz Dooley"><P>Acute bronchiolitis is the most frequent lower respiratory tract infection in infants (<LINK REF="REF-Klassen-1997a" TYPE="REFERENCE">Klassen 1997a</LINK>), and the most common causative organism is respiratory syncytial virus (RSV). Other less common pathogens include parainfluenza viruses, adenovirus, influenza A and B, rhinovirus, human metapneumovirus and <I>Mycoplasma pneumoniae</I> (<LINK REF="REF-Garc_x00ed_a_x002d_Garc_x00ed_a-2006" TYPE="REFERENCE">García-García 2006</LINK>; <LINK REF="REF-Henderson-1979" TYPE="REFERENCE">Henderson 1979</LINK>; <LINK REF="REF-Jacques-2006" TYPE="REFERENCE">Jacques 2006</LINK>; <LINK REF="REF-Rose-1987" TYPE="REFERENCE">Rose 1987</LINK>; <LINK REF="REF-Shay-2001" TYPE="REFERENCE">Shay 2001</LINK>). Virtually all infants are infected by RSV by the age of two years, around 40% to 50% develop involvement of the lower respiratory tract, and 1% to 2% develop severe disease leading to hospitalisation (<LINK REF="REF-Meissner-2003" TYPE="REFERENCE">Meissner 2003</LINK>; <LINK REF="REF-Rakshi-1994" TYPE="REFERENCE">Rakshi 1994</LINK>; <LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>). It is estimated that globally in 2015, 1.4 million (uncertainty range (UR) 1.2 to 1.7) hospital admissions, and 27,300 (UR 20700 to 36200) in-hospital deaths were due to RSV-acute lower respiratory infection in infants younger than six months of age (<LINK REF="REF-Shi-2017" TYPE="REFERENCE">Shi 2017</LINK>).</P><P>The principal pathological findings in acute bronchiolitis include a peribronchial infiltrate of inflammatory cells, mucosal and submucosal oedema, necrosis and desquamation of ciliated epithelial cells, proliferation of cuboidal cells, and excess mucus secretion (<LINK REF="REF-Panitch-1993" TYPE="REFERENCE">Panitch 1993</LINK>; <LINK REF="REF-Wohl-1978" TYPE="REFERENCE">Wohl 1978</LINK>). The combination of airway wall swelling, sloughing of necrotic debris, increased mucus production, and impaired secretion clearance eventually leads to airway obstruction, gas trapping, atelectasis, and impaired gas exchange.</P><P>The diagnosis of acute bronchiolitis is usually based on clinical grounds. Despite differences in defining bronchiolitis, it is generally accepted that acute bronchiolitis refers to the first episode of acute wheezing in children aged less than two years, starting as a viral upper respiratory infection (coryza, cough, or fever) (<LINK REF="REF-Panitch-1993" TYPE="REFERENCE">Panitch 1993</LINK>). These criteria for diagnosis of acute bronchiolitis have also been widely used in clinical trials (<LINK REF="REF-Bertrand-2001" TYPE="REFERENCE">Bertrand 2001</LINK>; <LINK REF="REF-Klassen-1997b" TYPE="REFERENCE">Klassen 1997b</LINK>; <LINK REF="REF-Schuh-1992" TYPE="REFERENCE">Schuh 1992</LINK>; <LINK REF="REF-Wainwright-2003" TYPE="REFERENCE">Wainwright 2003</LINK>; <LINK REF="REF-Zhang-2003" TYPE="REFERENCE">Zhang 2003</LINK>). Direct fluorescent antibody tests, enzyme immuno-assay techniques, and cultures of the nasopharyngeal aspirate may be used to identify the causative pathogen.</P></CONDITION><INTERVENTION MODIFIED="2017-11-18 04:57:07 -0200" MODIFIED_BY="[Empty name]"><P>The standard treatment for acute bronchiolitis remains supportive care and includes ensuring adequate oxygen exchange, fluid intake, and feeding of the infant (<LINK REF="REF-Panitch-2003" TYPE="REFERENCE">Panitch 2003</LINK>; <LINK REF="REF-Wohl-2003" TYPE="REFERENCE">Wohl 2003</LINK>). Convincing evidence for any other therapy is lacking. Because airway oedema and mucus plugging are the predominant pathological features in acute bronchiolitis, any therapy that can reduce these changes and improve the clearance of airway secretions may be beneficial.</P><P>Epinephrine has a theoretical effect on acute bronchiolitis because it contains alpha adrenergic properties which lead to vasoconstriction and reduction of airway oedema (<LINK REF="REF-Wohl-1978" TYPE="REFERENCE">Wohl 1978</LINK>). However, a Cochrane Review showed that nebulised epinephrine for acute bronchiolitis results in a modest short-term improvement in outpatients, but not among inpatients (<LINK REF="REF-Hartling-2011" TYPE="REFERENCE">Hartling 2011</LINK>). Inhaled recombinant deoxyribonuclease (rhDNase), a mucolytic agent, has also been tested in hospitalised infants with acute bronchiolitis (<LINK REF="REF-Nasr-2001" TYPE="REFERENCE">Nasr 2001</LINK>). This drug is thought to exert its major effect by enhancing airway secretion clearance. However, no significant effect was observed on clinical severity scores or length of hospital stay (<LINK REF="REF-Enriquez-2012" TYPE="REFERENCE">Enriquez 2012</LINK>). Another widely used approach is chest physiotherapy, which is thought to assist infants by enhancing the clearance of secretions and reducing ventilatory effort. However, current evidence has shown that chest physiotherapy (vibration and percussion or passive expiratory techniques) does not reduce the length of hospital stay or oxygen requirements or improve the severity of the disease respiratory parameters in hospitalised infants with acute bronchiolitis (<LINK REF="REF-Roqu_x00e9_-i-Figuls-2016" TYPE="REFERENCE">Roqué i Figuls 2016</LINK>).</P><P>Hypertonic saline has been used as a treatment for infants with acute bronchiolitis. Most randomised trials demonstrate that nebulised 3% saline may significantly reduce the length of hospital stay and improve the clinical severity score in infants with acute viral bronchiolitis (<LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>).</P></INTERVENTION><THEORY MODIFIED="2017-11-18 04:59:23 -0200" MODIFIED_BY="[Empty name]"><P>Hypertonic saline solution has been shown to increase mucociliary clearance in disease-free people and people with asthma, bronchiectasis, cystic fibrosis, and sinonasal diseases (<LINK REF="REF-Daviskas-1996" TYPE="REFERENCE">Daviskas 1996</LINK>; <LINK REF="REF-Kellett-2005" TYPE="REFERENCE">Kellett 2005</LINK>; <LINK REF="REF-Shoseyov-1998" TYPE="REFERENCE">Shoseyov 1998</LINK>; <LINK REF="REF-Wark-2009" TYPE="REFERENCE">Wark 2009</LINK>). Such benefits would also be expected in infants with acute bronchiolitis (<LINK REF="REF-Mandelberg-2010" TYPE="REFERENCE">Mandelberg 2010</LINK>). The postulated mechanisms of benefit of hypertonic saline are:</P><UL><LI>induces an osmotic flow of water into the mucus layer, rehydrating the airway surface liquid and improving mucus clearance (<LINK REF="REF-Mandelberg-2010" TYPE="REFERENCE">Mandelberg 2010</LINK>; <LINK REF="REF-Robinson-1997" TYPE="REFERENCE">Robinson 1997</LINK>);</LI><LI>breaks the ionic bonds within the mucus gel, thereby reducing the degree of cross-linking and entanglements and lowering the viscosity and elasticity of the mucus secretion (<LINK REF="REF-Ziment-1978" TYPE="REFERENCE">Ziment 1978</LINK>);</LI><LI>stimulates cilial beat via the release of prostaglandin E2 (<LINK REF="REF-Assouline-1977" TYPE="REFERENCE">Assouline 1977</LINK>).</LI></UL><P>Moreover, by absorbing water from the mucosa and submucosa, hypertonic saline solution can theoretically reduce oedema of the airway wall in infants with acute bronchiolitis (<LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="REF-Mandelberg-2010" TYPE="REFERENCE">Mandelberg 2010</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>). Hypertonic saline inhalation can also cause sputum induction and cough, which can help to clear the sputum outside of the bronchi and thus improve airway obstruction (<LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>).</P><P>These theoretical benefits provide the rationale for the treatment of acute bronchiolitis with nebulised hypertonic saline solution.</P></THEORY><IMPORTANCE MODIFIED="2017-11-18 05:02:39 -0200" MODIFIED_BY="[Empty name]"><P>The hypothesis of this review is that nebulised hypertonic saline solution is beneficial in the management of acute bronchiolitis as assessed by clinically relevant outcomes, both in inpatients and outpatients. The establishment of a therapeutic role for hypertonic saline solution in acute bronchiolitis has relevant clinical implications. This modality may provide a cheap and effective therapy for children with acute bronchiolitis.<BR/></P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2017-09-29 13:23:03 -0300" MODIFIED_BY="[Empty name]"><P>To assess the effects of nebulised hypertonic (&#8805; 3%) saline solution in infants with acute bronchiolitis.</P></OBJECTIVES><METHODS MODIFIED="2017-12-01 13:58:22 -0200" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2017-11-28 22:47:27 -0200" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2017-11-18 05:04:49 -0200" MODIFIED_BY="[Empty name]"><P>We included randomised controlled trials and quasi-randomised controlled trials (in which there is alternate allocation to treatment and control groups) in this review. We excluded studies including participants who had recurrent wheezing or who were intubated and ventilated, and studies that assessed pulmonary function alone.</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2017-11-18 05:05:41 -0200" MODIFIED_BY="[Empty name]"><P>Children up to 24 months of age diagnosed with acute bronchiolitis. Acute bronchiolitis was defined as the first episode of acute wheezing associated with clinical evidence of a viral infection (cough, coryza, or fever). Confirmation of viral aetiology was not necessary for study inclusion. We included studies of inpatients, emergency department patients, or outpatients.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2017-11-28 22:47:27 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Nebulised hypertonic saline alone versus nebulised 0.9% saline.</LI><LI>Nebulised hypertonic saline plus bronchodilator versus nebulised 0.9% saline.</LI><LI>Nebulised hypertonic saline plus bronchodilator versus nebulised 0.9% saline plus same bronchodilator.</LI><LI>Nebulised hypertonic saline alone or plus bronchodilator versus standard treatment.</LI></UL><P>Given that we identified few studies initially in 2007, we subsequently added comparisons of nebulised hypertonic saline alone versus nebulised 0.9% saline or no intervention (<LINK REF="REF-Zhang-2008" TYPE="REFERENCE">Zhang 2008</LINK>). Hypertonic saline was defined as a concentration of saline greater than or equal to 3%.</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2017-11-18 19:03:26 -0200" MODIFIED_BY="[Empty name]"><CRIT_OUTCOMES_PRIMARY MODIFIED="2017-03-30 02:50:23 -0300" MODIFIED_BY="[Empty name]"><OL><LI>Length of hospital stay or time taken to be ready for discharge (inpatients).</LI><LI>Rate of hospitalisation (outpatients or emergency department patients).</LI></OL></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2017-11-18 19:03:26 -0200" MODIFIED_BY="[Empty name]"><OL><LI>Clinical severity score.</LI><LI>Rate of re-admission to hospital.</LI><LI>Haemoglobin saturation (oximetry).</LI><LI>Respiratory rate.</LI><LI>Heart rate.</LI><LI>Time to resolution of symptoms or signs.</LI><LI>Duration of in-hospital oxygen supplementation.</LI><LI>Need for add-on treatment (bronchodilator, systemic corticosteroids, antibiotics, and oxygen supplementation).</LI><LI>Results of pulmonary function tests.</LI><LI>Radiological findings.</LI><LI>Adverse events (tachycardia, hypertension, pallor, tremor, nausea, vomiting, diarrhoea, and acute urinary retention).</LI></OL></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-11-18 18:36:15 -0200" MODIFIED_BY="[Empty name]"><ELECTRONIC_SEARCHES MODIFIED="2017-11-18 18:34:35 -0200" MODIFIED_BY="[Empty name]"><P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 4), part of <A HREF="http://www.thecochranelibrary.com">the Cochrane Library</A> (searched 11 August 2017), which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE Ovid, MEDLINE Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE Daily (April 2013 to 11 August 2017), Embase.com (April 2013 to 11 August 2017), CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EBSCO; May 2013 to 11 August 2017), LILACS (Latin American and Caribbean Health Science Information Database) (May 2013 to 11 August 2017), and Web of Science (May 2013 to 11 August 2017) for this update. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> provides details of searches conducted for previous versions of this review.</P><P>We used the search strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> to search MEDLINE and CENTRAL. Because there were so few search results, we used no filter to identify randomised trials in MEDLINE. We adapted the terms to search Embase (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), CINAHL (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), and Web of Science (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-11-18 18:36:15 -0200" MODIFIED_BY="[Empty name]"><P>We searched the World Health Organization International Clinical Trials Registery Platform (WHO ICTRP) and US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov to identify ongoing trials on 8 April 2017. We checked reference lists of all primary studies and review articles for additional relevant trials.<BR/></P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2017-12-01 13:58:22 -0200" MODIFIED_BY="[Empty name]"><P>We conducted the review update according to the published protocol and reported any deviations from it in the <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK> section.</P><STUDY_SELECTION MODIFIED="2017-11-18 18:41:05 -0200" MODIFIED_BY="[Empty name]"><P>Two review authors (LZ, RAM) independently screened titles and abstracts of all studies identified as a result of the search for potential inclusion in the review. We retrieved the full-text study reports of all potentially eligible studies, and two review authors (LZ, RAM) independently screened the full-text reports to identify studies for inclusion and identify and record reasons for exclusion of ineligible studies. Any disagreements were resolved through discussion or, if required, by consulting a third review author (CW). We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in a PRISMA flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. There were no language or publication restrictions.</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2017-11-18 18:42:56 -0200" MODIFIED_BY="[Empty name]"><P>One review author (LZ) extracted study details from the included trials using a standardised data extraction form. Another review author (RAM) checked the data extraction. We resolved any disagreements by discussion. We entered the extracted the following data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P><OL><LI>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study.</LI><LI>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria.</LI><LI>Interventions: intervention, comparison, concomitant medications, and excluded medications.</LI><LI>Outcomes: primary and secondary outcomes specified and collected, and time points reported.</LI><LI>Notes: funding for trial, and notable conflicts of interest of trial authors.</LI></OL><P>We used <A HREF="http://digitizer.sourceforge.net">Engauge</A> digitising software to extract the first and third quartile values of length of hospital stay from a figure in <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>. For this trial, we estimated mean and standard deviation from median and interquartile range of length of hospital stay using methods described by <LINK REF="REF-Wan-2014" TYPE="REFERENCE">Wan 2014</LINK>.</P></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2017-11-18 18:48:04 -0200" MODIFIED_BY="[Empty name]"><P>Two review authors (LZ, RAM) independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreements were resolved by discussion or by involving a third review author (CW). We assessed risk of bias according to the following domains.</P><OL><LI>Random sequence generation.</LI><LI>Allocation concealment.</LI><LI>Blinding of participants and personnel.</LI><LI>Blinding of outcome assessment.</LI><LI>Incomplete outcome data.</LI><LI>Selective outcome reporting.</LI><LI>Other bias.</LI></OL><P>We graded each potential source of bias as high, low, or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary. Where information on risk of bias related to unpublished data or correspondence with a trialist, this was noted in the 'Risk of bias' table.</P><P>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2017-11-18 18:49:26 -0200" MODIFIED_BY="[Empty name]"><P>We entered outcome data for each study into data tables in Review Manager 5 to calculate the treatment effects (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used risk ratio for dichotomous outcomes, and mean differences or standardised mean differences for continuous outcomes.</P><P>We conducted meta-analyses only where this was meaningful, that is if treatments, participants, and the underlying clinical question were sufficiently similar for pooling to make sense.</P></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2017-11-28 22:43:44 -0200" MODIFIED_BY="[Empty name]"><P>The participants in each intervention arm were the unit of analysis in a single parallel group design. When trials recruited multiple groups, we combined data to create hypertonic saline and normal saline groups. We used the Review Manager 5 calculator to combine groups (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We combined data for the 5% and 3% saline groups into the hypertonic saline group for <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK> and 7% and 3% saline groups into the hypertonic saline group for <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>. We combined four groups reported by <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK> (3% saline mixed with epinephrine, 3% saline mixed with salbutamol, 0.9% saline mixed with epinephrine, and 0.9% saline mixed with salbutamol) and <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK> (3% saline plus salbutamol, 3% saline alone, 0.9% saline plus salbutamol, and 0.9% saline alone) into the hypertonic and normal saline groups.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2017-11-18 18:55:52 -0200" MODIFIED_BY="[Empty name]"><P>We planned to contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified as an abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing sensitivity analyses.</P><P>If numerical outcome data such as standard deviations or correlation coefficients were missing and could not be obtained from the authors, we planned to calculate these from other available statistics such as P values according to the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P><P>We contacted the authors of seven studies for additional trial data (<LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>), of whom five responded and provided data (<LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>).</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-18 18:57:44 -0200" MODIFIED_BY="[Empty name]"><P>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity, we reported this and explored possible causes in subgroup analysis. We used I² values of 25%, 50%, and 75% corresponding to low, moderate, and high heterogeneity, respectively (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-11-18 18:58:55 -0200" MODIFIED_BY="[Empty name]"><P>If we were able to pool more than 10 trials, we planned to create and examine a funnel plot to explore possible small-study effects and publication bias. We created the funnel plot using <A HREF="http://StataCorp 2009">Stata</A> version 11.0.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2017-11-21 02:48:56 -0200" MODIFIED_BY="[Empty name]"><P>We pooled data from studies we judged to be clinically homogeneous using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). If more than one study provided usable data in any single comparison, we performed meta-analysis using the random-effects model. Whenever possible, we used intention-to-treat analysis data.</P><SUBSECTION><HEADING LEVEL="3">GRADE and 'Summary of findings' table</HEADING><P>We created a 'Summary of findings' table using the following outcomes: length of hospital stay; clinical severity score post-treatment at days 1, 2, and 3; rate of hospitalisation; rate of re-admission; and adverse events<I>. </I>We used the five factors of the GRADE approach (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence relating to the studies that contributed data to meta-analyses for outcomes (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), employing GRADEpro GDT software (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>). We justified all decisions to down- or upgrade the quality of studies using footnotes, and made comments to aid readers' understanding of the review where necessary.</P></SUBSECTION></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2017-12-01 13:58:22 -0200" MODIFIED_BY="[Empty name]"><P>We performed pre-planned subgroup analysis on clinical scores according to patient status (outpatient, emergency department patient, and inpatient). For length of hospital stay, we conducted post hoc subgroup analyses according to availability of virological investigation (available versus not available), upper age limits for participants (12 months versus 18 to 24 months), hypertonic saline concentration (3% versus &gt; 3%), administration interval (every 4 to 6 hours versus every 8 hours), co-administration with bronchodilators (&#946;&#8322; agonist, epinephrine versus no), length of hospital stay in the control group (&lt; 3 days versus &#8805; 3 days), year of publication (before 2013 versus 2013 and thereafter), and risk of selection bias in the trials (low versus unclear/high). For hospitalisation rate, we conducted the same subgroup analyses, except for length of stay in the control group.</P><P>We performed post hoc random-effects meta-regression using restricted maximum likelihood (REML) estimation to investigate the potential modifiers of effects of hypertonic saline on length of hospital stay and clinical severity score. We conducted meta-regression using Stata version 11.0 (<LINK REF="REF-StataCorp-2009" TYPE="REFERENCE">StataCorp 2009</LINK>).</P></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2017-11-18 19:16:03 -0200" MODIFIED_BY="[Empty name]"><P>For length of hospital stay, we performed post hoc sensitivity analyses excluding open trials, trials in which mean and standard deviation were estimated from median and interquartile range, trials with withdrawal rate over 15%, and trials with very short (&lt; two days) or very long (&gt; six days) length of stay in the control group.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2017-12-05 19:45:18 -0200" MODIFIED_BY="Liz Dooley"><STUDY_DESCRIPTION MODIFIED="2017-12-05 19:45:18 -0200" MODIFIED_BY="Liz Dooley"><SEARCH_RESULTS MODIFIED="2017-12-01 13:48:16 -0200" MODIFIED_BY="[Empty name]"><P>In this 2017 update, we identified 364 records from searches of databases and trials registers. After de-duplication, we assessed 239 records by title and abstract and excluded 203 that did not meet our inclusion criteria. We obtained 26 full-text reports of studies, and following assessment included 17 new trials involving 3105 participants. These were added to the 11 trials (representing 1090 participants) included in the 2013 update (<LINK REF="REF-Zhang-2013" TYPE="REFERENCE">Zhang 2013</LINK>). Nine studies identified from searches of trials registers are awaiting classification (see <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>).</P><P>This update included 28 trials (4195 participants). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><P>All 28 included studies were randomised, parallel-group, controlled trials. All but two trials were double-blinded (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>). Four studies were multicentre: a hospital in the United Arab Emirates and two hospitals in Canada in <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; 10 centres in England and Wales in <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; two centres in the USA in <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>; and 24 centres in France in <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>. Three trials were conducted by the same group of investigators in Israel (<LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>), and two trials were conducted by one group of investigators in China (<LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>). The remaining 23 studies were conducted in Argentina (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>), Canada (<LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>), China (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>), France (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>), India (<LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>), Italy (<LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>), Nepal (<LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>), the Netherlands (<LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>), Poland (<LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>), Portugal (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>), Qatar (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>), Tunisia (<LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>), Turkey (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>), the UK (<LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>), and the USA (<LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P><SUBSECTION><HEADING LEVEL="4">Participants</HEADING><P>Two trials recruited outpatient participants (N = 194) (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>); eight trials recruited emergency department participants (N = 1873) (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>); 17 trials recruited inpatients (N = 2028) (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>); and one trial recruited both outpatients and emergency department participants (N = 100) (<LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>). The mean age of participants was from 2.6 to 12.5 months (range: 9 days to 24 months).</P><P>Criteria for diagnosis of viral bronchiolitis were clearly defined in all but six trials (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>).</P><P>Virological investigation was reported in 15 trials (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). The positive rate for respiratory syncytial virus (RSV) varied from 42% to 88%.</P><P>Infants who had previous wheezing episodes were excluded from all 28 trials. Infants hospitalised with severe bronchiolitis (requiring mechanical ventilation or intensive care, or oxygen saturation &lt; 85% on room air) were excluded from all but two trials (<LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Interventions</HEADING><P>The concentration of hypertonic saline was defined as 3% in all but four trials (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>). Two concentrations were used by <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK> (3% and 5%) and <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK> (3% and 7%). The concentration of hypertonic saline was defined at 5% in <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK> and 7% in <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>.</P><P>Treatment regimens of nebulised hypertonic saline (volume, interval of administration, addition of bronchodilator, and treatment duration) varied across studies, especially in emergency department-based trials (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Oxygen or compressed air-driven jet nebulisers were used for drug deliveries in all trials but <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>, which used ultrasonic nebulisers.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Outcome measures</HEADING><P>All 17 inpatient trials except <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK> used length of hospital stay as the primary outcome measure. Length of hospital stay was defined as time from hospital admission to discharge in all but two trials (<LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>), in which both time until fit for discharge and time until discharge were reported. We used time until fit for discharge as length of hospital stay for <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK> and <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>.</P><P>The same clinical severity score was used by 11 inpatient trials as a secondary outcome measure (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>). This clinical score was initially described by <LINK REF="REF-Wang-1992" TYPE="REFERENCE">Wang 1992</LINK>, grading respiratory rate, wheezing, retraction, and general condition on a scale from 0 to 3, with a higher score indicating increased severity. Other clinical scoring systems were used by two inpatient trials (<LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>).</P><P>For outpatient or emergency department participants, outcome measures used were rate of hospitalisation in <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>, <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>, <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>, <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>, <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>, <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>, <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>, and <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>, and rate of re-admission (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>). All outpatient or emergency department trials measured clinical severity score.</P><P>Other outcome measures were haemoglobin saturation (oximetry) (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>), heart rate (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>), respiratory rate (<LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>), time to resolution of signs and symptoms (<LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>), and need for add-on treatment (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>).</P><P>The radiological assessment score initially described by <LINK REF="REF-Nasr-2001" TYPE="REFERENCE">Nasr 2001</LINK> was used in two trials (<LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>).</P><P>Side effects associated with inhaled therapies were reported in all but four trials (<LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>).</P></SUBSECTION></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-12-05 19:45:18 -0200" MODIFIED_BY="Liz Dooley"><P>We excluded nine studies in this update (<LINK REF="STD-Al_x002d_bahadily-2017" TYPE="STUDY">Al-bahadily 2017</LINK>; <LINK REF="STD-Bagus-2012" TYPE="STUDY">Bagus 2012</LINK>; <LINK REF="STD-Bueno-Campa_x00f1_a-2014" TYPE="STUDY">Bueno Campaña 2014</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2015" TYPE="STUDY">Flores-González 2015</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2016" TYPE="STUDY">Flores-González 2016</LINK>; <LINK REF="STD-Gupta-2016" TYPE="STUDY">Gupta 2016</LINK>; <LINK REF="STD-Malik-2015" TYPE="STUDY">Malik 2015</LINK>; <LINK REF="STD-Nenna-2014" TYPE="STUDY">Nenna 2014</LINK>; <LINK REF="STD-Silver-2015" TYPE="STUDY">Silver 2015</LINK>). Reasons for exclusion were: other comparisons (<LINK REF="STD-Bueno-Campa_x00f1_a-2014" TYPE="STUDY">Bueno Campaña 2014</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2015" TYPE="STUDY">Flores-González 2015</LINK>; <LINK REF="STD-Flores_x002d_Gonz_x00e1_lez-2016" TYPE="STUDY">Flores-González 2016</LINK>; <LINK REF="STD-Nenna-2014" TYPE="STUDY">Nenna 2014</LINK>), inclusion of infants with previous history of wheezing (<LINK REF="STD-Silver-2015" TYPE="STUDY">Silver 2015</LINK>), not a randomised controlled trial (<LINK REF="STD-Al_x002d_bahadily-2017" TYPE="STUDY">Al-bahadily 2017</LINK>), and abstract only (<LINK REF="STD-Bagus-2012" TYPE="STUDY">Bagus 2012)</LINK>. Two trials from different groups in India presented almost identical results (<LINK REF="STD-Gupta-2016" TYPE="STUDY">Gupta 2016</LINK>; <LINK REF="STD-Malik-2015" TYPE="STUDY">Malik 2015</LINK>). We contacted the editors of both journals and the corresponding authors of two papers, but neither editors nor authors provided any explanation or information. We excluded both trials because of suspected plagiarism. These were added to studies excluded from previous versions of this review for a total of 13 excluded studies. Reasons for exclusion of the other four studies were: other comparison (<LINK REF="STD-Amirav-2005" TYPE="STUDY">Amirav 2005</LINK>), abstract only (<LINK REF="STD-Guomo-2007" TYPE="STUDY">Guomo 2007</LINK>), not a randomised controlled trial (<LINK REF="STD-Tribastone-2003" TYPE="STUDY">Tribastone 2003</LINK>), and inclusion of infants with previous history of wheezing (<LINK REF="STD-Kuzik-2010" TYPE="STUDY">Kuzik 2010</LINK>).</P><SUBSECTION><HEADING LEVEL="3">Studies awaiting classification</HEADING><P>We identified nine records that appeared to be potentially eligible for inclusion, but published reports or unpublished data were not available (<LINK REF="STD-CTRI_x002f_2010_x002f_091_x002f_003065" TYPE="STUDY">CTRI/2010/091/003065</LINK>; <LINK REF="STD-EudraCT2009_x002d_014758_x002d_14" TYPE="STUDY">EudraCT2009-014758-14</LINK>; <LINK REF="STD-NCT00677729" TYPE="STUDY">NCT00677729</LINK>; <LINK REF="STD-NCT01777347" TYPE="STUDY">NCT01777347</LINK>; <LINK REF="STD-NCT01834820" TYPE="STUDY">NCT01834820</LINK>; <LINK REF="STD-NCT02029040" TYPE="STUDY">NCT02029040</LINK>; <LINK REF="STD-NCT02045238" TYPE="STUDY">NCT02045238</LINK>; <LINK REF="STD-NCT02233985" TYPE="STUDY">NCT02233985</LINK>; <LINK REF="STD-NCT02834819" TYPE="STUDY">NCT02834819</LINK>). We will search for published reports or seek unpublished data for assessment to include in a future update. However, if no publication has resulted from studies completed for more than five years, these records will be discarded. See <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table.</P></SUBSECTION></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><P>Summary assessment of six key domains is described below and presented in the 'Risk of bias' tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) and 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P><ALLOCATION MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><P>Four trials used an online randomisation tool (<LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>); 18 trials used a computer-based random number program (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>); and one trial used a random numbers table to generate the random sequence (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>). Two trials used block randomisation (<LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>), but it was unclear how blocks were chosen at random to create the allocation sequence. <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK> assigned infants to treatment groups according to the consecutive order of their admission to the emergency department. Three trials did not provide information regarding random sequence generation (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>).</P><P>Fourteen trials used sequentially numbered or coded drug containers of identical appearance for allocation concealment (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). Six trials used sequentially numbered, sealed envelopes for allocation concealment (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>). <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK> used a centralised web-based randomisation system. In <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>, study solutions were prepared by the local hospital pharmacy, but the method of allocation concealment was not described. Seven trials did not provide information regarding allocation concealment (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK>).</P></ALLOCATION><BLINDING MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><P>In all but seven trials (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>), infants, investigators, and care providers were blinded to group assignment. Three trials were open-label (<LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>). Another three trials were reported as being double-blinded (<LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>), but details were not provided. One trial did not provide information regarding blinding (<LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>).</P></BLINDING><EXCLUSIONS MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><P>The number of withdrawals after randomisation was small in all but two trials; the withdrawal rate was 18% in <LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK> and <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>. The baseline characteristics of participants were similar between treatment groups in all 28 trials. Incomplete outcome data may thus not be a source of bias in this review. Seven trials reported using intention-to-treat analysis (<LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>).</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2017-11-18 20:00:58 -0200" MODIFIED_BY="[Empty name]"><P>There appeared to be no evidence of selective reporting of outcomes in the included studies. All outcomes proposed in the methods or study protocols were reported in the results. The funnel plots did not suggest small-study effects and publication bias for length of hospital stay among inpatient trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>; P = 0.29 for Egger's test).</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2017-11-18 20:01:41 -0200" MODIFIED_BY="[Empty name]"><P>We observed no other potential sources of bias in the included trials.</P></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2017-12-05 19:36:24 -0200" MODIFIED_BY="Liz Dooley"><SUBSECTION><HEADING LEVEL="3">Primary outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">1. Length of hospital stay or time taken to be ready for discharge (inpatients)</HEADING><P>All but one of the 17 inpatient trials investigated length of hospital stay as the primary outcome (<LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>). <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK> investigated clinical severity score as the primary outcome and length of stay as the secondary outcome. Two emergency department trials reported the length of stay in infants who required inpatient admission (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). We did not include the data from these two trials in the meta-analysis because inpatients represent only a part of randomised participants. The pooled results of 17 trials with a total of 1867 inpatients showed that infants treated with nebulised hypertonic saline had a statistically significant shorter mean length of hospital stay compared to those treated with nebulised 0.9% saline (mean difference (MD) of -0.41 days, 95% confidence interval (CI) -0.75 to -0.07; P = 0.02; low-quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was significant heterogeneity in results among studies (I² = 79%).</P><P><LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> shows the results of seven post hoc subgroup analyses. The effect size of hypertonic saline on length of stay appeared to be greater in subgroups of trials in which virological testing was available, length of stay equal or longer than three days in the control group, use of 3% hypertonic saline, addition of epinephrine to hypertonic saline solution, and year of publication before 2013. Moderate to high levels of heterogeneity persisted in most subgroup analyses.</P><P>The meta-regression analysis did not reveal an independent effect of availability of virological testing, hypertonic saline concentration, co-administration with bronchodilators, length of hospital stay in the control group, and year of publication.</P><P><LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> shows the results of five post hoc sensitivity analyses. Only one sensitivity analysis excluding two trials, <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK> and <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>, with very long (greater than six days) and one trial, <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>, with very short (less than two days) length of hospital stay in the control group reduced the heterogeneity to a moderate level (I² from 79% to 50%), but the results were no longer statistically significant (MD of -0.22 days, 95% CI -0.48 to 0.05; P = 0.11).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Rate of hospitalisation (outpatients or emergency department patients)</HEADING><P><LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>, an outpatient trial, and seven emergency department trials, <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>, <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>, <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>, <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>, <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>, <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>, and <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>, (N = 1723) assessed the efficacy of hypertonic saline in reducing risk of hospitalisation. The pooled risk ratio (RR) was 0.86 (95% CI 0.76 to 0.98; P = 0.02; moderate-quality evidence; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no significant heterogeneity among studies (I² = 7%).</P><P><LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> shows the results of six post hoc subgroup analyses. The effect size of hypertonic saline on reduction of risk of hospitalisation appeared to be greater in the subgroups of trials in which virological testing was available and multiple doses (&#8805; two) of saline solutions were administered.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Secondary outcomes</HEADING><SUBSECTION><HEADING LEVEL="4">1. Clinical severity scores</HEADING><P>One outpatient trial (<LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>), one emergency department trial (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>), and seven inpatient trials, <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>, <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>, <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>, <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>, <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>, <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>, and <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>, compared post-inhalation Wang clinical severity score between infants treated with nebulised hypertonic saline and those treated with nebulised 0.9% saline on the first three days of treatment. The baseline clinical scores were comparable between groups in all nine trials.</P><P>On the first day of treatment, <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK> (N = 65 outpatients) showed that the 3% saline group had a statistically significant lower clinical severity score compared to the 0.9% saline group (MD -1.28, 95% CI -1.92 to -0.64; P &lt; 0.001). Seven inpatient trials (N = 576) also demonstrated significant benefits from hypertonic saline in reducing clinical severity score (pooled MD -0.82, 95% CI -1.25 to -0.38; P = 0.005; I² = 67%) (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>). In contrast, <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK> (N = 171 emergency department patients) did not show superiority of hypertonic saline over normal saline in reducing clinical score (MD -0.09, 95% CI -0.51 to 0.33; P = 0.68). The pooled results of nine trials showed a statistically significant lower clinical severity score favouring treatment with nebulised hypertonic saline over nebulised 0.9% saline on the first day of treatment (pooled MD -0.77, 95% CI -1.18 to -0.36; P &lt; 0.001; I² = 74%; low-quality evidence; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P><P>On the second day of treatment, <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK> (N = 65 outpatients) showed a lower clinical severity score in the 3% saline group compared to the 0.9% saline group (MD -2.0, 95% CI -2.93 to -1.07; P &lt; 0.001). We also observed a statistically significant difference between treatment and control groups among 467 inpatients (pooled MD -1.39, 95% CI -1.95 to -0.84; P &lt; 0.001; I² = 76%) favouring the 3% saline group (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>). <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK> (N = 171 emergency department patients) did not demonstrate significant benefits of hypertonic saline in reducing clinical score (MD -0.27, 95% CI -0.63 to 0.09; P = 0.14). Meta-analysis of eight trials demonstrated superiority of nebulised 3% saline over 0.9% saline in reducing clinical severity score on the second day of treatment (pooled MD -1.28, 95% CI -1.91 to -0.65; P &lt; 0.001; I² = 88%; low-quality evidence; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P><P>On the third day of treatment, <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK> (N = 65 outpatients) showed a lower clinical severity score in the 3% saline group compared to the 0.9% saline group (MD -2.64, 95% CI -3.85 to -1.43; P &lt; 0.001). Six inpatient trials (N = 434) also showed a lower clinical severity score in the 3% saline group (pooled MD -1.35, 95% CI -1.72 to -0.98; P &lt; 0.001; I² = 57%). The pooled results from seven trials demonstrated superiority of nebulised 3% saline over 0.9% saline in reducing clinical severity score on the third day of treatment (pooled MD -1.43, 95% CI -1.82 to -1.04; P &lt; 0.001; I² = 61%; low-quality evidence; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P><P>We performed post hoc meta-regression analysis to explore possible causes of heterogeneity among studies regarding the effect size of hypertonic saline on clinical score during the first three days of treatment. The small number of studies enabled inclusion of only one relevant covariate in the model, which was the severity of bronchiolitis assessed by baseline clinical score in the 0.9% saline group. The meta-regression analysis yielded a regression coefficient of -0.11 (95% CI -0.35 to 0.11; P = 0.30), suggesting that disease severity did not significantly influence the effect size of hypertonic saline on clinical score.</P><P>Eight emergency department-based trials assessed short-term effects (30 minutes to 120 minutes) of up to three doses of nebulised hypertonic saline in improving clinical severity score among infants with acute bronchiolitis (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). Variation in scoring methods and assessment time points made conducting meta-analyses inappropriate. Only two trials showed the superiority of hypertonic saline over normal saline in improving clinical severity scores (<LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>). <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK> found that participants who received nebulised hypertonic saline had more significant improvement in baseline clinical severity scores at the end of two hours of treatment. <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK> revealed that the change in Respiratory Distress Assessment Instrument (RDAI) score before and after nebulisation was greater in the hypertonic saline group than that in the normal saline group (adjusted difference &#8211;0.7, 95% CI &#8211;1.2 to &#8211;0.2; P = 0.006). <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>, an emergency department trial, compared nebulised 5% and 3% hypertonic saline with nebulised 0.9% saline, given at enrolment and every four hours thereafter until child was ready for discharge. There was a small but statistically significant lower clinical score favouring treatment with nebulised 5% saline over nebulised 0.9% saline at 48 hours after randomisation (3.69 ± 1.09 versus 4.12 ± 1.11, P = 0.04) but not 24 hours after randomisation (3.75 ± 1.27 versus 3.97 ± 1.40, P = 0.38). <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK> did not find a significant difference in clinical score at 24 hours and 48 hours after randomisation between 3% saline and 0.9% saline.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">2. Rate of re-admission to hospital</HEADING><P>Four emergency department trials, <LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>, <LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>, <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>, and <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>, and one inpatient trial, <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>, included rate of re-admission after discharge as an outcome. The pooled results of these trials did not demonstrate significant benefits of nebulised hypertonic saline in reducing the risk of re-admission (pooled RR 0.77, 95% CI 0.48 to 1.25; P = 0.30; I² = 36%; moderate-quality evidence; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">3. Haemoglobin saturation (oximetry)</HEADING><P>Eight trials reported the results of haemoglobin saturation (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>). Only <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK> revealed a significant difference between the hypertonic saline group and the 0.9% saline group in terms of room air saturation of oxyhaemoglobin throughout the study period, showing a significantly higher haemoglobin saturation in the hypertonic saline group than the 0.9% saline group at 60 minutes and 120 minutes after treatment.<BR/></P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">4. Respiratory rate</HEADING><P>Five trials reported no difference in respiratory rate between the hypertonic saline group and the 0.9% saline group (<LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">5. Heart rate</HEADING><P>Seven trials reported no difference in heart rate between the hypertonic saline group and the 0.9% saline group (<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK>; <LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">6. Time to resolution of symptoms and signs</HEADING><P><LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK> and <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK> reported time to resolution of wheezing, cough, and pulmonary moist crackles. The pooled results showed that infants treated with nebulised 3% saline had a shorter duration of respiratory symptoms and signs compared to those treated with nebulised 0.9% saline (pooled MD -1.19 days, 95% CI -1.54 to -0.84; P &lt; 0.001). There was significant heterogeneity in results between studies ( P &lt; 0.001; I² = 77.0%; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">7. Duration of in-hospital oxygen supplementation</HEADING><P><LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK> and <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK> (both inpatient trials) reported no difference in duration of in-hospital oxygen supplementation between the hypertonic saline group and the 0.9% saline group.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">8. Need for add-on treatment (bronchodilator, systemic corticosteroids, antibiotics, and oxygen supplementation)</HEADING><P>Eight trials compared the need for add-on treatment between treatment groups (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK>; <LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK>; <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>). None of the trials revealed a significant difference between hypertonic saline and 0.9% saline groups.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">9. Results of pulmonary function tests</HEADING><P>No included studies reported pulmonary function test results.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">10. Radiological findings</HEADING><P>In <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK> and <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK> the second chest radiograph was obtained on the third day after hospital admission. The pooled results did not show a significant difference in radiological score between the hypertonic saline and 0.9% saline groups (pooled MD -0.08, 95% CI -0.90 to 0.75; P = 0.85; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). There was no significant heterogeneity between studies (P = 0.95; I² = 0%).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">11. Adverse events (tachycardia, hypertension, pallor, tremor, nausea, vomiting, diarrhoea, and acute urinary retention)</HEADING><P>Four trials did not report safety data (<LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK>; <LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK>). The remaining 24 trials involving 3723 participants reported adverse events in treatment groups. Among the 3723 participants, 1968 received nebulised hypertonic saline (3% saline: N = 1634; 5% saline: N = 165; 6% saline: N = 83; 7% saline: N = 86). Thirteen trials did not find any significant adverse events among a total of 1363 infants, of whom 703 received nebulised hypertonic saline (co-administered with bronchodilators: N = 672, 96%; hypertonic saline alone: N = 31, 4%). In the remaining 11 trials involving 2360 infants, of whom 1265 received nebulised hypertonic saline (co-administered with bronchodilators: N = 388, 31%; hypertonic saline alone: N = 877, 69%), at least one adverse event was reported. Variations in reporting and outcomes precluded the possibility of conducting meta-analysis of safety data. We narratively summarised the safety data of 11 trials (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Various adverse events were reported in both hypertonic saline and control groups; in most cases, these were mild and resolved spontaneously. Only one inpatient trial involving 142 participants who received 3% saline alone without bronchodilator reported one serious adverse event (bradycardia and desaturation), possibly related to hypertonic saline inhalation, but it resolved the following day.</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2017-12-05 19:36:35 -0200" MODIFIED_BY="Liz Dooley"><SUMMARY_OF_RESULTS MODIFIED="2017-12-05 19:36:35 -0200" MODIFIED_BY="Liz Dooley"><P>We included 28 trials involving 4195 infants (2222 infants received nebulised hypertonic saline) with acute viral bronchiolitis (17 inpatient trials (N = 2028); 2 outpatient trials (N = 194); 7 emergency department trials (N = 1873); 1 outpatient and emergency department trial (N = 100)) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P><P>Hospitalised infants treated with nebulised hypertonic saline had a statistically significant shorter mean length of hospital stay compared to those treated with nebulised 0.9% saline (MD -0.41 days, 95% CI -0.75 to -0.07; P = 0.02; 17 trials). Children who received hypertonic saline also had a statistically significant lower post-inhalation clinical score than the 0.9% saline group in the first three days of treatment (day 1: MD -0.77, 95% CI -1.18 to -0.36, P = &lt;0.001; day 2: MD -1.28, 95% CI -1.91 to -0.65, P &lt; 0.001; day 3: MD -1.43, 95% CI -1.82 to -1.04, P &lt; 0.001). Nebulised hypertonic saline reduced the risk of hospitalisation by 14% compared with nebulised 0.9% saline among children treated as outpatients and in emergency departments (RR 0.86, 95% CI 0.76 to 0.98; P = 0.02; 7 trials). Among eight emergency department trials assessing short-term effects (30 minutes to 120 minutes) of up to three doses of nebulised hypertonic saline in improving clinical score, only two trials showed significant effects of the treatment.</P><P>Post hoc subgroup analyses demonstrated that the effect size of nebulised hypertonic saline on length of stay among inpatients appeared to be greater in subgroups of trials in which virological testing was available, length of stay equal or longer than three days in the control group, use of 3% hypertonic saline, addition of epinephrine to hypertonic saline solution, and year of publication before 2013. However, the meta-regression analysis did not reveal independent effect of these factors on the effect size of hypertonic saline.</P><P>Among children treated as outpatients and in emergency departments, post hoc subgroup analyses revealed that the effect size of nebulised hypertonic saline on reduction of risk of hospitalisation appeared to be greater in subgroups of trials in which virological testing was available and multiple doses (&#8805; two) of saline solution were administered.</P><P>Twenty-four trials involving 3723 participants (of which 1968 received nebulised hypertonic saline) reported treatment safety data. Thirteen of these trials did not report any significant adverse events among a total of 1363 infants (of which 703 received nebulised hypertonic saline, mixed with bronchodilators in 96% of infants). At least one adverse event was reported in 11 trials involving 2360 infants (of which 1265 received nebulised hypertonic saline, alone in 69% of infants). In most cases, adverse events were mild and resolved spontaneously.</P></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-29 22:48:12 -0200" MODIFIED_BY="[Empty name]"><P>In this update, we found that the effect size of nebulised hypertonic saline on reducing length of stay in hospitalised infants was approximately a third of what was found in the last (2013) update of this review. <LINK REF="REF-Zhang-2013" TYPE="REFERENCE">Zhang 2013</LINK> included six inpatient trials involving 500 infants (MD -1.15 days, 95% CI -1.49 to -0.82 days). Moreover, all 10 trials published in 2013 and thereafter, including two European multicentre studies with relatively large sample sizes, did not find significant effects of nebulised hypertonic saline on length of stay among inpatients with bronchiolitis. We found two main differences between recently published trials and those published before 2013. Virological investigation was available in 86% of trials published before 2013, whereas such testing was available in only 30% of trials published in 2013 and thereafter. Another difference was that none of the seven older trials had a mean length of stay in the control group of less than three days, while 40% of the recently published trials had a mean length of stay in the control group of less than three days. These two factors may partially explain the inconsistency in results between older trials and trials published in 2013 and thereafter; however, the meta-regression analysis did not confirm an independent effect of these factors on the effect size of hypertonic saline.</P><P>For outpatients and emergency department patients, we found a 14% (RR 0.86, 95% CI 0.76 to 0.98) reduction in the risk of hospitalisation associated with nebulised hypertonic saline, in contrast with a 37% non-statistically significant reduction shown in the 2013 review, which included four outpatient and emergency department trials involving 380 infants (RR 0.63, 95% CI 0.37 to 1.07).</P><P>Clinical score is generally considered a relatively objective measure to assess the severity of illness. In this review, 11 trials used the clinical severity score system proposed by <LINK REF="REF-Wang-1992" TYPE="REFERENCE">Wang 1992</LINK>, which assesses respiratory rate, wheezing, retraction, and general condition. The benefits of nebulised hypertonic saline in improving clinical score were observed in the first three days of treatment in both outpatients and inpatients. However, most emergency department trials failed to demonstrate significant effects of hypertonic saline in improving clinical score over a short period of time (30 minutes to 120 minutes). The validity of <LINK REF="REF-Wang-1992" TYPE="REFERENCE">Wang 1992</LINK> score system has not yet been assessed. Another commonly used approach for grading clinical severity was the Respiratory Distress Assessment Instrument (RDAI). However, RDAI may have poor to moderate construct validity, considerable test-retest measurement error, and does not encompass all determinants of bronchiolitis severity (<LINK REF="REF-Fernandes-2015" TYPE="REFERENCE">Fernandes 2015</LINK>).</P><P>Potential side effects, principally acute bronchospasm, remain a concern with nebulised hypertonic saline. No significant adverse events were observed in 13 trials involving 1363 infants (703 treated with nebulised hypertonic saline). Saline solutions were co-administered with bronchodilators in 96% of these infants. In contrast, there were 11 trials involving 2360 participants (1265 treated with nebulised hypertonic saline) reported at least one adverse event. The majority of patients (69%) received saline solution alone. Most adverse events were mild and resolved spontaneously. These results suggest that nebulised hypertonic saline is a safe treatment in infants with bronchiolitis, especially when administered in conjunction with a bronchodilator.</P><P>Inhalation therapy was administrated via jet nebulisers in all of the included studies except for <LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>, which used ultrasonic nebulisers. There are some theoretical differences in the physical properties of aerosols produced by jet nebulisers and ultrasonic nebulisers, which may affect their therapeutic efficacy. On the one hand, ultrasonic nebulisers induce sputum more efficiently than jet nebulisers; on the other hand, jet nebulisers generate aerosols with smaller aerodynamic mass median diameter, which may more easily reach smaller bronchi and bronchioles. We could not provide direct evidence regarding the impact of the physical properties of aerosols generated by different types of nebulisers on the efficacy of inhaled hypertonic saline in infants with viral bronchiolitis. However, at least one trial demonstrated that both jet nebulisers and ultrasonic nebulisers are efficient methods of delivery of hypertonic saline for infants with bronchiolitis (<LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK>).</P><P>The optimal treatment regimen for nebulised hypertonic saline in acute bronchiolitis remains unclear. Among inpatients, study solutions were given more frequently in 12 trials (every 4 to 6 hours) and less frequently in 5 trials (every 8 hours). Subgroup analysis did not reveal a significant difference in reduction of length of hospital stay between regimens. Among outpatients and emergency department patients, effect size of nebulised hypertonic saline appeared to be greater when multiple doses (&#8805; two) of saline solutions were administered compared to a single dose.</P><P>The concentration of nebulised hypertonic saline was 3% in all but five trials (<LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK>; <LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK>; <LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK>; <LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK>). We did not observe the superiority of higher concentration (5%, 6%, and 7%) of hypertonic saline over 3% saline in improving clinical outcomes. On the contrary, subgroup analysis showed a larger effect of 3% saline on reducing length of hospital stay among inpatients compared to hypertonic saline with higher concentration.</P><P>We included trials conducted in high- and low-income countries and in different settings (inpatient, outpatient, and emergency department). The evidence derived from this review thus may have wide applicability. However, as all but two included trials only recruited infants with mild to moderate bronchiolitis (<LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK>; <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK>), care should be taken when extrapolating the findings of this review to infants with more severe bronchiolitis, such as those requiring mechanical ventilation, intensive care, or with oxygen saturation readings below 85% on room air. The underlying airway pathological changes may differ between severe and mild to moderate bronchiolitis, so different responses to treatments with hypertonic saline may be expected in children with more severe illness. Further trials are needed to assess the potential effects of nebulised hypertonic saline in infants hospitalised with severe acute bronchiolitis.</P><P>Despite our findings that the effects of nebulised hypertonic saline on reduction in length of hospital stay are smaller than were previously estimated, a reduction of 10 hours in length of hospital stay in infants with bronchiolitis may still be considered clinically relevant given the relatively short disease course, high prevalence, and huge burden of illness on healthcare systems around the world. Moreover, nebulised hypertonic saline may have benefits on other outcomes such as rate of hospitalisation and clinical severity score in infants with acute bronchiolitis, providing a good safety profile and low cost.</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2017-11-19 18:46:19 -0200" MODIFIED_BY="[Empty name]"><P>We had no serious concerns on three domains of the GRADE approach (indirectness, imprecision, and publication bias). We downgraded the quality of the evidence to low for length of hospital stay due to high levels of statistical heterogeneity and potential risk of selection bias in one-third of the included trials. High heterogeneity could be expected given variations among trials in definitions of acute bronchiolitis, disease severity, standard care, intervention regimen, criteria for discharge, and risk of potential bias. We conducted several subgroup analyses to investigate the potential sources of heterogeneity, but moderate to high levels of heterogeneity persisted in most subgroup analyses.</P><P>We downgraded the quality of the evidence to low for clinical severity score due to high heterogeneity and risk of bias, as mentioned above.</P><P>In spite of the fact that there was no statistically significant heterogeneity, we downgraded the quality of evidence to moderate for rate of hospitalisation due to substantial clinical heterogeneity between studies.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2017-11-19 18:45:03 -0200" MODIFIED_BY="[Empty name]"><P>We searched for both published and unpublished trials to identify all relevant studies. We obtained additional trial data from five principal investigators. All included inpatient trials contributed data for meta-analysis of length of hospital stay. However, the results of meta-analyses of some secondary outcomes, such as clinical severity score and rate of re-admission, may be biased because only some included trials contributed data for analysis. The number of trials and participants in outpatient and emergency department settings was limited: <LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK> and <LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK> contributed 73% of weight to the overall summary estimate of effects of hypertonic saline on reduction of risk of hospitalisation. All studies except for <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK> used 0.9% saline as the comparison. The use of normal saline enables the trial to be double-blind, however normal saline is not technically a placebo, as high-volume normal saline inhalation could potentially have physiological effects by improving airway mucociliary clearance, which may have beneficial effects on acute bronchiolitis (<LINK REF="REF-Wohl-2003" TYPE="REFERENCE">Wohl 2003</LINK>). Use of normal saline as the control may tend to minimise the effect size of hypertonic saline.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2017-11-19 18:46:01 -0200" MODIFIED_BY="[Empty name]"><P>Four published systematic reviews addressed efficacy and safety of nebulised hypertonic saline in children with acute bronchiolitis (<LINK REF="REF-Badgett-2015" TYPE="REFERENCE">Badgett 2015</LINK>; <LINK REF="REF-Chen-2014" TYPE="REFERENCE">Chen 2014</LINK>; <LINK REF="REF-Maguire-2015" TYPE="REFERENCE">Maguire 2015</LINK>; <LINK REF="REF-Zhang-2015" TYPE="REFERENCE">Zhang 2015</LINK>). We comparatively summarised the main findings of these four reviews in <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2017-11-19 18:57:34 -0200" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2017-10-26 09:02:19 -0200" MODIFIED_BY="[Empty name]"><P>Current evidence suggests that nebulised hypertonic saline may modestly reduce the length of hospital stay among infants hospitalised with acute viral bronchiolitis and improve clinical severity scores. Nebulised hypertonic saline may also reduce the risk of hospitalisation among outpatients and emergency department patients. Treatment with nebulised hypertonic saline has a good safety profile. However, the quality of evidence in this review was insufficient to support routine use of nebulised hypertonic saline in infants with acute bronchiolitis.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2017-11-19 18:57:34 -0200" MODIFIED_BY="[Empty name]"><P>Further multicentre randomised trials are required to evaluate the efficacy and safety of nebulised hypertonic saline in infants with acute bronchiolitis, in inpatient, outpatient, and emergency department settings. There are some common challenges for all clinical trials in infants with acute bronchiolitis. The currently used definition of 'bronchiolitis' may include a heterogeneous group of patients with different underlying aetiologies and pathologies. The development of valid diagnostic criteria for acute bronchiolitis in infants is urgently needed. There is a lack of robust and well-accepted efficacy outcome measures. Length of hospital stay and rate of hospitalisation are the most clinically important endpoints, but they are usually more susceptible to bias. Well-defined valid admission and discharge criteria should thus be used. Further trials should have sufficient statistical power to detect modest but clinically relevant effects of the intervention. The optimal treatment regimen of nebulised hypertonic saline for infants with acute bronchiolitis remains to be determined. The mechanism of action of nebulised hypertonic saline in infants with viral bronchiolitis also needs to be addressed in future studies.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2017-11-19 18:59:09 -0200" MODIFIED_BY="[Empty name]"><P>Thanks to Ruth Foxlee, Sarah Thorning, Justin Clark, and David Honeyman for help in defining the search strategy and running literature searches. Thanks also to Libby Lissiman for assistance in the early stages of this review and to the Cochrane Acute Respiratory Infections Group, especially Liz Dooley and Ann Jones, for editorial assistance. The authors wish to thank the following people for commenting on drafts of this review: Hayley Edmonds, Avigdor Mandelberg, Federico Martinón Torres, Sree Nair, Amy Zelmer, Karen Lee, Anne Lyddiatt, Federico Martinón Torres, and Meenu Singh.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2017-12-05 04:06:31 -0200" MODIFIED_BY="Liz Dooley"><P>Linjie Zhang: None known.<BR/>Raúl A Mendoza-Sassi: None known.<BR/>Claire Wainwright: received travel grants from the North American Cystic Fibrosis Foundation and the European Cystic Fibrosis Society, travel and accommodation expenses from Novartis Pharmaceuticals and Vertex Pharmaceuticals, and travel and accommodation expenses from the University of Miami; has served as a consultant for/an advisory board member for Vertex Pharmaceuticals; has previously and is currently receiving grants or grants pending from the National Health and Medical Research Council (Australia), and has previously and currently is receiving funds from Vertex Pharmaceuticals for site costs associated with clinical trial participation and has previously received funds from Ablynx, and Novo Nordisk Phamaceuticals for site participation in clinical trials; and her institution has previously received payment for her providing lectures from Novartis Pharmaceuticals and Vertex Pharmaceuticals. None of the declared benefits were received in relation to this review or review topic or scope.<BR/>Terry P Klassen: None known.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2017-11-19 19:01:45 -0200" MODIFIED_BY="[Empty name]"><P>Linjie Zhang conceived the idea and wrote the draft protocol, primary review, and review updates.</P><P>Linjie Zhang and Raúl A Mendoza-Sassi were responsible for study selection, quality assessment, data collection, and data analysis.</P><P>Raúl A Mendoza-Sassi, Claire Wainwright, and Terry P Klassen provided input in the writing of the protocol and primary and updated reviews.</P><P>All authors approved the final version of this review update.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-11-19 19:09:09 -0200" MODIFIED_BY="[Empty name]"><P>Given the very limited number of studies that were identified initially (<LINK REF="REF-Zhang-2011" TYPE="REFERENCE">Zhang 2011</LINK>), we added the comparison of nebulised hypertonic saline alone versus nebulised 0.9% saline since the first version of the review. We also clarified the population according to age and changed the title to specify infants. We performed post hoc subgroup analyses, post hoc meta-regression, and post hoc sensitivity analyses in the updated review. We also created and examined a funnel plot to explore possible small-study effects and publication bias. Cochrane Review methods have evolved over time, and these have been applied.</P></PRO_REV_DIFF><PUBLIC_NOTES MODIFIED="2017-03-29 00:45:48 -0300" MODIFIED_BY="[Empty name]"/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2017-12-05 22:45:39 +0000" MODIFIED_BY="Liz Dooley">
<STUDIES MODIFIED="2017-12-05 03:45:34 -0200" MODIFIED_BY="Liz Dooley">
<INCLUDED_STUDIES MODIFIED="2017-12-05 03:45:34 -0200" MODIFIED_BY="Liz Dooley">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Ansari-2010" MODIFIED="2017-04-13 16:13:17 -0300" MODIFIED_BY="[Empty name]" NAME="Al-Ansari 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-04-13 16:13:17 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Ansari K, Sakran M, Davidson BL, Sayyed RE, Mahjoub H, Ibrahim K</AU>
<TI>Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2010</YR>
<VL>157</VL>
<NO>4</NO>
<PG>630-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angoulvant-2017" MODIFIED="2017-08-28 19:39:38 -0300" MODIFIED_BY="[Empty name]" NAME="Angoulvant 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-08-28 19:39:38 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angoulvant F, Bellêttre X, Milcent K, Teglas JP, Claudet I, Le Guen CG, et al</AU>
<TI>Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial</TI>
<SO>JAMA Pediatrics</SO>
<YR>2017</YR>
<VL>171</VL>
<NO>8</NO>
<PG>e171333</PG>
<IDENTIFIERS MODIFIED="2017-08-28 19:39:38 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221662"/><IDENTIFIER MODIFIED="2017-08-28 19:39:38 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1001/jamapediatrics.2017.1333"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221661"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010" MODIFIED="2013-04-20 21:48:56 -0300" MODIFIED_BY="[Empty name]" NAME="Anil 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-20 21:48:56 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N</AU>
<TI>High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145915"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145914"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Everard-2014" MODIFIED="2017-04-13 16:04:51 -0300" MODIFIED_BY="[Empty name]" NAME="Everard 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-04-13 16:04:05 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al</AU>
<TI>SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis</TI>
<SO>Thorax</SO>
<YR>2014</YR>
<VL>69</VL>
<NO>12</NO>
<PG>1105-12</PG>
<IDENTIFIERS MODIFIED="2017-04-13 15:47:49 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221664"/><IDENTIFIER MODIFIED="2017-04-13 15:47:49 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/thoraxjnl-2014-205953"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221663"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores-2016" MODIFIED="2017-04-13 16:03:43 -0300" MODIFIED_BY="[Empty name]" NAME="Flores 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-04-13 16:03:43 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores P, Mendes AL, Neto AS</AU>
<TI>A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2016</YR>
<VL>51</VL>
<NO>4</NO>
<PG>418-25</PG>
<IDENTIFIERS MODIFIED="2017-04-13 16:03:43 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221666"/><IDENTIFIER MODIFIED="2017-04-13 16:03:43 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/ppul.23306"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221665"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Florin-2014" MODIFIED="2017-05-04 04:41:27 -0300" MODIFIED_BY="[Empty name]" NAME="Florin 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-05-04 04:41:27 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ</AU>
<TI>Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial</TI>
<SO>JAMA Pediatrics</SO>
<YR>2014</YR>
<VL>168</VL>
<NO>7</NO>
<PG>664&#8211;70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145918"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grewal-2009" MODIFIED="2013-04-20 21:49:21 -0300" MODIFIED_BY="[Empty name]" NAME="Grewal 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-04-20 21:49:21 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grewal S, Ali S, McConnell DW, Vandermeer B, Klassen TP</AU>
<TI>A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2009</YR>
<VL>163</VL>
<NO>11</NO>
<PG>1007-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145923"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145922"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ipek-2011" MODIFIED="2017-05-04 04:40:47 -0300" MODIFIED_BY="[Empty name]" NAME="Ipek 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-05-04 04:40:47 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ipek IO, Yalcin EU, Sezer RG, Bozaykut A</AU>
<TI>The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>24</VL>
<NO>6</NO>
<PG>633-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145925"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145924"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2014" MODIFIED="2017-11-21 02:08:20 -0200" MODIFIED_BY="[Empty name]" NAME="Jacobs 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-11-21 02:08:20 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs JD, Foster M, Wan J, Pershad J</AU>
<TI>7% hypertonic saline in acute bronchiolitis: a randomized controlled trial</TI>
<SO>Pediatrics</SO>
<YR>2014</YR>
<VL>133</VL>
<NO>1</NO>
<PG>e8&#8211;13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145927"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145926"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khanal-2015" MODIFIED="2017-11-21 02:08:47 -0200" MODIFIED_BY="[Empty name]" NAME="Khanal 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-11-21 02:08:47 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khanal A, Sharma A, Basnet S, Sharma PR, Gami FC</AU>
<TI>Nebulised hypertonic saline (3%) among children with mild to moderately severe bronchiolitis - a double blind randomized controlled trial</TI>
<SO>BMC Pediatrics</SO>
<YR>2015</YR>
<VL>15</VL>
<PG>115</PG>
<IDENTIFIERS MODIFIED="2017-04-13 16:07:16 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221668"/><IDENTIFIER MODIFIED="2017-04-13 16:07:16 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/s12887-015-0434-4"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221667"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f6_se-2016" MODIFIED="2017-05-04 04:39:35 -0300" MODIFIED_BY="[Empty name]" NAME="Köse 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-04 04:39:35 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Köse S, &#350;ehriyaro&#287;lu A, Esen F, Özdemir A, Karda&#351; Z, Altu&#287; U, et al</AU>
<TI>Comparing the efficacy of 7%, 3% and 0.9% saline in moderate to severe bronchiolitis in infants</TI>
<SO>Balkan Medical Journal</SO>
<YR>2016</YR>
<VL>33</VL>
<NO>2</NO>
<PG>193-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221670"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221669"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzik-2007" MODIFIED="2017-04-13 16:08:15 -0300" MODIFIED_BY="[Empty name]" NAME="Kuzik 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-04-13 16:08:15 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzik BA, Al Qaghi SA, Kent S, Flavin MP, Hopman W, Hotte S, et al</AU>
<TI>Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>151</VL>
<NO>3</NO>
<PG>266-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145929"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145928"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014" MODIFIED="2017-04-20 04:21:24 -0300" MODIFIED_BY="[Empty name]" NAME="Li 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-04-20 04:21:24 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Zhao J</AU>
<TI>Effectiveness of inhaled hypertonic saline in children with bronchiolitis</TI>
<SO>Zhonghua Er Ke Za Zh</SO>
<YR>2014</YR>
<VL>25</VL>
<NO>8</NO>
<PG>607-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145931"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145930"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2010" MODIFIED="2017-04-13 16:09:04 -0300" MODIFIED_BY="[Empty name]" NAME="Luo 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-04-13 16:09:04 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X, et al</AU>
<TI>Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>2</NO>
<PG>199-202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145933"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145932"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2011" MODIFIED="2017-04-13 16:09:50 -0300" MODIFIED_BY="[Empty name]" NAME="Luo 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-04-13 16:09:50 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Z, Fu Z, Liu E, Xu X, Fu X, Peng D, et al</AU>
<TI>Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1829-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145935"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145934"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahesh-Kumar-2013" MODIFIED="2017-06-06 23:30:21 -0300" MODIFIED_BY="[Empty name]" NAME="Mahesh Kumar 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-06-06 23:30:21 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahesh Kumar KB, Karunakara BP, Manjunath MN, Mallikarjuna HB</AU>
<TI>Aerosolised hypertonic saline in hospitalized young children with acute bronchiolitis: a randomized controlled clinical trial</TI>
<SO>Journal of Pediatric Sciences</SO>
<YR>2013</YR>
<VL>5</VL>
<NO>1</NO>
<PG>e174</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221672"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221671"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandelberg-2003" MODIFIED="2017-04-13 16:10:36 -0300" MODIFIED_BY="[Empty name]" NAME="Mandelberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-04-13 16:10:36 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, et al</AU>
<TI>Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<NO>2</NO>
<PG>481-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145937"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145936"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miraglia-Del-Giudice--2012" MODIFIED="2017-04-11 11:58:02 -0300" MODIFIED_BY="[Empty name]" NAME="Miraglia Del Giudice  2012" YEAR="2012">
<REFERENCE MODIFIED="2017-04-11 11:58:02 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miraglia Del Giudice M, Saitta F, Leonardi S, Capasso M, Niglio B, Chinellato I, et al</AU>
<TI>Effectiveness of nebulized hypertonic saline and epinephrine in hospitalized infants with bronchiolitis</TI>
<SO>International Journal of Immunopathology and Pharmacology</SO>
<YR>2012</YR>
<VL>25</VL>
<NO>2</NO>
<PG>485-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221674"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221673"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01238848" MODIFIED="2017-12-05 03:45:34 -0200" MODIFIED_BY="Liz Dooley" NAME="NCT01238848" YEAR="2012">
<REFERENCE MODIFIED="2017-12-05 03:45:34 -0200" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>NCT01238848</AU>
<TI>Efficacy of nebulized hypertonic saline in the treatment of acute bronchiolitis</TI>
<TO>A randomized controlled trial to evaluate efficacy of nebulized hypertonic saline vs. normal saline in the treatment of hospitalized children with bronchiolitis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT01238848</SO>
<YR>(first received 11 November 2010)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221676"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-04-11 11:49:03 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221675"/><IDENTIFIER MODIFIED="2017-04-11 11:49:03 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01238848"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ojha-2014" MODIFIED="2017-11-21 02:12:41 -0200" MODIFIED_BY="[Empty name]" NAME="Ojha 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-11-21 02:12:41 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ojha AR, Mathema S, Sah S, Aryal UR</AU>
<TI>A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis</TI>
<SO>Journal of Nepal Health Research Council</SO>
<YR>2014</YR>
<VL>12</VL>
<NO>26</NO>
<PG>39&#8211;43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145945"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145944"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pandit-2013" MODIFIED="2016-11-27 15:27:50 -0200" MODIFIED_BY="[Empty name]" NAME="Pandit 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-11-27 15:27:50 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pandit S, Dhawan N, Thakur D</AU>
<TI>Utility of hypertonic saline in the management of acute bronchiolitis in infants: a randomized controlled study</TI>
<SO>International Journal of Clinical Pediatrics</SO>
<YR>2013</YR>
<VL>2</VL>
<NO>1</NO>
<PG>24&#8211;9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145947"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145946"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratajczyk_x002d_Pekrul-2016" MODIFIED="2017-11-21 02:13:31 -0200" MODIFIED_BY="[Empty name]" NAME="Ratajczyk-Pekrul 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-11-21 02:13:31 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratajczyk-Pekrul K, Gonerko P, Peregud-Pogorzelski J</AU>
<TI>The clinical use of hypertonic saline/salbutamol in treatment of bronchiolitis</TI>
<SO>Pediatria Polska</SO>
<YR>2016</YR>
<VL>91</VL>
<NO>4</NO>
<PG>301-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221678"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221677"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarrell-2002" MODIFIED="2017-04-13 16:11:23 -0300" MODIFIED_BY="[Empty name]" NAME="Sarrell 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-04-13 16:11:23 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, et al</AU>
<TI>Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>6</NO>
<PG>2015-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145949"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145948"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2013" MODIFIED="2017-05-04 04:37:32 -0300" MODIFIED_BY="[Empty name]" NAME="Sharma 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-05-04 04:37:32 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma BS, Gupta MK, Rafik SP</AU>
<TI>Hypertonic (3%) saline for acute viral bronchiolitis: a randomized trial</TI>
<SO>Indian Pediatrics</SO>
<YR>2013</YR>
<VL>50</VL>
<NO>8</NO>
<PG>743-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221680"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221679"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-2006" MODIFIED="2017-04-13 16:12:24 -0300" MODIFIED_BY="[Empty name]" NAME="Tal 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-04-13 16:12:24 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal G, Cesar K, Oron A, Houri S, Ballin A, Mandelberg A</AU>
<TI>Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience</TI>
<SO>Israel Medical Association Journal</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>3</NO>
<PG>169-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145951"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145950"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teunissen-2014" MODIFIED="2016-11-27 11:40:38 -0200" MODIFIED_BY="[Empty name]" NAME="Teunissen 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-27 11:40:05 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teunissen J, Hochs AH, Vaessen-Verberne A, Boehmer AL, Smeets CC, Brackel H, et al</AU>
<TI>The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>44</VL>
<NO>4</NO>
<PG>913&#8211;21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221681"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tinsa-2014" MODIFIED="2016-11-27 11:48:28 -0200" MODIFIED_BY="[Empty name]" NAME="Tinsa 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-27 11:48:28 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tinsa F, Abdelkafi S, Bel Haj I, Hamouda S, Brini I, Zouari B, et al</AU>
<TI>A randomized, controlled trial of nebulized 5% hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis</TI>
<SO>La Tunisie Medicale</SO>
<YR>2014</YR>
<VL>92</VL>
<NO>11</NO>
<PG>674-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145955"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145954"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2014" MODIFIED="2016-11-27 15:21:19 -0200" MODIFIED_BY="[Empty name]" NAME="Wu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-11-27 15:21:19 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu S, Baker C, Lang ME, Schrager SM, Liley FF, Papa C, et al</AU>
<TI>Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial</TI>
<SO>JAMA Pediatrics</SO>
<YR>2014</YR>
<VL>168</VL>
<NO>7</NO>
<PG>657-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145957"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145956"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-11-21 02:23:34 -0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_bahadily-2017" MODIFIED="2017-09-26 15:03:03 -0300" MODIFIED_BY="[Empty name]" NAME="Al-bahadily 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-09-26 15:03:03 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-bahadily AJM, Al-Omrani AAM, Atiya AA</AU>
<TI>Hypertonic 3% saline in comparison with 0.9% (normal) saline in treatment of acute bronchiolitis</TI>
<SO>International Journal of Pediatrics</SO>
<YR>2017</YR>
<VL>5</VL>
<NO>1</NO>
<PG>4209-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221684"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221683"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amirav-2005" MODIFIED="2013-04-20 21:51:23 -0300" MODIFIED_BY="[Empty name]" NAME="Amirav 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-20 21:51:23 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amirav I, Oron A, Tal G, Cesar K, Ballin A, Houri S, et al</AU>
<TI>Aerosol delivery in RSV bronchiolitis: hood or face-mask?</TI>
<SO>Journal of Pediatrics</SO>
<YR>2005</YR>
<VL>147</VL>
<NO>5</NO>
<PG>627-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145958"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bagus-2012" MODIFIED="2017-11-21 02:16:52 -0200" MODIFIED_BY="[Empty name]" NAME="Bagus 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-21 02:16:52 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bagus SI, Putu SP</AU>
<TI>Efficacy of nebulized hypertonic saline and albuterol combination for the management of acute bronchiolitis: a randomized, double-blind controlled trial</TI>
<SO>Paediatric Respiratory Reviews</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>Suppl 1</NO>
<PG>S76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221686"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221685"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bueno-Campa_x00f1_a-2014" MODIFIED="2017-05-04 04:35:57 -0300" MODIFIED_BY="[Empty name]" NAME="Bueno Campaña 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-05-04 04:35:57 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bueno Campaña M, Olivares Ortiz J, Notario Muñoz C, Rupérez Lucas M, Fernández Rincón A, Patiño Hernández O, et al</AU>
<TI>High flow therapy versus hypertonic saline in bronchiolitis: randomised controlled trial</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2014</YR>
<VL>99</VL>
<NO>6</NO>
<PG>511-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221688"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221687"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores_x002d_Gonz_x00e1_lez-2015" MODIFIED="2017-11-21 02:18:15 -0200" MODIFIED_BY="[Empty name]" NAME="Flores-González 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-11-21 02:18:15 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores-González JC, Matamala-Morillo MA, Rodríguez-Campoy P, Pérez-Guerrero JJ, Serrano-Moyano B, Comino-Vazquez P, et al</AU>
<TI>Epinephrine improves the efficacy of nebulized hypertonic saline in moderate bronchiolitis: a randomised clinical trial</TI>
<SO>PLoS ONE</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>11</NO>
<PG>e0142847</PG>
<IDENTIFIERS MODIFIED="2017-05-20 14:39:12 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221690"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221689"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flores_x002d_Gonz_x00e1_lez-2016" MODIFIED="2017-05-20 14:40:50 -0300" MODIFIED_BY="[Empty name]" NAME="Flores-González 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-20 14:40:41 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flores-González JC, Dominguez-Coronel MT, Matamala Morillo MA, Aragón Ramírez M, García Ortega RM, Dávila Corrales FJ, et al</AU>
<TI>Does nebulized epinephrine improve the efficacy of hypertonic saline solution in the treatment of hospitalized moderate acute bronchiolitis? A double blind, randomized clinical trial</TI>
<SO>Minerva Pediatrica</SO>
<YR>2016</YR>
<VL>68</VL>
<NO>2</NO>
<PG>81-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221692"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221691"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guomo-2007" MODIFIED="2017-06-06 23:07:52 -0300" MODIFIED_BY="[Empty name]" NAME="Guomo 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-06-06 23:07:52 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guomo R, Cossettini M, Saretta F, Fasoli L, Guerrera T, Canciani M</AU>
<TI>Efficacy of hypertonic saline solution in infants with acute bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>Suppl</NO>
<PG>E3016</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145961"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2016" MODIFIED="2017-11-21 02:19:29 -0200" MODIFIED_BY="[Empty name]" NAME="Gupta 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-11-21 02:19:29 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta HV, Gupta VV, Kaur G, Baidwan AS, George PP, Shah JC, et al</AU>
<TI>Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: a quasi experimental study</TI>
<SO>Perspectives in Clinical Research</SO>
<YR>2016</YR>
<VL>7</VL>
<NO>2</NO>
<PG>88-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221694"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221693"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzik-2010" MODIFIED="2013-07-19 06:46:53 -0300" MODIFIED_BY="[Empty name]" NAME="Kuzik 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-07-19 06:46:53 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzik BA, Flavin MP, Kent S, Zielinski D, Kwan CW, Adeleye A, et al</AU>
<TI>Effect of inhaled hypertonic saline on hospital admission rate in children with viral bronchiolitis: a randomized trial</TI>
<SO>Canadian Journal of Emergency Medicine</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>477-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3145963"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3145962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malik-2015" MODIFIED="2017-11-21 02:21:34 -0200" MODIFIED_BY="[Empty name]" NAME="Malik 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-11-21 02:21:34 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik G, Singh A, Singh K, Pannu MS, Singh P, Banga S, et al</AU>
<TI>A comparative study to assess the effects of nebulised 3% hypertonic saline, 0.9% normal saline and salbutamol in management of acute bronchiolitis among Indian children</TI>
<SO>Journal of Evolution of Medical and Dental Sciences</SO>
<YR>2015</YR>
<VL>4</VL>
<NO>21</NO>
<PG>3662-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221696"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221695"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nenna-2014" MODIFIED="2017-06-06 23:06:13 -0300" MODIFIED_BY="[Empty name]" NAME="Nenna 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-06 23:06:13 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nenna R, Papoff P, Moretti C, De Angelis D, Battaglia M, Papasso S, et al</AU>
<TI>Seven percent hypertonic saline - 0.1% hyaluronic acid in infants with mild-to-moderate bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2014</YR>
<VL>49</VL>
<NO>9</NO>
<PG>919-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221698"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221697"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-2015" MODIFIED="2017-11-21 02:23:34 -0200" MODIFIED_BY="[Empty name]" NAME="Silver 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-11-21 02:23:34 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver AH, Esteban-Cruciani N, Azzarone G, Douglas LC, Lee DS, Liewehr S, et al</AU>
<TI>3% hypertonic saline versus normal saline in inpatient bronchiolitis: a randomized controlled trial</TI>
<SO>Pediatrics</SO>
<YR>2015</YR>
<VL>136</VL>
<NO>6</NO>
<PG>1036-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221700"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221699"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tribastone-2003" MODIFIED="2017-06-06 23:05:07 -0300" MODIFIED_BY="[Empty name]" NAME="Tribastone 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-06-06 23:05:07 -0300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tribastone AD</AU>
<TI>Nebulized 3% saline effective for viral bronchiolitis</TI>
<SO>Journal of Family Practice</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>5</NO>
<PG>359-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221702"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-06-06 22:46:23 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221701"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-12-01 11:19:18 -0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-CTRI_x002f_2010_x002f_091_x002f_003065" MODIFIED="2017-12-01 11:18:10 -0200" MODIFIED_BY="[Empty name]" NAME="CTRI/2010/091/003065" YEAR="2011">
<REFERENCE MODIFIED="2017-12-01 11:18:10 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>CTRI/2010/091/003065</AU>
<TI>A clinical trial to study the effect of nebulized hypertonic saline as compared to normal saline in infants and children with bronchiolitis</TI>
<TO>Study of nebulized hypertonic saline in the treatment of bronchiolitis in infants and children</TO>
<SO>ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=2459</SO>
<YR>(first received 1 November 2011)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:20:08 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221703"/><IDENTIFIER MODIFIED="2017-05-10 21:20:08 -0300" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CTRI/2010/091/003065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-EudraCT2009_x002d_014758_x002d_14" MODIFIED="2017-12-01 11:19:18 -0200" MODIFIED_BY="[Empty name]" NAME="EudraCT2009-014758-14" YEAR="2012">
<REFERENCE MODIFIED="2017-12-01 11:19:05 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>EudraCT2009-014758-14</AU>
<TI>Nebulised hypertonic (3%) saline in the treatment of bronchiolitis</TI>
<TO>Does nebulised hypertonic (3%) saline reduce the duration of hospital admission in infants with bronchiolitis?</TO>
<SO>https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014758-14/GB</SO>
<YR>(first received 17 March 2010)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221706"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 22:01:40 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221705"/><IDENTIFIER MODIFIED="2017-05-10 22:01:40 -0300" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="EUCTR200901475814GB"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00677729" MODIFIED="2017-11-21 02:39:35 -0200" MODIFIED_BY="[Empty name]" NAME="NCT00677729" YEAR="2008">
<REFERENCE MODIFIED="2017-06-12 22:30:59 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00677729</AU>
<TI>Hypertonic saline to reduce hospital admissions in bronchiolitis</TI>
<TO>Inhaled hypertonic saline to reduce hospital admissions in infants with viral bronchiolitis (HS in ER study)</TO>
<SO>clinicaltrials.gov/ct2/show/NCT00677729</SO>
<YR>(first received 2 May 2008)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221708"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:14:59 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221707"/><IDENTIFIER MODIFIED="2017-05-07 15:29:39 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00677729"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01777347" MODIFIED="2017-11-21 02:39:28 -0200" MODIFIED_BY="[Empty name]" NAME="NCT01777347" YEAR="2012">
<REFERENCE MODIFIED="2017-06-12 22:30:54 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01777347</AU>
<TI>Efficacy of 3% hypertonic saline in acute viral bronchiolitis (GUERANDE)</TI>
<TO>3% hypertonic saline to reduce hospitalization rate in acute viral bronchiolitis: a randomized double blind clinical trial</TO>
<SO>clinicaltrials.gov/ct2/show/NCT01777347</SO>
<YR>(first received 14 November 2012)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221710"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:17:41 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221709"/><IDENTIFIER MODIFIED="2017-05-10 21:17:41 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01777347"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT01834820" MODIFIED="2017-11-21 02:39:17 -0200" MODIFIED_BY="[Empty name]" NAME="NCT01834820" YEAR="2013">
<REFERENCE MODIFIED="2017-11-21 02:28:57 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01834820</AU>
<TI>Epinephrine, dexamethasone, and hypertonic saline in bronchiolitis, randomised clinical trial of efficacy and safety</TI>
<TO>Pilot study: epinephrine, dexamethasone, and hypertonic saline in children with bronchiolitis, randomised clinical trial of efficacy and safety</TO>
<SO>clinicaltrials.gov/ct2/show/NCT01834820</SO>
<YR>(first received 15 January 2013)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:16:12 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221711"/><IDENTIFIER MODIFIED="2017-05-10 21:16:12 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01834820"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02029040" MODIFIED="2017-11-21 02:38:53 -0200" MODIFIED_BY="[Empty name]" NAME="NCT02029040" YEAR="2014">
<REFERENCE MODIFIED="2017-11-21 02:24:22 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02029040</AU>
<TI>Nebulized 3% hypertonic saline in the treatment of acute bronchiolitis</TI>
<TO>A randomized trial of nebulized 3% hypertonic saline in the treatment of acute bronchiolitis in the emergency department</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02029040</SO>
<YR>(first received 3 January 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221714"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-06-08 20:33:00 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221713"/><IDENTIFIER MODIFIED="2017-05-10 21:10:17 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02029040"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02045238" MODIFIED="2017-11-21 02:47:31 -0200" MODIFIED_BY="[Empty name]" NAME="NCT02045238" YEAR="2014">
<REFERENCE MODIFIED="2017-11-21 02:36:45 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02045238</AU>
<TI>Inhaled hypertonic saline use in the emergency department to treat acute viral bronchiolitis</TI>
<TO>Study of the effect of inhaled 3% hypertonic saline compared with normal saline (0.9%) for the treatment of acute viral bronchiolitis in a short stay ward</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02045238</SO>
<YR>(first received 22 January 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221716"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:18:29 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221715"/><IDENTIFIER MODIFIED="2017-05-10 21:18:29 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02045238"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02233985" MODIFIED="2017-11-21 02:47:53 -0200" MODIFIED_BY="[Empty name]" NAME="NCT02233985" YEAR="2014">
<REFERENCE MODIFIED="2017-06-12 22:31:27 -0300" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02233985</AU>
<TI>Nebulized 3% hypertonic saline solution treatment of bronchiolitis in infants</TI>
<TO>A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in pediatric hospital</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02233985</SO>
<YR>(first received 7 May 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221718"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:24:04 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221717"/><IDENTIFIER MODIFIED="2017-05-10 21:24:04 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02233985"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT02834819" MODIFIED="2017-12-01 10:47:20 -0200" MODIFIED_BY="[Empty name]" NAME="NCT02834819" YEAR="2016">
<REFERENCE MODIFIED="2017-12-01 10:47:20 -0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02834819</AU>
<TI>Nebulized 3% hypertonic saline vs. standard of care in patients with bronchiolitis</TI>
<TO>A randomized controlled trial of nebulized 3% hypertonic saline vs. standard of care in patients with bronchiolitis</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02834819</SO>
<YR>(first received 15 July 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7221720"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-05-10 21:14:53 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7221719"/><IDENTIFIER MODIFIED="2017-05-10 21:13:06 -0300" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02834819"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2017-06-08 20:44:48 -0300" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-12-05 04:14:46 -0200" MODIFIED_BY="Liz Dooley">
<ADDITIONAL_REFERENCES MODIFIED="2017-12-05 04:14:46 -0200" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Assouline-1977" MODIFIED="2017-05-04 04:14:22 -0300" MODIFIED_BY="[Empty name]" NAME="Assouline 1977" TYPE="JOURNAL_ARTICLE">
<AU>Assouline G, Leibson V, Danon A</AU>
<TI>Stimulation of prostaglandin output from rat stomach by hypertonic solution</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1977</YR>
<VL>44</VL>
<NO>3</NO>
<PG>271-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2017-11-21 02:48:56 -0200" MODIFIED_BY="[Empty name]" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al; GRADE Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Badgett-2015" MODIFIED="2017-05-04 04:09:06 -0300" MODIFIED_BY="[Empty name]" NAME="Badgett 2015" TYPE="JOURNAL_ARTICLE">
<AU>Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R</AU>
<TI>A living systematic review of nebulized hypertonic saline for acute bronchiolitis in infants</TI>
<SO>JAMA Pediatrics</SO>
<YR>2015</YR>
<VL>169</VL>
<NO>8</NO>
<PG>788-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertrand-2001" NAME="Bertrand 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bertrand P, Aranibar H, Castro E, Sanchez I</AU>
<TI>Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>4</NO>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2014" MODIFIED="2017-06-06 23:31:13 -0300" MODIFIED_BY="[Empty name]" NAME="Chen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Chen YJ, Lee WL, Wang CM, Chou HH</AU>
<TI>Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: an updated meta-analysis</TI>
<SO>Pediatrics and Neonatology</SO>
<YR>2014</YR>
<VL>55</VL>
<NO>6</NO>
<PG>431-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daviskas-1996" MODIFIED="2011-01-23 16:36:31 -0200" MODIFIED_BY="[Empty name]" NAME="Daviskas 1996" TYPE="JOURNAL_ARTICLE">
<AU>Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP, et al</AU>
<TI>Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>4</NO>
<PG>725-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enriquez-2012" MODIFIED="2017-05-04 04:15:15 -0300" MODIFIED_BY="[Empty name]" NAME="Enriquez 2012" TYPE="COCHRANE_REVIEW">
<AU>Enriquez A, Chu IW, Mellis C, Lin WY</AU>
<TI>Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-04-23 00:37:06 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-23 00:37:06 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008395.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fernandes-2015" MODIFIED="2017-10-08 19:51:41 -0300" MODIFIED_BY="Liz Dooley" NAME="Fernandes 2015" TYPE="JOURNAL_ARTICLE">
<AU>Fernandes RM, Plint AC, Terwee CB, Sampaio C, Klassen TP, Offringa M, et al</AU>
<TI>Validity of bronchiolitis outcome measures</TI>
<SO>Pediatrics</SO>
<YR>2015</YR>
<VL>135</VL>
<NO>6</NO>
<PG>e1399-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x00ed_a_x002d_Garc_x00ed_a-2006" MODIFIED="2017-05-04 04:11:14 -0300" MODIFIED_BY="[Empty name]" NAME="García-García 2006" TYPE="JOURNAL_ARTICLE">
<AU>García-García ML, Calvo C, Pérez-Breña P, De Cea JM, Acosta B, Casas I</AU>
<TI>Prevalence and clinical characteristics of human metapneumovirus infections in hospitalized infants in Spain</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>9</NO>
<PG>863-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2017-04-20 03:51:24 -0300" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>2014</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2011" MODIFIED="2013-04-23 00:36:02 -0300" MODIFIED_BY="[Empty name]" NAME="Hartling 2011" TYPE="COCHRANE_REVIEW">
<AU>Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al</AU>
<TI>Epinephrine for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-04-23 00:35:27 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-23 00:35:27 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003123.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson-1979" MODIFIED="2017-05-04 04:15:59 -0300" MODIFIED_BY="[Empty name]" NAME="Henderson 1979" TYPE="JOURNAL_ARTICLE">
<AU>Henderson FW, Clyde WA Jr, Collier AM, Denny FW, Senior RJ, Sheaffer CI, et al</AU>
<TI>The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice</TI>
<SO>Journal of Pediatrics</SO>
<YR>1979</YR>
<VL>95</VL>
<NO>2</NO>
<PG>183-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-07-19 06:46:53 -0300" MODIFIED_BY="Jenny Bellorini" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-11-21 02:53:58 -0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacques-2006" MODIFIED="2011-01-23 16:36:58 -0200" MODIFIED_BY="[Empty name]" NAME="Jacques 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jacques J, Bouscambert-Duchamp M, Moret H, Carquin J, Brodard V, Lina B, et al</AU>
<TI>Association of respiratory picornaviruses with acute bronchiolitis in French infants</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>4</NO>
<PG>463-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kellett-2005" NAME="Kellett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kellett F, Redfern J, Niven RM</AU>
<TI>Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis</TI>
<SO>Respiratory Medicine</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1997a" NAME="Klassen 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP</AU>
<TI>Recent advances in the treatment of bronchiolitis and laryngitis</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>1</NO>
<PG>249-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1997b" MODIFIED="2017-11-21 02:55:59 -0200" MODIFIED_BY="[Empty name]" NAME="Klassen 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM</AU>
<TI>Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>130</VL>
<NO>2</NO>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maguire-2015" MODIFIED="2017-11-21 02:56:39 -0200" MODIFIED_BY="[Empty name]" NAME="Maguire 2015" TYPE="JOURNAL_ARTICLE">
<AU>Maguire C, Cantrill H, Hind D, Bradburn M, Everard M</AU>
<TI>Hypertonic saline (HS) for acute bronchiolitis: systematic review and meta-analysis</TI>
<SO>BMC Pulmonary Medicine</SO>
<YR>2015</YR>
<VL>15</VL>
<PG>148</PG>
<IDENTIFIERS MODIFIED="2017-05-04 04:17:22 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-05-04 04:17:22 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/s12890-015-0140-x"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mandelberg-2010" MODIFIED="2017-11-21 02:57:06 -0200" MODIFIED_BY="[Empty name]" NAME="Mandelberg 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mandelberg A, Amirav I</AU>
<TI>Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>1</NO>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meissner-2003" MODIFIED="2013-04-14 20:50:06 -0300" MODIFIED_BY="[Empty name]" NAME="Meissner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Meissner HC</AU>
<TI>Selected populations at increased risk from respiratory syncytial virus infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 2</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nasr-2001" MODIFIED="2011-01-23 16:37:35 -0200" MODIFIED_BY="[Empty name]" NAME="Nasr 2001" TYPE="JOURNAL_ARTICLE">
<AU>Nasr SZ, Strouse PJ, Soskoline E, Maxvold NJ, Garver KA, Rubin BK, et al</AU>
<TI>Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>120</VL>
<NO>1</NO>
<PG>203-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panitch-1993" NAME="Panitch 1993" TYPE="JOURNAL_ARTICLE">
<AU>Panitch HB, Callahan CW, Schidlow DV</AU>
<TI>Bronchiolitis in children</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>4</NO>
<PG>715-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panitch-2003" NAME="Panitch 2003" TYPE="JOURNAL_ARTICLE">
<AU>Panitch HB</AU>
<TI>Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl</NO>
<PG>83-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rakshi-1994" MODIFIED="2008-05-13 20:39:57 -0300" MODIFIED_BY="[Empty name]" NAME="Rakshi 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rakshi K, Couriel JM</AU>
<TI>Management of acute bronchiolitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1994</YR>
<VL>71</VL>
<NO>5</NO>
<PG>463-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-02-23 08:57:58 -0300" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-1997" MODIFIED="2011-01-23 16:37:43 -0200" MODIFIED_BY="[Empty name]" NAME="Robinson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Hemming A, Regnis J, Wong A, Bailey D, Bautotvich GJ, et al</AU>
<TI>Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>10</NO>
<PG>900-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roqu_x00e9_-i-Figuls-2016" MODIFIED="2017-04-06 22:54:13 -0300" MODIFIED_BY="[Empty name]" NAME="Roqué i Figuls 2016" TYPE="COCHRANE_REVIEW">
<AU>Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C, Vilaró J</AU>
<TI>Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2016</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-04-06 22:51:01 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-04-06 22:51:01 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004873.pub5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rose-1987" MODIFIED="2017-05-04 04:19:04 -0300" MODIFIED_BY="[Empty name]" NAME="Rose 1987" TYPE="JOURNAL_ARTICLE">
<AU>Rose RM, Pinkston P, O'Donnell C, Jensen WA</AU>
<TI>Viral infection of the lower respiratory tract</TI>
<SO>Clinical Chest Medicine</SO>
<YR>1987</YR>
<VL>8</VL>
<PG>405-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schuh-1992" MODIFIED="2017-05-04 04:20:40 -0300" MODIFIED_BY="[Empty name]" NAME="Schuh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, et al</AU>
<TI>Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>90</VL>
<NO>6</NO>
<PG>920-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-1999" MODIFIED="2008-07-06 09:59:36 -0300" MODIFIED_BY="Jenny Bellorini" NAME="Shay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ</AU>
<TI>Bronchiolitis hospitalizations</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>15</NO>
<PG>1440-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-2001" MODIFIED="2017-05-04 04:21:33 -0300" MODIFIED_BY="[Empty name]" NAME="Shay 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ</AU>
<TI>Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children 1979-1997</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shi-2017" MODIFIED="2017-12-05 04:14:46 -0200" MODIFIED_BY="Liz Dooley" NAME="Shi 2017" TYPE="JOURNAL_ARTICLE">
<AU>Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al</AU>
<TI>Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study</TI>
<SO>Lancet</SO>
<YR>2017</YR>
<VL>390</VL>
<NO>10098</NO>
<PG>946-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shoseyov-1998" NAME="Shoseyov 1998" TYPE="JOURNAL_ARTICLE">
<AU>Shoseyov D, Bibi H, Shai P, Ahoseyov N, Shazberg G, Hurvitz H</AU>
<TI>Treatment with hypertonic saline versus normal saline nasal wash of pediatric chronic sinusitis</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>5</NO>
<PG>602-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-StataCorp-2009" MODIFIED="2017-04-20 03:50:50 -0300" MODIFIED_BY="[Empty name]" NAME="StataCorp 2009" TYPE="COMPUTER_PROGRAM">
<TI>Stata Statistical Software</TI>
<YR>2009</YR>
<EN>11</EN>
<PB>StataCorp LP</PB>
<CY>College Station, TX</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wainwright-2003" MODIFIED="2017-05-04 04:22:14 -0300" MODIFIED_BY="[Empty name]" NAME="Wainwright 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wainwright C, Altamirano L, Cheney M, Cheney J, Barber S, Price D, et al</AU>
<TI>A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>1</NO>
<PG>27-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wan-2014" MODIFIED="2017-05-04 04:23:19 -0300" MODIFIED_BY="[Empty name]" NAME="Wan 2014" TYPE="JOURNAL_ARTICLE">
<AU>Wan X, Wang W, Liu J, Tong T</AU>
<TI>Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>135</PG>
<IDENTIFIERS MODIFIED="2017-05-04 04:23:19 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-05-04 04:23:19 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2288-14-135"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-1992" MODIFIED="2008-07-06 09:59:49 -0300" MODIFIED_BY="Jenny Bellorini" NAME="Wang 1992" TYPE="JOURNAL_ARTICLE">
<AU>Wang EE, Milner RA, Navas L, Maj H</AU>
<TI>Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1992</YR>
<VL>145</VL>
<NO>1</NO>
<PG>106-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wark-2009" MODIFIED="2013-04-20 23:10:11 -0300" MODIFIED_BY="[Empty name]" NAME="Wark 2009" TYPE="COCHRANE_REVIEW">
<AU>Wark PAB, McDonald V</AU>
<TI>Nebulised hypertonic saline for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-03-31 01:02:33 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-03-31 01:02:33 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001506.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wohl-1978" MODIFIED="2017-05-04 04:25:35 -0300" MODIFIED_BY="[Empty name]" NAME="Wohl 1978" TYPE="JOURNAL_ARTICLE">
<AU>Wohl MEB, Chernick V</AU>
<TI>State of the art: bronchiolitis</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1978</YR>
<VL>118</VL>
<NO>4</NO>
<PG>759-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wohl-2003" MODIFIED="2017-05-04 04:28:45 -0300" MODIFIED_BY="[Empty name]" NAME="Wohl 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wohl ME, Chernick VC</AU>
<TI>Treatment of acute bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>1</NO>
<PG>82-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2003" MODIFIED="2017-05-04 04:29:21 -0300" MODIFIED_BY="[Empty name]" NAME="Zhang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Ferruzzi E, Bonfanti T, Auler MI, Davila NE, Faria CS, et al</AU>
<TI>Long and short-term effect of prednisolone in hospitalized infants with acute bronchiolitis</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>7</NO>
<PG>548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ziment-1978" MODIFIED="2013-07-19 06:46:53 -0300" MODIFIED_BY="[Empty name]" NAME="Ziment 1978" TYPE="BOOK">
<AU>Ziment I</AU>
<SO>Respiratory Pharmacology and Therapeutics</SO>
<YR>1978</YR>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-11-21 03:07:51 -0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Zhang-2008" MODIFIED="2013-04-15 02:22:01 -0300" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP</AU>
<TI>Nebulized hypertonic saline solution for acute bronchiolitis in infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-15 02:22:01 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-15 02:22:01 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006458.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2011" MODIFIED="2013-04-15 02:22:51 -0300" MODIFIED_BY="[Empty name]" NAME="Zhang 2011" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP</AU>
<TI>Nebulized hypertonic saline solution for acute bronchiolitis in infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006458.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2013" MODIFIED="2017-02-18 19:06:04 -0200" MODIFIED_BY="[Empty name]" NAME="Zhang 2013" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP</AU>
<TI>Nebulised hypertonic saline solution for acute bronchiolitis in infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2017-02-18 19:06:04 -0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-18 19:06:04 -0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006458.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2015" MODIFIED="2017-06-06 23:02:48 -0300" MODIFIED_BY="[Empty name]" NAME="Zhang 2015" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C</AU>
<TI>Nebulized hypertonic saline for acute bronchiolitis: a systematic review</TI>
<SO>Pediatrics</SO>
<YR>2015</YR>
<VL>136</VL>
<NO>4</NO>
<PG>687-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2016" MODIFIED="2017-11-21 03:07:51 -0200" MODIFIED_BY="[Empty name]" NAME="Zhang 2016" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C</AU>
<TI>Nebulized hypertonic saline for acute bronchiolitis: a systematic review [erratum]</TI>
<SO>Pediatrics</SO>
<YR>2016</YR>
<VL>137</VL>
<NO>4</NO>
<PG>e20160017</PG>
<IDENTIFIERS MODIFIED="2017-05-21 20:46:18 -0300" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-05-21 20:46:18 -0300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1542/peds.2016-0017"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2017-12-05 19:37:14 -0200" MODIFIED_BY="Liz Dooley"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-12-05 19:37:14 -0200" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2017-11-19 19:26:57 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Ansari-2010"><CHAR_METHODS MODIFIED="2013-04-15 04:14:01 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:26:57 -0200" MODIFIED_BY="[Empty name]"><P>Setting: paediatric emergency facility in Qatar<BR/>Assessed for eligibility: 187<BR/>Randomised: 115 hypertonic saline group (5% saline: 57; 3% saline: 58); 56 normal saline group<BR/>Completed: 115 hypertonic saline group; 56 normal saline group<BR/>Gender (male): 59.1%<BR/>Age (mean ± SD): 3.8 ± 2.8 months in 3% saline group; 4.0 ± 2.5 months in 5% saline group; 3.3 ± 2.4 months in normal saline group</P><P>Inclusion criteria: infants aged &#8804; 18 months, with a prodromal history of viral upper respiratory tract infection, followed by wheezing or crackles, or both on auscultation and Wang clinical severity score &#8805; 4</P><P>Exclusion criteria: born at &#8804; 34 weeks&#8217; gestation, previous history of wheezing, steroid use within 48 h of presentation, obtundation and progressive respiratory failure requiring ICU admission, history of apnoea within 24 hours before presentation, SaO&#8322; &#8804; 85% on room air at the time of recruitment, history of a diagnosis of chronic lung disease, congenital heart disease, or immunodeficiency</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-19 19:18:13 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups:<BR/>Group 1: nebulised 5% hypertonic saline (5 mL) plus 1.5 mL of epinephrine<BR/>Group 2: nebulised 3% hypertonic saline (5 mL) plus 1.5 mL of epinephrine</P><P>Control group: nebulised 0.9% normal saline (5 mL) plus 1.5 mL of epinephrine<BR/></P><P>Treatment was given every 4 hours, until the patient was ready for discharge. Nebulised medications were delivered through a tight-fitting face mask by pressurised oxygen with the flow meter set at 10 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:18:19 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Oxygen saturation</LI><LI>Length of stay</LI><LI>Need for ICU admission</LI><LI>Rate of re-admission</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2013-03-31 15:02:44 -0300" MODIFIED_BY="[Empty name]"><P>Virological identification not available</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-19 19:26:40 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Angoulvant-2017"><CHAR_METHODS MODIFIED="2017-08-28 19:53:13 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:26:40 -0200" MODIFIED_BY="[Empty name]"><P>Setting: 24 paediatric emergency departments in France<BR/>Assessed for eligibility: 2445<BR/>Randomised: 387 hypertonic saline group; 390 normal saline group<BR/>Completed: 385 hypertonic saline group; 387 normal saline group<BR/>Gender (male): 60.2%<BR/>Age: median (interquartile range): 3 (2 to 5) months in hypertonic saline group; 3 (2 to 5) months in normal saline group</P><P>Inclusion criteria: infants aged 6 weeks to 12 months with first episode of moderate to severe bronchiolitis defined as viral upper respiratory tract infection plus wheezing or crackles, or both on chest auscultation with respiratory distress</P><P>Exclusion criteria: premature birth (birth before 37 weeks of gestation), immunologic, cardiac or chronic pulmonary disease, bone malformation of the chest, previous use of nebulised hypertonic saline, inability to communicate with the family (a language barrier or lack of telephone for contact), need of admission to a paediatric ICU</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-19 19:21:55 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups: nebulised 3% hypertonic saline (4 mL)<BR/></P><P>Control groups: nebulised 0.9% normal saline (4 mL)<BR/></P><P>Study medication was given at 0 and 30 min using a jet nebuliser through a firmly applied face mask with an oxygen flow rate of 6 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:22:17 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Hospital admission up to 24 hours after enrolment</LI><LI>Admission within 28 days</LI><LI>Changes in RDAI score</LI><LI>Duration of symptoms</LI><LI>Length of hospital stay for hospitalised infants</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-08-28 20:25:41 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 84.5% in hypertonic saline group; 88.2% in control group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-19 19:31:06 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010"><CHAR_METHODS MODIFIED="2013-04-15 04:14:05 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:28:02 -0200" MODIFIED_BY="[Empty name]"><P>Setting: emergency department of a teaching hospital in Turkey<BR/>Assessed for eligibility: 190<BR/>Randomised: 75 hypertonic saline group; 111 normal saline group<BR/>Completed: 75 hypertonic saline group; 111 normal saline group<BR/>Gender (male): 64.5%<BR/>Age (mean ± SD): 9.5 ± 5.3 months (range 1.5 to 24 months)</P><P>Inclusion criteria: infants with diagnosis of bronchiolitis requiring a history of upper respiratory infection and the presence of bilateral wheezing or crackles, or both on chest auscultation, plus clinical severity score between 1 and 9</P><P>Exclusion criteria: prematurity, any underlying disease (e.g. cystic fibrosis, bronchopulmonary dysplasia, and cardiac or renal disease), prior history of wheezing, atopic dermatitis, allergic rhinitis or asthma, SaO&#8322; &lt; 85% on room air, clinical severity score &gt; 9, obtunded consciousness, progressive respiratory failure requiring mechanical ventilation, previous treatment with bronchodilators, and any steroid therapy within 2 weeks</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-19 19:30:23 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups:<BR/>Group 1: nebulised 3% hypertonic saline (4 mL) plus 1.5 mg epinephrine<BR/>Group 2: nebulised 3% hypertonic saline (4 mL) plus 2.5 mg salbutamol</P><P>Control groups:<BR/>Group 3: nebulised 0.9% normal saline (4 mL) plus 1.5 mg epinephrine<BR/>Group 4: nebulised 0.9% normal saline (4 mL) plus 2.5 mg salbutamol<BR/>Group 5: nebulised 0.9% normal saline (4 mL) alone<BR/></P><P>The study drug was administered at 0 and 30 min by Medic-Aid Sidestream nebuliser (Medic-Aid Ltd., West Sussex, UK) using a face mask with continuous flow of 100% oxygen at 6 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:30:52 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Oxygen saturation</LI><LI>Heart rate</LI><LI>Rate of hospitalisation</LI><LI>Rate of re-admission</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-19 19:31:06 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-19 19:42:41 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Everard-2014"><CHAR_METHODS MODIFIED="2016-11-27 16:21:05 -0200" MODIFIED_BY="[Empty name]"><P>Design: multicentre, parallel-group, open, randomised controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:35:46 -0200" MODIFIED_BY="[Empty name]"><P>Setting: assessment units and paediatric wards of 10 participating centres in England and Wales<BR/>Assessed for eligibility: 772<BR/>Randomised: 158 hypertonic saline group (3% saline); 159 standard care group<BR/>Completed: 141 hypertonic saline group; 149 standard care group<BR/>Gender (male): 54.5%<BR/>Age (mean ± SD): 3.3 ± 2.6 months in hypertonic saline group; 3.4 ± 2.8 months in standard care group</P><P>Inclusion criteria: infants &lt; 12 months with diagnosis of bronchiolitis defined as an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation, needing supplementary oxygen for SaO&#8322; of &lt; 92% in air</P><P>Exclusion criteria: history of wheezy bronchitis or asthma, gastro-oesophageal reflux, previous lower respiratory tract infections, risk factors for severe disease, carers lacking fluent English in the absence of translator service, and requiring admission to high dependency or intensive care units at presentation</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-19 19:40:27 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: 4 mL 3% saline + standard care<BR/></P><P>Control group: standard care<BR/></P><P>Hypertonic saline given every 6 h, administered via PARI Sprint nebuliser with appropriate face mask, until primary outcome achieved.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:42:41 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Time to fit for discharge (75% of usual intake and SaO&#8322; &#8805; 92% for 6 h at room air)</LI><LI>Actual time to discharge</LI><LI>Re-admission within 28 days from randomisation</LI><LI>Health care usage</LI><LI>Duration of respiratory symptoms postdischarge</LI><LI>Infant Toddler Quality of Life</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:35:18 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 58.5% in hypertonic saline group; 64.4% in control group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:19:49 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores-2016"><CHAR_METHODS MODIFIED="2017-02-16 09:51:22 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:47:25 -0200" MODIFIED_BY="[Empty name]"><P>Setting: paediatric ward of a general urban hospital in Portugal<BR/>Assessed for eligibility: not stated<BR/>Randomised: 38 hypertonic saline group (3% saline); 40 normal saline group<BR/>Completed: 33 hypertonic saline group; 35 normal saline group<BR/>Gender (male): 52.9%<BR/>Age (mean ± SD): 3.3 ± 2.4 months hypertonic saline group; 3.8 ± 2.5 months normal saline group</P><P>Inclusion criteria: infants aged &lt; 12 months with acute bronchiolitis, defined as an apparent viral respiratory tract infection manifest by nasal discharge and wheezy cough, with presence of fine inspiratory crackles and/or high-pitched expiratory wheeze, even apnoea</P><P>Exclusion criteria: previous episodes of wheezing, personal history of prematurity (gestational age &lt; 34 weeks), physician diagnosis of eczema, food allergy, or chronic (cardiac, respiratory, immunological, neurological, or metabolic) disease and high severity criteria (coma, respiratory rate &gt; 80 breaths/minute, SaO&#8322; &lt; 88% on room air or need for assisted ventilation)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:19:49 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (3 mL) plus 0.25 mL (1.25 mg) salbutamol</P><P>Control group: nebulised 0.9% normal saline (3 mL) plus 0.25 mL (1.25 mg) salbutamol</P><P>Treatment was given every 6 h until discharge. All inhaled therapies were delivered through a tight-fitting face mask from an oxygen-driven nebuliser (Cirrus 2 Nebuliser, Wokingham, Berkshire, UK), connected to a source of pressurised oxygen from the wall, set to a flow rate of 6 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:51:24 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay (fit to discharge and actual discharge)</LI><LI>Wang severity score</LI><LI>Need for supplemental oxygen and tube feeding and their duration</LI><LI>Need for other treatments (further doses of salbutamol, nebulised epinephrine, systemic corticosteroids, antibiotics, or diuretics)</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:43:48 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 87.9% in hypertonic saline group; 82.9% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-19 19:59:48 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Florin-2014"><CHAR_METHODS MODIFIED="2017-02-16 09:55:20 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:56:15 -0200" MODIFIED_BY="[Empty name]"><P>Setting: urban paediatric emergency department in USA<BR/>Assessed for eligibility: 2256<BR/>Randomised: 31 hypertonic saline group (3% saline); 31 normal saline group<BR/>Completed: 31 hypertonic saline group; 31 normal saline group<BR/>Gender (male): 45.2%<BR/>Age (mean ± SD): 7.2 ± 5.1 months in hypertonic saline group; 6.1 ± 3.6 months in normal saline group</P><P>Inclusion criteria: children aged 2 months up to 24 months presenting to the emergency department with acute bronchiolitis, defined as a first episode of wheezing associated with signs and symptoms of respiratory distress and upper respiratory infection, with RDAI score of 4 to 15 (moderate to severe)</P><P>Exclusion criteria: infants with a history of wheezing or asthma, bronchodilator therapy prior to the current illness, chronic lung or heart disease, critical illness, inability to receive nebulised medications, and infants with non&#8211;English-speaking guardians</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-19 19:59:00 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL)</P><P>Control group: nebulised 0.9% normal saline (4 mL)</P><P>Treatment delivered using a jet nebuliser with an oxygen flow rate of 8 L/min. Study medication was given within 90 minutes after albuterol administration.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:59:19 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Respiratory assessment change score (RACS)</LI><LI>Heart rate</LI><LI>Respiratory rate</LI><LI>Oxygen saturation</LI><LI>Rate of hospitalisation</LI><LI>Physician clinical impression (i.e. overall rating of clinical severity, categorised as mild, moderate, or severe)</LI><LI>Parental perception of improvement in breathing and feeding (i.e. improved, worse, or unchanged)</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-19 19:59:48 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-12-05 19:36:53 -0200" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Grewal-2009"><CHAR_METHODS MODIFIED="2013-04-15 04:14:09 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-09-26 18:06:03 -0300" MODIFIED_BY="[Empty name]"><P>Setting: emergency department of a children's hospital in Canada<BR/>Assessed for eligibility: not stated<BR/>Randomised: 24 hypertonic saline group; 24 normal saline group<BR/>Completed: 23 hypertonic saline group; 23 normal saline group<BR/>Gender (male): 60.9%<BR/>Age (mean ± SD): 5.6 ± 4.0 months in hypertonic saline group; 4.4 ± 3.4 months in normal saline group</P><P>Inclusion criteria: infants aged 6 weeks to 12 months presenting with a first episode of wheezing and clinical symptoms of a viral respiratory infection, plus an initial SaO&#8322; of 85% or more but 96% or less, and RDAI score &#8805; 4</P><P>Exclusion criteria: pre-existing cardiac or pulmonary disease, previous diagnosis of asthma by a physician, any previous use of bronchodilators (except for treatment of the current illness), severe disease requiring resuscitation room care, inability to take medication using a nebuliser, inability to obtain informed consent secondary to a language barrier, or no phone access for follow-up</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-12-05 19:36:53 -0200" MODIFIED_BY="Liz Dooley"><P>Intervention group: nebulised 3% hypertonic saline (2.5 mL) plus 0.5 mL 2.25% racaemic epinephrine<BR/>Control group: nebulised 0.9% normal saline (2.5 mL) plus 0.5 mL 2.25% racaemic epinephrine<BR/>Both groups received inhalation solutions at 0 minutes.</P><P>Each treatment was given by nebuliser with continuous flow of oxygen at 6 L/min. 2 doses of the study drug were available for each infant such that, if the physician felt that a second dose of racaemic epinephrine was needed during the 120-minute study period, the infant received the same drug combination again.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 00:52:01 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Respiratory assessment change score</LI><LI>Oxygen saturation</LI><LI>Rate of hospitalisation</LI><LI>Rate of re-admission</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:44:11 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 82.6% in hypertonic saline group; 81.8% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 00:58:24 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ipek-2011"><CHAR_METHODS MODIFIED="2017-09-15 08:48:06 -0300" MODIFIED_BY="[Empty name]"><P>Design: quasi-randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 00:53:19 -0200" MODIFIED_BY="[Empty name]"><P>Setting: paediatric emergency department of a training and research hospital in Turkey<BR/>Eligible: not stated<BR/>Randomised: 60 hypertonic saline group; 60 normal saline group<BR/>Completed: 60 hypertonic saline group; 60 normal saline group<BR/>Gender (male): 59.2%<BR/>Age (mean ± SD): 7.9 ± 3.9 months</P><P>Inclusion criteria: age &lt; 2 years, a history of preceding viral upper respiratory infection followed by wheezing and crackles on auscultation, and a clinical severity score of 4 to 8 on admission</P><P>Exclusion criteria: infants with clinical severity score &lt; 4 or &gt; 8, SaO&#8322; &lt; 85% on room air, chronic cardiac illness, premature birth, birth weight &lt; 2500 g, history of recurrent wheezing episodes, proven immune deficiency, severe neurological disease, age &lt; 1 month or &gt; 2 years, consolidation or atelectasis on a chest roentgenogram</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 00:57:57 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups:<BR/>Group 1: nebulised 3% hypertonic saline (4 mL) plus salbutamol 0.15 mg/kg<BR/>Group 2: nebulised 3% hypertonic saline (4 mL) alone</P><P>Control groups:<BR/>Group 1: nebulised 0.9% hypertonic saline (4 mL) plus salbutamol 0.15 mg/kg<BR/>Group 2: nebulised 0.9% hypertonic saline (4 mL) alone<BR/></P><P>The treatment was given every 20 min until 3 doses had been administered (0, 20, and 40 min). All inhaled therapies were delivered via a compressor nebuliser through a face mask with continued flow of oxygen at 4 to 5 L/min (Mini Compressor Nebulizer, CN-02WD, Ace-Tec Co., Ltd., Guangdong, China).</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 00:58:11 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Oxygen saturation</LI><LI>Respiratory rate</LI><LI>Heart rate</LI><LI>Corticosteroid need</LI><LI>Rate of hospitalisation</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 00:58:24 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-12-05 19:37:01 -0200" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Jacobs-2014"><CHAR_METHODS MODIFIED="2017-02-16 10:50:00 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:02:26 -0200" MODIFIED_BY="[Empty name]"><P>Setting: emergency department of an urban tertiary care centre in the USA<BR/>Assessed for eligibility: 128<BR/>Randomised: 52 hypertonic saline group; 49 normal saline group<BR/>Completed: 52 hypertonic saline group; 49 normal saline group<BR/>Gender (male): 63.3%<BR/>Age (mean ± SD): 6.0 ± 3.9 months in hypertonic saline group; 5.6 ± 3.3 months in normal saline group</P><P>Inclusion criteria: infants aged 6 weeks to 18 months presenting to the emergency department with acute bronchiolitis, defined as viral respiratory illness and first episode of wheeze, and a modified Wang clinical severity score of &#8805; 4</P><P>Exclusion criteria: previous history of wheezing, any use of bronchodilators within 2 hours of presentation, gestational age &#8804; 34 weeks, history of congenital heart disease or chronic pulmonary or chronic renal disease, SaO&#8322; &#8804; 85% at the time of recruitment, severe disease requiring ICU admission, or inability to obtain informed consent</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-12-05 19:37:01 -0200" MODIFIED_BY="Liz Dooley"><P>Intervention group: nebulised 7% hypertonic saline (3 mL) plus 2.25% racaemic epinephrine (0.5 mL)<BR/>Control group: nebulised 0.9% hypertonic saline (3 mL) plus 2.25% racemic epinephrine (0.5 mL)<BR/></P><P>The medication was given via a nebuliser driven by oxygen flow at 6 L/min after initial screening and assessment. If admitted, the infant continued to receive the same designated medication every 6 h until discharge or 24 h after admission.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:04:48 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Modified Wang clinical severity score</LI><LI>Rate of hospitalisation</LI><LI>Discharge rate at 23 h (observation status)</LI><LI>Length of hospital stay</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:36:31 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 68% in hypertonic saline group; 50% in control group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:13:38 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khanal-2015"><CHAR_METHODS MODIFIED="2017-02-16 10:54:43 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:12:31 -0200" MODIFIED_BY="[Empty name]"><P>Setting: emergency and outpatient departments of a children's hospital in Nepal<BR/>Assessed for eligibility: 146<BR/>Randomised: 50 hypertonic saline group (3% saline); 50 normal saline group</P><P>Completed: 49 hypertonic saline group; 50 normal saline group</P><P>Gender (male): 48%<BR/>Age (mean ± SD): 9.8 ± 5.0 months in hypertonic saline group; 9.5 ± 4.2 months in normal saline group</P><P>Inclusion criteria: infants aged 6 weeks to 2 years with acute bronchiolitis defined as the first episode of acute wheezing, starting as a viral upper respiratory infection (coryza, cough or fever), with Wang clinical severity score between 1 and 9</P><P>Exclusion criteria: any underlying disease (e.g. cystic fibrosis, bronchopulmonary dysplasia, and cardiac or renal disease), prior history of wheezing, diagnosed case of asthma, SaO&#8322; &lt; 85% on room air, clinical severity score &gt; 9, progressive respiratory distress requiring mechanical ventilation, previous treatment with bronchodilators within last 4 h, and any steroid therapy within 48 h</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:13:05 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL) plus L-epinephrine (1.5 mg)</P><P>Control group: nebulised 0.9% normal saline (4 mL) plus L-epinephrine (1.5 mg)</P><P>The study drug was administered at 0 and 30 min by a jet nebuliser using a face mask.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:13:34 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Oxygen saturation</LI><LI>Respiratory rate</LI><LI>Heart rate</LI><LI>Discharge readiness at the end of 2 h of observation</LI><LI>Re-admission rate within 24 h following discharge</LI><LI>Socioeconomic burden of illness</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 01:13:38 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:18:52 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuzik-2007"><CHAR_METHODS MODIFIED="2013-04-15 04:14:10 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:16:29 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient wards of 3 regional tertiary care hospitals, 1 in United Arab Emirates and 2 in Canada<BR/>Eligible: not stated<BR/>Randomised: 47 hypertonic saline group; 49 normal saline group<BR/>Completed: 45 hypertonic saline group; 46 normal saline group<BR/>Gender (male): 59.4%<BR/>Age (mean ± SD): 4.7 ± 4.2 months (range 10 days to 18 months)</P><P>Inclusion criteria: infants with diagnosis of moderately severe bronchiolitis requiring a history of a preceding viral upper respiratory infection, the presence of wheezing or crackles on chest auscultation, plus either an SaO&#8322; &lt; 94% in room air or RDAI score &#8805; 4</P><P>Exclusion criteria: previous episode of wheezing, chronic cardiopulmonary disease or immunodeficiency, critical illness at presentation requiring admission to intensive care, the use of nebulised hypertonic saline within the previous 12 h, or premature birth (gestational age &#8804; 34 weeks)<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:18:39 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL)<BR/>Control group: nebulised 0.9% normal saline (4 mL)</P><P>The treatment was given every 2 h for 3 doses, followed by every 4 h for 5 doses, followed by every 6 h until discharge. All inhaled therapies were delivered to a settled infant from a standard oxygen-driven hospital nebuliser through a tight-fitting face mask or head box, whichever the infant tolerated better.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:18:52 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Treatments received during the study</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:45:32 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 62% in hypertonic saline group; 75% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 04:36:00 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-K_x00f6_se-2016"><CHAR_METHODS MODIFIED="2017-02-16 11:08:32 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 04:36:00 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient wards of a children's hospital in Turkey</P><P>Assessed for eligibility: not stated<BR/>Randomised: 35 (3% saline group); 34 (7% saline group); 35 (normal saline group)<BR/>Completed: 35 (3% saline group); 32 (7% saline group); 35 (normal saline group)</P><P>Gender (male): 40.3%<BR/>Age: median (min-max): 7.6 (2 to 23) months in 3% saline group; 7.7 (1 to 24) months in 7% saline group; 7.6 (1 to 18) months in 0.9% saline group</P><P>Inclusion criteria: infants aged 1 to 24 months with clinical diagnosis of bronchiolitis, defined as the first wheezing episode followed by a viral upper respiratory infection, with crackles on auscultation, and Wang clinical severity score &#8805; 4</P><P>Exclusion criteria: infants with clinical severity score &lt; 4, SaO&#8322; &lt; 80% in room air, chronic cardiopulmonary or neurological disease, premature birth, birth weight &lt; 2500 g, history of recurrent wheezing episodes, proven immune deficiency, age &lt; 1 month or &gt; 2 years, proven or suspected acute bacterial infection, previous treatment with bronchodilators or corticosteroids, the presence of symptoms &gt; 7 days, consolidation or atelectasis on a chest roentgenogram</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:27:15 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups: </P><P>Nebulised 3% hypertonic saline (2.5 mL) plus salbutamol (0.15 mg/kg)</P><P>Nebulised 7% hypertonic saline (2.5 mL) plus salbutamol (0.15 mg/kg)<BR/>Control group: nebulised 0.9% normal saline (2.5 mL) plus salbutamol (0.15 mg/kg)</P><P>2 doses were given at 30-minute interval, followed by every 6 h until discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:27:27 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 01:27:48 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:35:23 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2014"><CHAR_METHODS MODIFIED="2017-02-16 11:39:57 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:32:00 -0200" MODIFIED_BY="[Empty name]"><P>Setting: outpatient department of a children's hospital in China<BR/>Assessed for eligibility: not stated<BR/>Randomised: 85 hypertonic saline groups (5% saline: 41; 3% saline: 44); 44 normal saline group<BR/>Completed: 82 hypertonic saline groups (5% saline: 40; 3% saline: 42); 42 normal saline group</P><P>Gender (male): 73.3%<BR/>Age: median (quartiles): 6.7 (3.1) months in 3% saline group; 6.7 (3.6) months in 5% saline group; 7.6 (3.9) months in 0.9% saline group</P><P>Inclusion criteria: infants aged 2 months to 18 months with clinical diagnosis of acute bronchiolitis and Wang clinical severity score &#8805; 4</P><P>Exclusion criteria: severe bronchiolitis (respiratory rate &gt; 80 breaths per minute, SaO&#8322; &lt; 85% on room air or need for mechanical ventilation), immunological deficiency diseases, cardiac diseases, neurological or metabolic diseases, chronic respiratory diseases, prematurity, and previous history of wheezing</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:35:09 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups: </P><P>Nebulised 3% hypertonic saline (3 mL)</P><P>Nebulised 5% hypertonic saline (3 mL)</P><P>Control group: nebulised 0.9% normal saline (3 mL)</P><P>The study drug was administered by a jet nebuliser, twice daily for 3 days.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:35:20 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 01:35:23 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:40:08 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2010"><CHAR_METHODS MODIFIED="2013-04-15 04:14:10 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-04-05 01:46:14 -0300" MODIFIED_BY="[Empty name]"><P>Setting: inpatient wards of a teaching hospital for children in China<BR/>Eligible: not stated<BR/>Randomised: 50 hypertonic saline group; 43 normal saline group<BR/>Completed: 50 hypertonic saline group; 43 normal saline group<BR/>Gender (male): 60.2%<BR/>Age (mean ± SD): 6.0 ± 4.3 months in hypertonic saline group; 5.6 ± 4.5 months in normal saline group</P><P>Inclusion criteria: infants with a diagnosis of mild to moderately severe bronchiolitis</P><P>Exclusion criteria: age &gt; 24 months, previous episode of wheezing, chronic cardiac and pulmonary disease, immunodeficiency, accompanying respiratory failure, requiring mechanical ventilation, inhaling the nebulised 3% hypertonic saline solution and salbutamol 12 h before treatment, and premature infants born at less than 34 weeks gestation<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:40:00 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL) plus 2.5 mg salbutamol<BR/>Control group: nebulised 0.9% normal saline (4 mL) plus 2.5 mg salbutamol<BR/>Infants in each group received 3 treatments every day, delivered at intervals of 8 h until discharge using air-compressed nebulisers.<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:40:08 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Duration of symptoms and signs</LI><LI>Wang clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:46:19 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 70% in hypertonic saline group; 69.7% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:44:25 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2011"><CHAR_METHODS MODIFIED="2013-04-15 04:14:11 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:43:04 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a teaching hospital for children in China<BR/>Assessed for eligibility: not stated<BR/>Randomised: 64 hypertonic saline group; 62 normal saline group<BR/>Completed: 57 hypertonic saline group; 55 normal saline group<BR/>Gender (male): 56.3%<BR/>Age (mean ± SD): 5.9 ± 4.1 months in hypertonic saline group; 5.8 ± 4.3 months in normal saline group</P><P>Inclusion criteria: infants aged &lt; 24 months with a first episode of wheezing, hospitalised for treatment of moderate to severe bronchiolitis</P><P>Exclusion criteria: age &gt; 24 months, previous episode of wheezing, chronic cardiac and pulmonary disease, immunodeficiency, accompanying respiratory failure, requiring mechanical ventilation, inhaling the nebulised 3% hypertonic saline solution 12 h before treatment, and prematurity with birth at &lt; 34 weeks of gestation</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:44:18 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL)<BR/>Control group: nebulised 0.9% normal saline (4 mL)<BR/>The treatment was given every 2 h for 3 doses, followed by every 4 h for 5 doses, followed by every 6 h until discharge. All inhaled treatments were delivered to infants from standard air-compressed nebulisers (PARI Corporation, Stanford, Germany).</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:44:25 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Duration of symptoms and signs</LI><LI>Wang clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:46:25 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 73.7% in hypertonic saline group; 72.7% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:50:13 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahesh-Kumar-2013"><CHAR_METHODS MODIFIED="2017-02-16 13:27:31 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:48:00 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a teaching hospital in India</P><P>Assessed for eligibility: 78<BR/>Randomised: 20 hypertonic saline group; 20 normal saline group<BR/>Completed: 20 hypertonic saline group; 20 normal saline group<BR/>Gender (male): 62.5%<BR/>Age (mean ± SD): 5.9 ± 3.8 months</P><P>Inclusion criteria: children aged &lt; 2 years, hospitalised with acute bronchiolitis defined as the first episode of lower respiratory tract infection with wheeze and having a moderate respiratory distress with clinical severity score between 4 and 8</P><P>Exclusion criteria: children with pre-existing cardiac disease, previous wheezing episodes, severe disease (clinical severity score &gt; 8) requiring mechanical ventilation (SaO&#8322; &lt; 85% on room air, cyanosis, obtunded consciousness, and/or progressive respiratory failure)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:49:45 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (3 mL) plus salbutamol (0.15 mg/kg)<BR/>Control group: nebulised 0.9% normal saline (3 mL) plus salbutamol (0.15 mg/kg)<BR/>The medication was given via a nebuliser driven by oxygen flow at 5 to 6 L/min, every 6 h until ready for discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:49:50 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang clinical severity score</LI><LI>Number of add-on nebulisation</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 01:50:13 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 01:58:49 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandelberg-2003"><CHAR_METHODS MODIFIED="2013-04-15 04:14:11 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 01:53:57 -0200" MODIFIED_BY="[Empty name]"><P>Setting: paediatric inpatient ward, Edith Wolfson Medical Center, Israel<BR/>Eligible: not stated<BR/>Randomised: 27 (3% saline group); 26 (0.9% saline group)<BR/>Completed: 27 hypertonic saline group; 25 normal saline group<BR/>Gender (male): 57.7%<BR/>Age (mean ± SD): 2.9 ± 2.1 months (range 0.5 to 12 months)</P><P>Inclusion criteria: infants with clinical presentation of viral bronchiolitis with temperature &gt; 38 ºC that led to hospitalisation</P><P>Exclusion criteria: cardiac disease, chronic respiratory disease, previous wheezing episode, age &gt; 12 months, SaO&#8322; &lt; 85% in room air, changes in consciousness and/or progressive respiratory failure requiring mechanical ventilation<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 01:58:31 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% saline solution (4 mL) plus 1.5 mg epinephrine<BR/>Control group: nebulised 0.9% saline solution (4 mL) plus 1.5 mg epinephrine<BR/>The treatment was given 3 times/day at intervals of 8 h, until the infant was ready for discharge. All inhaled treatments were delivered using a nebuliser (Aeromist Nebulizer Set 61400; B&amp;F Medical by Allied; Toledo, OH) connected to a source of pressurised oxygen at a flow rate of 5 L/min.<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 01:58:49 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang clinical severity score</LI><LI>Oxygen saturation</LI><LI>Pulse rate</LI><LI>Radiograph assessment score</LI><LI>Number of add-on treatments</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:46:46 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 85% in hypertonic saline group; 88% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-12-05 04:08:10 -0200" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><CHAR_METHODS MODIFIED="2013-05-11 15:44:25 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 02:00:06 -0200" MODIFIED_BY="[Empty name]"><P>Setting: division of paediatrics of a general hospital in Italy<BR/></P><P>Assessed for eligibility: 136<BR/>Randomised: 53 hypertonic saline group; 56 normal saline group<BR/>Completed: 52 hypertonic saline group; 54 normal saline group<BR/>Gender (male): 65.1%<BR/>Age (mean ± SD): 4.8 ± 2.3 months in hypertonic saline group; 4.2 ± 1.6 months in normal saline group</P><P>Inclusion criteria: children aged under 2 years with a diagnosis of bronchiolitis, defined as the first episode of wheezing and clinical symptoms of a viral respiratory infection and SaO&#8322; &lt; 94% in room air and significant respiratory distress</P><P>Exclusion criteria: pre-existing cardiac or pulmonary diseases, premature birth &lt; 36 weeks of gestational age, previous diagnosis of asthma, initial SaO&#8322; &#8804; 85% or respiratory distress severe enough to require resuscitation</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-12-05 04:08:10 -0200" MODIFIED_BY="Liz Dooley"><P>Intervention group: nebulised 3.0% hypertonic saline (the volume not reported) plus 1.5 mg epinephrine<BR/></P><P>Control group: nebulised 0.9% normal saline (the volume not reported) plus 1.5 mg epinephrine<BR/></P><P>Study solutions were given at intervals of 6 h until discharge. Each treatment was delivered by a nebuliser with continuous flow of oxygen at 6 L/min through a tight-fitting face mask</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 02:03:59 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang clinical severity score</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 02:04:12 -0200" MODIFIED_BY="[Empty name]"><P>RSV positive: 80.7% in hypertonic saline group; 83.3% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-12-05 04:08:36 -0200" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-NCT01238848"><CHAR_METHODS MODIFIED="2017-02-17 21:58:03 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, open-label, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-19 19:33:11 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a children&#8217;s hospital, Buenos Aires, Argentina</P><P>Assessed for eligibility: not stated</P><P>Randomised: 50 hypertonic saline group; 50 normal saline group<BR/>Completed: 37 hypertonic saline group; 45 normal saline group<BR/>Gender (male): 50.0%<BR/>Age (mean ± SD): 4.5 ± 3.8 months</P><P>Inclusion criteria: infants aged 1 to 24 months, hospitalised for first episode of bronchiolitis, with severity score &#8805; 5 and oxygen saturation &#8805; 97%</P><P>Exclusion criteria: chronic respiratory or cardiovascular disease, respiratory failure</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-04-05 03:40:49 -0300" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3.0% normal saline (3 mL) plus albuterol (0.25 mg/kg/day)</P><P>Control group: nebulised 0.9% normal saline (3 mL) plus albuterol (0.25 mg/kg/day)</P><P>Study solutions were given 4 times a day for 5 days.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-19 19:33:58 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Length of oxygen use</LI><LI>Clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-12-05 04:08:36 -0200" MODIFIED_BY="Liz Dooley"><P>Virological identification not available</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 03:40:50 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ojha-2014"><CHAR_METHODS MODIFIED="2017-02-16 15:19:33 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 03:39:40 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a teaching hospital in Nepal</P><P>Assessed for eligibility: 104<BR/>Randomised: 36 hypertonic saline group; 36 normal saline group<BR/>Completed: 28 hypertonic saline group; 31 normal saline group<BR/>Gender (male): 74%<BR/>Age (mean ± SD): 8.5 ± 5.0 months</P><P>Inclusion criteria: children aged over 6 weeks up to 24 months, hospitalised with acute bronchiolitis, defined as the first episode of wheezing associated with tachypnoea, increased respiratory effort, and an upper respiratory tract infection</P><P>Exclusion criteria: previous episode of wheezing, chronic cardiac and pulmonary disease, immunodeficiency, accompanying respiratory failure, requiring mechanical ventilation, inhaling the nebulised 3% hypertonic saline solution and salbutamol 12 h before treatment, premature infants born at less than 34 weeks gestation, SaO&#8322; &lt; 85% on room air</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-04-05 03:30:08 -0300" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL)</P><P>Control group: nebulised 0.9% normal saline (4 mL)<BR/>The treatment was given every 8 h until discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 03:40:46 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Clinical severity score</LI><LI>Duration of oxygen supplementation</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 03:40:50 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-12-05 19:37:14 -0200" MODIFIED_BY="Liz Dooley" STUDY_ID="STD-Pandit-2013"><CHAR_METHODS MODIFIED="2017-02-16 15:28:15 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, non-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-12-05 19:37:14 -0200" MODIFIED_BY="Liz Dooley"><P>Setting: paediatric department of a government multi-speciality hospital in India</P><P>Assessed for eligibility: not stated<BR/>Randomised: 51 hypertonic saline group; 49 normal saline group<BR/>Completed: 51 hypertonic saline group; 49 normal saline group<BR/>Gender (male): not reported<BR/>Age: mean age: not reported</P><P>Inclusion criteria: infants aged 2 months to 12 months, admitted with clinical diagnosis of acute bronchiolitis, defined as the first attack of wheezing after a short history of cough with or without fever of less than 7 days duration</P><P>Exclusion criteria: recurrent episodes of wheezing, 1 or more episodes of respiratory distress in past, family history of asthma, atopy, congenital heart disease, history of prematurity or mechanical ventilation in newborn period, very sick patients with shock, seizures, heart rate &gt; 180/min, respiratory rate &gt; 100/min and adjudged to be in incipient respiratory failure, severe malnutrition, consolidation lung on chest X-ray</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 03:47:20 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL) plus 1:1000 adrenaline (1 mL)</P><P>Control group: nebulised 0.9% normal saline (4 mL) plus 1:1000 adrenaline (1 mL)<BR/>The medication was given 3 times with an interval of 1 hour, via a nebuliser driven by oxygen flow at 6 to 8 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 03:47:47 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>RDAI</LI><LI>Oxygen saturation</LI><LI>Respiratory rate</LI><LI>Heart rate</LI><LI>Number of add-on treatments</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 03:47:52 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 03:53:53 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><CHAR_METHODS MODIFIED="2017-05-20 16:17:57 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 03:51:58 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a general hospital in Poland</P><P>Assessed for eligibility: 80<BR/>Randomised: 41 hypertonic saline group; 37 normal saline group<BR/>Completed: 41 hypertonic saline group; 36 normal saline group<BR/>Gender (male): 58.9%<BR/>Age (mean): 5.34 months in hypertonic saline group; 4.43 months in normal saline group</P><P>Inclusion criteria: children aged 0 to 18 months, hospitalised with acute bronchiolitis, defined as prolonged expiration, wheezes, and crepitations, with a history of a preceding viral upper respiratory infection, and with SaO&#8322; &#8804; 95% or Wang score &#8805; 5</P><P>Exclusion criteria: preterm babies &lt; 34 weeks, chronic cardiac or respiratory disease, immunological deficiencies, 2 or more episodes of bronchial obstruction, treatment with systemic glucocorticosteroids, received a hypertonic saline nebulisation in 24 hours prior to admission, or with SaO&#8322; &lt; 85%</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 03:53:14 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (3 mL) plus salbutamol (0.15 mg/kg, max 1.5 mg)</P><P>Control group: nebulised 0.9% normal saline (3 mL) plus salbutamol (0.15 mg/kg, max 1.5 mg)<BR/>The medication was given 6 times daily until discharge, via a nebuliser driven by oxygen flow at 6 to 8 L/min.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 03:53:25 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Improvement in clinical severity score at 24, 48, and 72 h after hospital admission</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 03:53:53 -0200" MODIFIED_BY="[Empty name]"><P>RSV positive: 51% in hypertonic saline group; 56% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 03:58:06 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarrell-2002"><CHAR_METHODS MODIFIED="2013-04-15 04:14:11 -0300" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 03:56:21 -0200" MODIFIED_BY="[Empty name]"><P>Setting: Paediatrics and Adolescent Ambulatory Community Clinic of General Health Services of Petach-Tikva, Israel<BR/>Eligible: not stated<BR/>Randomised: 70<BR/>Completed: 33 (3% saline group); 32 (0.9% saline group)<BR/>Gender (male): 59%<BR/>Age (mean ± SD): 12.5 ± 6.0 months (range 3 to 24 months)</P><P>Inclusion criteria: infants with clinical presentation of mild to moderate viral bronchiolitis<BR/>Exclusion criteria: cardiac disease, chronic respiratory disease, previous wheezing episode, age &#8805; 24 months, SaO&#8322; &lt; 96% on room air, and need for hospitalisation</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 03:58:02 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% saline solution (2 mL) plus 5 mg (0.5 mL) terbutaline<BR/>Control group: nebulised 0.9% saline solution (2 mL) plus 5 mg (0.5 mL) terbutaline<BR/>The treatment was given 3 times/day at intervals of 8 h for 5 days.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 03:58:06 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Hospitalisation rate</LI><LI>Radiograph assessment score</LI><LI>Pulse rate</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:47:43 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 82% in hypertonic saline group; 78% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 04:25:26 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2013"><CHAR_METHODS MODIFIED="2017-02-16 15:36:31 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-05-22 21:49:11 -0300" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a tertiary care teaching hospital in India</P><P>Assessed for eligibility: 277<BR/>Randomised: 125 hypertonic saline group; 125 normal saline group<BR/>Completed: 125 hypertonic saline group; 123 normal saline group<BR/>Gender (male): 76.2%<BR/>Age (mean ± SD): 8.5 ± 5.0 months</P><P>Inclusion criteria: infants aged 1 to 24 months, hospitalised with moderate (clinical severity score 3 to 6) acute bronchiolitis, defined by the first episode of wheezing along with prodrome of upper respiratory tract infection</P><P>Exclusion criteria: children with obtunded consciousness, cardiac disease, chronic respiratory disease, previous wheezing episode, progressive respiratory distress requiring respiratory support other than supplemental oxygen, use of nebulised hypertonic saline within the previous 12 h</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 04:24:52 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL) plus salbutamol (2.5 mg)</P><P>Control group: nebulised 0.9% normal saline (4 mL) plus salbutamol (2.5 mg)<BR/>The medication was given via a jet nebuliser with tight-fitting face mask, driven by oxygen flow at 7 L/min, every 4 h until the infant was ready for discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 04:24:59 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 04:25:26 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 04:31:34 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tal-2006"><CHAR_METHODS MODIFIED="2017-02-16 16:10:35 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-05-08 23:08:36 -0300" MODIFIED_BY="[Empty name]"><P>Setting: paediatric inpatient ward, Wolfson Medical Center, Israel<BR/>Eligible: not stated<BR/>Randomised: 22 hypertonic saline group; 22 normal saline group<BR/>Completed: 21 hypertonic saline group; 20 normal saline group<BR/>Gender (male): 56.1%<BR/>Age (mean ± SD): 2.6 ± 1.0 months (range 1 to 5 months)</P><P>Inclusion criteria: infants with clinical presentation of viral bronchiolitis that led to hospitalisation</P><P>Exclusion criteria: cardiac disease, chronic respiratory disease, previous wheezing episode, age &gt; 12 months, SaO&#8322; &lt; 85% on room air, obtunded consciousness and/or progressive respiratory failure requiring mechanical ventilation<BR/></P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 04:31:03 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% saline solution (4 mL) plus 1.5 mg epinephrine<BR/>Control group: nebulised 0.9% saline solution (4 mL) plus 1.5 mg epinephrine. </P><P>The treatment was given 3 times/day at intervals of 8 h, until the infant was ready for discharge. All inhaled treatments were delivered using an ultrasonic nebuliser (Omron UI, OMRON Matsusaka Co. Ltd, Japan)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 04:31:34 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Wang clinical severity score</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:48:01 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 86% in hypertonic saline group; 75% in normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-28 23:08:40 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teunissen-2014"><CHAR_METHODS MODIFIED="2017-02-16 15:45:56 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-28 23:08:40 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient wards of 11 general hospitals and 1 tertiary medical centre in the Netherlands</P><P>Assessed for eligibility: not stated<BR/>Randomised: 97 (3% saline group); 102 (6% saline group); 93 (normal saline group)<BR/>Completed: 84 (3% saline group); 83 (6% saline group); 80 (normal saline group)<BR/>Gender (male): 57.1%<BR/>Age: median 3.4 months (range 10 days to 23 months)</P><P>Inclusion criteria: children aged birth to 24 months, hospitalised with mild to severe (Wang clinical severity score &#8805; 3) viral bronchiolitis, defined as symptoms of an upper respiratory tract infection with wheezing, tachypnoea, and dyspnoea</P><P>Exclusion criteria: Wang clinical severity score improved at least 2 points after inhalation of 2.5 mg salbutamol, haemodynamically important congenital heart disease, chronic pre-existent lung disease, T-cell immunodeficiency, treatment with corticosteroids, and previous wheezing, (food) allergy, or eczema</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 04:42:00 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups: </P><P>Nebulised 3% hypertonic saline (4 mL) plus salbutamol (2.5 mg)</P><P>Nebulised 6% hypertonic saline (4 mL) plus salbutamol (2.5 mg)</P><P>Control group: nebulised 0.9% normal saline (4 mL) plus salbutamol (2.5 mg)<BR/>The solutions were given via a HOT Top Plus Nebuliser (Intersurgical, Uden, Netherlands) with a tight-fitting face mask, driven by oxygen flow at 6 to 8 L/min, every 8 h until discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 04:42:06 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Length of hospital stay</LI><LI>Transfer to a paediatric intensive care unit because of respiratory insufficiency</LI><LI>Need and duration of supplemental oxygen or tube feeding</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-02-16 15:45:57 -0200" MODIFIED_BY="[Empty name]"><P>RSV positive: 83.7% in 3% saline group; 91.4% in 6% saline group; 88.6% in control group</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 04:52:39 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tinsa-2014"><CHAR_METHODS MODIFIED="2017-02-16 15:53:28 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 04:50:30 -0200" MODIFIED_BY="[Empty name]"><P>Setting: inpatient ward of a children&#8217;s hospital in Tunisia</P><P>Assessed for eligibility: not stated<BR/>Randomised: 32 (5% saline group); 37 (5% saline + epinephrine group); 28 (normal saline group)<BR/>Completed: 31 (5% saline group); 37 (5% saline + epinephrine group); 26 (normal saline group)<BR/>Gender (male): 61.7%<BR/>Age (mean ± SD): 3.7 ± 2.8 months in 5% saline group; 3.2 ± 2.5 months in 5% saline + epinephrine group; 3.0 ± 2.4 months in normal saline group</P><P>Inclusion criteria: children aged 1 to 12 months, hospitalised with moderate (Wang clinical severity score of 3) bronchiolitis, defined as an acute infection of the lower respiratory tract, preceded by or accompanied by fever or rhinitis, or both, and characterised by expiratory wheezing and increased respiratory effort</P><P>Exclusion criteria: prematurity (gestational age at birth &lt; 34 weeks), underlying chronic cardiac or pulmonary disease (e.g. bronchopulmonary dysplasia, cystic fibrosis), recurrent wheezing, severe respiratory distress (apnoeas, heart rate &gt; 200 beats per minute, respiratory rate &gt; 80 breaths/minute, profound lethargy, duration of illness exceeding 15 days)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 04:52:29 -0200" MODIFIED_BY="[Empty name]"><P>Intervention groups: </P><P>Nebulised 5% hypertonic saline (4 mL)</P><P>Nebulised 5% hypertonic saline (2 mL) plus standard epinephrine (2 mL)</P><P>Control group: nebulised 0.9% normal saline (4 mL)</P><P>The solutions were given via a jet nebuliser with a tight-fitting face mask, driven by oxygen flow at 6 to 7 L/min, every 4 h until discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 04:52:34 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Wang clinical severity score</LI><LI>Length of hospital stay</LI><LI>Oxygen saturation</LI><LI>Rerpiratory rate</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 04:52:39 -0200" MODIFIED_BY="[Empty name]"><P>Virological identification not available.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-20 04:58:27 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2014"><CHAR_METHODS MODIFIED="2017-02-16 15:58:12 -0200" MODIFIED_BY="[Empty name]"><P>Design: randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 04:55:22 -0200" MODIFIED_BY="[Empty name]"><P>Setting: emergency departments of 2 urban freestanding tertiary children&#8217;s hospitals in USA</P><P>Assessed for eligibility: 1254<BR/>Randomised: 211 hypertonic saline group; 197 normal saline group<BR/>Completed: 211 hypertonic saline group; 197 normal saline group<BR/>Gender (male): 56.8%<BR/>Age (mean ± SD): 6.5 ± 5.1 months in hypertonic saline group; 6.4 ± 5.3 months in normal saline group</P><P>Inclusion criteria: children younger than 24 months with a primary diagnosis of viral bronchiolitis during bronchiolitis season</P><P>Exclusion criteria: children with a prior illness with wheezing or bronchodilator use, premature (gestational age &lt; 34 weeks), cyanotic congenital heart disease, chronic lung disease, or tracheostomy</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 04:58:08 -0200" MODIFIED_BY="[Empty name]"><P>Intervention group: nebulised 3% hypertonic saline (4 mL)</P><P>Control group: nebulised 0.9% normal saline (4 mL)</P><P>The solutions were given via a small-volume wall nebuliser at study entry. Emergency department physicians could order 2 additional treatments every 20 minutes to a maximum of 3 inhaled doses. Admitted infants continued receiving study medication, every 8 h until discharge.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 04:58:27 -0200" MODIFIED_BY="[Empty name]"><UL><LI>Admission rate</LI><LI>Length of hospital stay</LI><LI>RDAI</LI><LI>Supplemental treatment use</LI><LI>Adverse events</LI></UL></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-04-05 01:48:36 -0300" MODIFIED_BY="[Empty name]"><P>RSV positive: 65.6% hypertonic saline group; 59.2% normal saline group</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P>ICU: intensive care unit<BR/>RDAI: Respiratory Distress Assessment Instrument<BR/>RSV: respiratory syncytial virus<BR/>SaO&#8322;: oxygen saturation<BR/>SD: standard deviation<BR/></P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-11-20 20:38:00 -0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2017-11-20 20:30:35 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_bahadily-2017"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:30:35 -0200" MODIFIED_BY="[Empty name]"><P>Not an RCT. The authors classified the study design as "prospective case second multicenter study" in the Abstract and "Prospective comparison study" in the Methods. We contacted the first author for more details about study design, but did not receive a reply.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:31:10 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amirav-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:31:10 -0200" MODIFIED_BY="[Empty name]"><P>Study of drug delivery (hood versus face mask)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:31:41 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bagus-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:31:41 -0200" MODIFIED_BY="[Empty name]"><P>Abstract available only</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:31:28 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bueno-Campa_x00f1_a-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:31:28 -0200" MODIFIED_BY="[Empty name]"><P>Other comparison (hypertonic saline versus high flow therapy)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-09-29 08:56:46 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores_x002d_Gonz_x00e1_lez-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-09-29 08:56:46 -0300" MODIFIED_BY="[Empty name]"><P>Other comparison (epinephrine versus placebo)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-09-29 08:56:54 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flores_x002d_Gonz_x00e1_lez-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-09-29 08:56:54 -0300" MODIFIED_BY="[Empty name]"><P>Other comparison (epinephrine versus placebo)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:31:46 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guomo-2007"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:31:46 -0200" MODIFIED_BY="[Empty name]"><P>Abstract available only</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:34:38 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:34:38 -0200" MODIFIED_BY="[Empty name]"><P>Suspected plagiarism. This trial presented results identical to those of the <LINK REF="STD-Malik-2015" TYPE="STUDY">Malik 2015</LINK> trial. We contacted the first authors of both trials and the editors of the journals in which the trials were published, but neither authors nor editors provided clarification.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:35:26 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuzik-2010"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:35:26 -0200" MODIFIED_BY="[Empty name]"><P>Inclusion of infants with previous history of wheezing</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:36:54 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malik-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:36:54 -0200" MODIFIED_BY="[Empty name]"><P>Suspected plagiarism. This trial presented results identical to those of the <LINK REF="STD-Gupta-2016" TYPE="STUDY">Gupta 2016</LINK> trial. We contacted the first authors of both trials and the editors of the journals in which the trials were published, but neither authors nor editors provided clarification.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-09-29 08:58:48 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nenna-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-09-29 08:58:48 -0300" MODIFIED_BY="[Empty name]"><P>Other comparison (hypertonic saline + 0.1% hyaluronic acid versus 0.9% saline)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:37:51 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silver-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:37:51 -0200" MODIFIED_BY="[Empty name]"><P>Inclusion of infants with previous history of wheezing</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-20 20:38:00 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tribastone-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-20 20:38:00 -0200" MODIFIED_BY="[Empty name]"><P>Not an RCT (summary of <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES><P>RCT: randomised controlled trial</P></FOOTNOTES></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-12-01 10:46:37 -0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><AWAITING_CHAR MODIFIED="2017-11-20 21:04:28 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2010_x002f_091_x002f_003065"><CHAR_METHODS MODIFIED="2017-05-10 21:40:25 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 21:01:36 -0200" MODIFIED_BY="[Empty name]"><P>Consecutive patients with moderate to severe bronchiolitis, aged 2 months to 2 years, of either sex, admitted to the hospital during the study period</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-05-10 21:40:51 -0300" MODIFIED_BY="[Empty name]"><P>Nebulised hypertonic saline versus nebulised normal saline</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 21:02:37 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcome:</P><P>Length of hospital stay (the time between study entry and the time at which the infant reached protocol-defined discharge criteria as measured by study physician)</P><P>Secondary outcomes:</P><P>Change in clinical severity scores</P><P>Change in oxygen saturation (pulse oximetry)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 21:04:28 -0200" MODIFIED_BY="[Empty name]"><P>Starting date: July 2009</P><P>Completion of data collection: February 2013</P><P>Last updated: 3 April 2017</P><P>Contact information: Lopamudra Mishra, 27A South Sinthee Road Kolkata 700050 Kolkata, West Bengal, India; email: lopamudra83.cmc@gmail.com</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-05-11 21:03:08 -0300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EudraCT2009_x002d_014758_x002d_14"><CHAR_METHODS MODIFIED="2017-05-10 22:02:56 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-05-10 22:03:17 -0300" MODIFIED_BY="[Empty name]"><P>Infants under the age of 12 months with a clinical diagnosis of bronchiolitis</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-05-10 22:04:44 -0300" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline plus salbutamol</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-05-10 22:06:36 -0300" MODIFIED_BY="[Empty name]"><P>Primary outcomes:</P><P>Duration of hospital stay</P><P>Secondary outcomes:</P><P>Duration of supplemental oxygen requirement</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:03:08 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: May 2010</P><P>Last updated: 19 March 2012</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 20:57:08 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00677729"><CHAR_METHODS MODIFIED="2017-05-10 21:04:03 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 20:55:37 -0200" MODIFIED_BY="[Empty name]"><P>Infants aged up to 24 months, presenting to ED or outpatient department with moderately severe viral bronchiolitis defined as history of viral upper respiratory tract infection within previous 7 days, presence of wheezing or crackles, or both on chest auscultation, and RDAI score &gt; 4 (of 17) or transcutaneous oxygen saturation &lt; 94% in room air</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:55:58 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (4 mL) plus 1.0 mg salbutamol versus nebulised 0.9% normal saline (4 mL) plus 1.0 mg salbutamol</P><P>Study solutions were given every 20 minutes for a total of 3 doses.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 20:56:03 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcome: rate of admission to hospital 1 hour after treatment end</P><P>Secondary outcomes: change in the RDAI score between study entry and post-treatment</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 20:57:08 -0200" MODIFIED_BY="[Empty name]"><P>Starting date: June 2008</P><P>Completion of data collection: April 2009</P><P>Last updated: November 2015</P><P>Contact information: Brian Kuzik, MD, The Royal Victoria Hospital of Barrie, Ontario, Canada L4M 6M2</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 21:05:32 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01777347"><CHAR_METHODS MODIFIED="2017-05-10 21:35:20 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 21:05:32 -0200" MODIFIED_BY="[Empty name]"><P>Children aged 6 weeks to 12 months with first moderate-to-severe episode of acute viral bronchiolitis (history of viral upper respiratory tract infection plus wheezing or crackles, or both on chest auscultation with respiratory distress), admitted in ED</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:53:43 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (4 mL) versus nebulised 0.9% normal saline (4 mL)</P><P>2 doses of study solutions were given every 20 minutes.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-05-10 21:36:07 -0300" MODIFIED_BY="[Empty name]"><P>Primary outcomes:</P><P>Admission rate at 24 hours</P><P>Secondary outcomes:</P><P>Change in RDAI score at 2 hours</P><P>Number of participants with adverse events at 2 hours</P><P>Length of hospitalisation for hospitalised infant</P><P>Health care utilisation within 1 month after discharge</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:03:22 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: October 2012</P><P>Completion of data collection: April 2014</P><P>Last updated: 25 July 2014</P><P>Contact information: Vincent Gajdos, MD, PhD, Assistance Publique Hôpitaux de Paris - Paris Sud Medical School</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 20:50:03 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01834820"><CHAR_METHODS MODIFIED="2017-05-10 21:31:35 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 20:46:04 -0200" MODIFIED_BY="[Empty name]"><P>Children under 2 years of age diagnosed with mild to moderate bronchiolitis, presenting to outpatient Department of Hospital General Naval de Alta Especialidad, Mexico</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:47:44 -0200" MODIFIED_BY="[Empty name]"><P>Intervention 1: epinephrine and dexamethasone</P><P>1 dose of nebulised dexamethasone (4 mg) was given, followed by 2 doses of nebulised 1:1000 epinephrine (3 mL) at an interval of 20 minutes on the first day. Nebulised dexamethasone (4 mg) was given every 24 hours for 3 days.</P><P>Intervention 2: 3% hypertonic saline</P><P>3 doses of nebulised 3% saline (4 mL) were given every 20 minutes on the first day of treatment, followed by nebulised 3% saline (4 mL) every 24 hours for 3 days</P><P>Active comparator: 0.9% normal saline</P><P>3 doses of nebulised 0.9% normal saline (4 mL) were given at an interval of 20 minutes on the first day of treatment, followed by nebulised 0.9% normal saline (4 mL) every 24 hours for 3 days</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 20:49:39 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcome:</P><P>Rate of hospital admissions until 7 days after treatment</P><P>Secondary outcomes:</P><P>Number of participants with adverse events in each arm of treatment</P><P>Change from baseline CBSS after 3 treatments in the first day</P><P>Change from baseline heart rate after 3 treatments in the first day</P><P>Change from baseline oxygen saturation after 3 treatments in the first day</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-20 20:50:03 -0200" MODIFIED_BY="[Empty name]"><P>Starting date: January 2013</P><P>Completion of data collection: June 2015</P><P>Last updated: 4 July 2015</P><P>Contact information: José Luis Rodríguez Cuevas, Hospital General Naval de Alta Especialidad, México, Distrito Federal, Distrito Federal, Mexico 04480</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 20:41:18 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02029040"><CHAR_METHODS MODIFIED="2017-05-10 21:24:50 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 20:40:50 -0200" MODIFIED_BY="[Empty name]"><P>Children aged 2 to 12 months, presenting to ED with a diagnosis of bronchiolitis (RDAI score = 6) defined as the first episode of wheezing or crackles, or both in a child younger than 12 months who has physical findings of a viral respiratory infection and there is no other explanation for the wheezing and/or crackles</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:41:18 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (3 mL) versus nebulised 0.9% normal saline (3 mL)</P><P>A single dose of study solution was given.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-10-08 19:41:13 -0300" MODIFIED_BY="Liz Dooley"><P>Primary outcomes:<BR/>Respiratory assessment change score (RACS) at 15 minutes and 1 hour<BR/>Secondary outcomes:<BR/>Rate of hospitalisations at 24 hours<BR/>Return to ED within 7 days following discharge</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:02:29 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: December 2013</P><P>Completion of data collection: December 2014</P><P>Last updated: 3 May 2016</P><P>Contact information: Mohamed Badawy, MD, University of Texas Southwestern Medical Center</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 21:00:31 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02045238"><CHAR_METHODS MODIFIED="2017-05-10 21:37:40 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 20:58:28 -0200" MODIFIED_BY="[Empty name]"><P>Children aged up to 12 months with clinical diagnosis of bronchiolitis (viral respiratory disease and first episode of wheezing) and with moderate respiratory distress, defined as having at least 2 of the following criteria: SaO&#8322; &lt; 93%, respiratory rate &gt; 60, and/or RDAI score &gt; 4</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:59:12 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (5 mL) versus nebulised 0.9% normal saline (5 mL)</P><P>Study solutions were initially given every 2 hours, then every 4 hours if the following criteria were met: SaO&#8322; &gt; 94%, respiratory rate &lt; 60, and RDAI score &lt; 4.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 21:00:31 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcomes:</P><P>Rate of admission at 24 hours</P><P>Time to ready for discharge at 24 hours (room air oxygen saturation &gt; 94%, respiratory rate &lt; 60, and RDAI score &lt; 4 over a 4-hour period)</P><P>Secondary outcomes:</P><P>Actual time to discharge at 24 hours</P><P>Rate of re-admission within 5 days after discharge</P><P>Incidence of adverse effects during 24-hour treatment period</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:03:51 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: July 2013</P><P>Completion of data collection: December 2014</P><P>Last updated: 5 January 2015</P><P>Contact information: Mateus D Leme, MD, Sao Paulo University, Brazil</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 21:11:47 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02233985"><CHAR_METHODS MODIFIED="2017-05-10 21:46:24 -0300" MODIFIED_BY="[Empty name]"><P>Randomised, double-blind, parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 21:09:58 -0200" MODIFIED_BY="[Empty name]"><P>Children aged 2 to 24 months attending the paediatric emergency service with moderate to severe bronchiolitis, defined as first episode of wheezing associated with respiratory distress and a history of upper respiratory tract infection</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 21:10:55 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (4 mL) plus salbutamol (100 mcg/kg) versus nebulised 0.9% normal saline (4 mL) plus salbutamol (100 mcg/kg)</P><P>3 doses of study solutions were initially given at an interval of 20 minutes, then every 4 hours during the entire hospital stay.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 21:11:47 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcomes:</P><P>Respiratory distress score (at baseline, 30 minutes after the end of the first 3 continuous nebulisation sessions, at 4 hours, 8 hours, and every 24 hours during the entire hospital stay)</P><P>Length of hospital stay (hours)</P><P>Secondary outcomes:</P><P>Hospital re-admission within 30 days after discharge</P><P>Frequency of complications within 30 days after discharge</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:04:25 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: August 2013</P><P>Completion of data collection: April 2015</P><P>Last updated: 25 January 2017</P><P>Contact information: Gloria P Sosa-Bustamante, MD, Unidad Medica de Alta Especialidad Bajio 48. Hospital de Gineco - Pediatria, Instituto Mexicano del Seguro Social, Mexico</P></CHAR_NOTES></AWAITING_CHAR><AWAITING_CHAR MODIFIED="2017-11-20 20:45:08 -0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02834819"><CHAR_METHODS MODIFIED="2017-11-20 20:43:12 -0200" MODIFIED_BY="[Empty name]"><P>Randomised, single-blind (investigator), parallel-group, controlled trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-20 20:43:25 -0200" MODIFIED_BY="[Empty name]"><P>Children aged 3 to 18 months, presenting to Children's Hospital Colorado Emergency Department with diagnosis of bronchiolitis and persistent hypoxia following initial supportive care</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-20 20:43:36 -0200" MODIFIED_BY="[Empty name]"><P>Nebulised 3% hypertonic saline (4 mL) plus standard care versus standard care alone</P><P>A single dose of study solution was given.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-20 20:45:08 -0200" MODIFIED_BY="[Empty name]"><P>Primary outcomes:</P><P>Hospitalisation rate at any point during enrolment visit or up to 7 days after enrolment visit</P><P>Need for supplemental oxygen at time of hospital discharge for up to 7 days</P><P>Persistent hypoxia at baseline and 90 minutes postintervention</P><P>Secondary outcomes:</P><P>Adverse outcomes during enrolment visit or within 7 days following enrolment visit</P><P>Hospital admission within 7 days following discharge from enrolment visit</P><P>Postintervention clinical severity score during enrolment visit - 90 minutes after randomisation</P><P>Pre-intervention clinical severity score during enrolment visit following randomisation</P><P>Unscheduled return ED visits 7 days post-enrolment visit</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-05-11 21:02:44 -0300" MODIFIED_BY="[Empty name]"><P>Starting date: September 2013</P><P>Completion of data collection: September 2015</P><P>Last updated: 14 July 2016</P><P>Contact information: Cortney Braund, MD, University of Colorado, Denver</P></CHAR_NOTES></AWAITING_CHAR><FOOTNOTES><P>CBSS: Clinical Bronchiolitis Severity Score<BR/>ED: emergency department<BR/>RDAI: Respiratory Distress Assessment Instrument<BR/>SaO&#8322;: oxygen saturation</P></FOOTNOTES></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-06-08 20:44:48 -0300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-12-05 04:08:43 -0200" MODIFIED_BY="Liz Dooley"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-12-05 04:08:37 -0200" MODIFIED_BY="Liz Dooley" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 23:53:19 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>Computer-based randomisation program</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:23:48 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>Computer-generated random allocation sequence using a 1:1 ratio and permutation<BR/>blocks with a block size of 4, stratified according to centre</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 23:53:29 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>Computer-based randomisation program</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:43:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>Computer-generated randomisation in blocks of size two, four, and six, stratified by hospital</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 09:54:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 09:59:20 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>Computer-generated random permuted block randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 23:58:31 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>Website randomisation scheme</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:58:52 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>Infants were assigned to 1 of 4 groups according to the consecutive order of their admission to the short-stay unit.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:05:39 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>Randomisation in blocks of 10, but it is unclear how to choose blocks at random to create the allocation sequence.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 11:00:13 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>Computer-generated block randomisation (in blocks of 10)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-22 23:58:41 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>Computer-based randomisation program</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 11:09:48 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>Computer-generated stratified randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:36:24 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>Random sequence generated using a random number table.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:40:55 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>No details were reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-23 00:04:22 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>Computer-based randomisation program</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 13:28:23 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:59:12 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-11 16:03:42 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>Computer-based randomisation program</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-12-05 04:08:37 -0200" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>The trial was stated as randomised, but no details were provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 15:20:26 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 15:29:02 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-20 16:45:41 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-23 00:04:24 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>Randomisation in blocks of 4, using an online randomiser</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 15:36:51 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-23 00:07:29 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>Randomisation in blocks of 4, using an online randomiser</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:43:13 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>Block randomisation (in blocks of 6), but it is unclear how to choose blocks at random to create the allocation sequence.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 15:54:50 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 15:58:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>Computer-generated randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-12-05 04:08:38 -0200" MODIFIED_BY="Liz Dooley" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-31 15:34:21 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>Sequentially numbered and sealed envelopes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:24:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>The investigational pharmacy prepared the study drugs in sequentially numbered and visually identical packets. Randomisation codes were kept secure until data entry was complete.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:31:46 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>Study medications were identical in appearance and odour, but no other details were provided regarding allocation concealment.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-16 09:49:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>Centralised web-based randomisation system</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:54:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>Both solutions were similar in appearance and smell, were stored in identical syringes, and were labelled only by a code number. Randomisation list was concealed by the pharmacy.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 20:01:08 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>The investigational pharmacy prepared the study medications, which were stored in sequentially numbered envelopes with blinded syringes labelled only with the study number.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:52:40 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>The solutions prepared by the hospital pharmacy were similar in appearance and smell, stored in identical syringes, labelled only by a code number, and placed in the research cupboard within the emergency department.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-31 16:04:41 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>As stated above</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:05:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>Sequentially numbered, concealed envelopes containing either 7% or 0.9% saline solution</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:14:02 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>Study solutions were labelled with the codes and wrapped in an envelope bearing the respective codes. Study solutions were identical in appearance and odour.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:20:34 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>Study solutions were prepared by a research pharmacist and were identical in appearance and odour. The identity of the study solutions was blinded to all participants, care providers, and investigators.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:28:08 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:36:26 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:41:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>No detectable difference in colour, smell, or other physical properties between the therapeutic packages containing 0.9% saline solution or 3% saline solution. The codes of the therapeutic packages were not available to the investigators, nurses, or parents.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-31 16:32:19 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>Sequentially numbered, sealed, opaque envelopes</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:51:10 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:59:30 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>Study solutions were similar in colour, smell, and other physical properties. The code of the therapeutic package (hypertonic saline versus normal saline solution) was deposited with the statistician.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 02:04:32 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>Study solutions were prepared by the local hospital pharmacy, but the method of allocation concealment was not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-12-05 04:08:38 -0200" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>No details provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:44:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>The random numbers were kept in a sealed envelope. The solutions looked similar in appearance and smell and were kept in 2 identical containers, labelled only by a code number.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:48:26 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>Group allocation was concealed in an opaque envelope.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:54:32 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:59:02 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>Study solutions were similar in colour, smell, and other physical properties. The code of the therapeutic package (hypertonic saline versus normal saline solution) was deposited with the statistician.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:28:20 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>Study solutions were similar in colour, smell, and other physical properties. The code of the therapeutic package (hypertonic saline versus normal saline solution) was deposited with the statistician.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:32:55 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>Study solutions were similar in colour, smell, and other physical properties. The code of the therapeutic package (hypertonic saline versus normal saline solution) was deposited with the statistician.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:43:23 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>Study solutions were identical in vial packaging, colour, smell, and other physical characteristics. The trial codes were kept by the pharmacist.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:53:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>Study solutions were similar in appearance and smell and were stored in identical syringes, labelled only by a code number.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:59:05 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>Saline solutions were prepared by the investigational pharmacy and stored in sequentially numbered identical vials.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-11-20 01:51:52 -0200" MODIFIED_BY="[Empty name]" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-31 15:34:40 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-10-08 19:38:29 -0300" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>Double-blinded</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:01:15 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 09:49:13 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>Open study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 09:54:28 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 09:59:35 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:02:40 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-20 00:59:17 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>The trial was stated to be double-blind, but no details were provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 10:51:07 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 11:00:17 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:05:08 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-20 01:28:13 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>The trial was stated to be double-blind, but no details were provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-20 01:36:28 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>No details provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-31 16:10:12 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-31 16:32:32 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-20 01:51:52 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>The trial was stated as double-blind, but no details were provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:10:25 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-11 16:07:35 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-17 21:58:29 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>Open-label</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 15:20:30 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 15:29:08 -0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>Non-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-05-20 16:46:10 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:17:55 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 15:36:55 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-05 23:20:39 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 15:47:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-02-16 15:54:54 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>Double-blind</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-10-08 19:39:41 -0300" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>Double-blinded</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-12-01 09:54:04 -0200" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 19:19:23 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>16 (9.3%) withdrawals after randomisation; baseline characteristics between treatment groups were balanced.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 19:24:50 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>Hospitalisation data were not available for 5 infants (2 in hypertonic saline group and 3 in normal saline group).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 19:31:53 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 19:43:51 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>27 (8.5%) withdrawals after randomisation (17 hypertonic saline group, 10 control group); baseline characteristics between treatment groups were balanced.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 19:55:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>10 (12.8%) withdrawals after randomisation (5 hypertonic saline group, 5 control group); baseline characteristics between treatment groups were balanced.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-19 20:01:14 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:44:14 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>2 (4.1%) withdrawals (1 hypertonic saline group; 1 normal saline group)<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 00:59:25 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 01:06:06 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:36:40 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>1 (1%) withdrawal after randomisation in hypertonic saline group</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 01:20:47 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>5 (5.2%) withdrawals after randomisation (2 hypertonic saline group; 3 normal saline group); intention-to-treat analysis used.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-27 15:01:04 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>2 (1.9%) withdrawals after randomisation in 7% saline group</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:46:12 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>5 (3.8%) withdrawals after randomisation (1 5% saline group, 2 3% saline group, 2 normal saline group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 01:41:27 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 01:44:51 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>14 (11.1%) withdrawals (7 infants from each group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 01:52:01 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-03-24 20:32:15 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>1 (1.8%) withdrawal after randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:47:02 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>3 withdrawals (1 hypertonic saline group; 2 normal saline group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:47:09 -0300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>18 (18%) withdrawals (13 hypertonic saline group, 5 normal saline group); unbalanced attrition between treatment groups</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 03:42:19 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>13 (18%) withdrawals after randomisation (8 hypertonic saline group; 5 normal saline group); baseline characteristics between treatment groups were balanced.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 03:48:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>No withdrawals reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 03:54:44 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>4 (5.1%) withdrawals (2 infants from each group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-27 15:14:08 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>5 (7.1%) withdrawals after randomisation</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:47:54 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>2 (0.8%) withdrawals after randomisation in normal saline group</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-04-05 01:48:05 -0300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>3 (6.8%) withdrawals after randomisation (1 hypertonic saline group; 2 normal saline group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 04:44:10 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>43 (14.7%) withdrawals after randomisation (13 (3% saline group), 18 (6% saline group), 12 (normal saline group)); baseline characteristics between treatment groups were balanced.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-12-01 09:54:04 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>3 (3.1%) withdrawals after randomisation (2 normal saline group, 1 hypertonic saline group)</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-20 04:59:28 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>No withdrawals reported at emergency department setting.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-12-05 04:08:43 -0200" MODIFIED_BY="Liz Dooley" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:19:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:24:52 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:31:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:44:16 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:55:20 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 20:01:16 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:52:51 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:59:27 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:06:08 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:14:20 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:20:51 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:28:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:36:45 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:41:30 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:44:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:52:08 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:59:34 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 02:04:38 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-12-05 04:08:43 -0200" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>All predefined outcomes reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:42:33 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:48:54 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:54:49 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:59:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:28:28 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:33:03 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:44:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:54:08 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:59:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>All predefined outcomes reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-12-05 04:08:43 -0200" MODIFIED_BY="Liz Dooley" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:19:48 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Ansari-2010"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:25:02 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Angoulvant-2017"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:32:06 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:44:36 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Everard-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 19:55:31 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flores-2016"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-19 20:01:27 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Florin-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:53:03 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grewal-2009"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 00:59:38 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ipek-2011"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:06:24 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:14:31 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khanal-2015"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:21:03 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzik-2007"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:28:32 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_se-2016"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:36:56 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:41:40 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2010"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:45:08 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luo-2011"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:52:18 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahesh-Kumar-2013"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 01:59:44 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mandelberg-2003"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 02:04:47 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miraglia-Del-Giudice--2012"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-12-05 04:08:43 -0200" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-NCT01238848"><DESCRIPTION><P>No other bias found</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:42:43 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ojha-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:49:06 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pandit-2013"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:55:00 -0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 03:59:21 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sarrell-2002"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:29:03 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:33:13 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tal-2006"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:45:11 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Teunissen-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:54:22 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-20 04:59:41 -0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wu-2014"><DESCRIPTION><P>No other bias found.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2017-12-01 09:57:21 -0200" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2017-12-01 09:57:21 -0200" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2017-03-29 00:53:55 -0300" MODIFIED_BY="[Empty name]">Nebulised hypertonic saline compared with nebulised 0.9% saline for acute bronchiolitis in infants</TITLE><TABLE COLS="7" ROWS="14"><TR><TD COLSPAN="7" VALIGN="BOTTOM"><P><B>Nebulised hypertonic saline compared with nebulised 0.9% saline for acute bronchiolitis in infants</B></P></TD></TR><TR><TD COLSPAN="7" VALIGN="BOTTOM"><P><B>Patient or population: </B>infants up to 24 months of age with acute bronchiolitis</P><P><B>Settings: </B>outpatient, emergency department, or inpatient</P><P><B>Intervention: </B>nebulised hypertonic saline (&#8805; 3%)</P><P><B>Comparison: </B>nebulised 0.9% saline or no intervention</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM"><P>Illustrative comparative risks* (95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM"><P>Number of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM"><P>Comments</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Assumed risk</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Corresponding risk</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Nebulis<B>ed 0.9% saline</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Nebulis<B>ed hypertonic saline</B></P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Length of hospital stay (days)</B></P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean length of hospital stay ranged across control groups from</P><P><B>1.8 to 7.4 days</B>.<BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean length of hospital stay in the intervention groups was on average</P><P><B>0.41 days shorter</B></P><P>(95% CI -0.75 to -0.07).</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>1867</P><P>(17 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>1</SUP></P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The effect size of nebulised hypertonic saline shown by this updated review is only approximately one-third of that shown by the 2013 review, which included 6 inpatient trials involving 500 infants (MD -1.15 days, 95% CI -1.49 to -0.82 days). All 10 trials published in 2013 and thereafter, including 2 European multicentre studies, did not find significant effects of hypertonic saline on length of stay among inpatients with acute bronchiolitis.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Clinical severity score (post-treatment) at day 1</B></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score ranged across control groups from</P><P><B>3.9 to 8.8</B>.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score in the intervention groups was on average</P><P><B>0.77 lower</B></P><P>(95% CI -1.18 to -0.36).</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>812</P><P>(9 trials: 1 outpatient, 1 ED, 7 inpatients)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>2</SUP></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The meta-analysis was based on data from only 9 trials.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Clinical severity score (post-treatment) at day 2</B></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score ranged across control groups from</P><P><B>3.8 to 8.2</B>.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score in the intervention groups was on average</P><P><B>1.28 lower</B></P><P>(95% CI -1.91 to -0.65).</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>603</P><P>(8 trials: 1 outpatient, 1 ED, 6 inpatient)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>2</SUP></P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Meta-analysis was based on data from only 8 trials.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Clinical severity score (post-treatment) at day 3</B></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score ranged across control groups from</P><P><B>1.9 to 7.6</B>.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>The mean clinical severity score in the intervention groups was on average</P><P><B>1.43 lower</B></P><P>(95% CI -1.82 to -1.04).</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>499</P><P>(7 trials: 1 outpatient, 6 inpatient)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>2</SUP></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Meta-analysis was based on data from only 7 trials.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Hospitalisation rate</B></P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>42 per 100</B></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>35 per 100</B><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>RR 0.86</B></P><P>(0.76 to 0.98)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>1723</P><P>(8 trials: 1 outpatient, 7 ED)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>3</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P/></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Re-admission rate</B></P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>15 per 100</B></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>12 per 100</B><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>RR 0.77</B></P><P>(0.48 to 1.25)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>787</P><P>(6 trials: 1 inpatient, 5 ED)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>4</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Meta-analysis was based on data from only 6 trials</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Adverse events</B></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Not estimable</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3723 (1968 received hypertonic saline)</P><P>(24 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Not applicable</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>13 trials (1363 infants, 703 treated with hypertonic saline) did not report any adverse events, and 11 trials (2360 infants, 1265 treated with hypertonic saline) reported at least 1 adverse event; most adverse events were mild and resolved spontaneously.</P></TD></TR><TR><TD COLSPAN="7"><P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/><B>CI:</B> confidence interval; <B>ED:</B> emergency department; <B>MD:</B> mean difference; <B>RR:</B> risk ratio</P></TD></TR><TR><TD COLSPAN="7"><P><B>GRADE Working Group grades of evidence (5 domains: limitations in design, inconsistency, indirectness, imprecision, reporting bias)</B><BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.</P></TD></TR></TABLE><FOOTNOTES><P>The assumed risk was based on data from the included trials.</P><P><SUP>1</SUP>We downgraded the quality of the evidence to low due to inconsistent results between studies (high heterogeneity) and risk of bias.<BR/><SUP>2</SUP>We downgraded the quality of the evidence to low due to inconsistent results between studies (high heterogeneity) and risk of bias.<BR/><SUP>3</SUP>We downgraded the quality of the evidence to moderate due to high clinical heterogeneity between studies.<BR/><SUP>4</SUP>We downgraded the quality of the evidence to moderate because the meta-analysis was based on data from a small part of the included trials.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2013-07-19 06:32:48 -0300" MODIFIED_BY="[Empty name]">Treatment regimens of nebulised hypertonic saline</TITLE><TABLE COLS="6" ROWS="32"><TR><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Study ID</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Saline concentration</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Saline volume</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Bronchodilator administered</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Administration interval</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P><B>Treatment duration</B></P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM"><P><B>Outpatient trials</B></P></TH></TR><TR><TD VALIGN="TOP"><P><LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK></P></TD><TD VALIGN="TOP"><P>3%, 5%</P></TD><TD VALIGN="TOP"><P>3 mL</P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>Twice daily</P></TD><TD VALIGN="TOP"><P>3 days</P></TD></TR><TR><TD VALIGN="TOP"><P><LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK></P></TD><TD VALIGN="TOP"><P>3%</P></TD><TD VALIGN="TOP"><P>2 mL</P></TD><TD VALIGN="TOP"><P>Terbutaline 5 mg</P></TD><TD VALIGN="TOP"><P>Every 8 hours</P></TD><TD VALIGN="TOP"><P>5 days</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="6" VALIGN="BOTTOM"><P><B>Emergency department trials</B></P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Al_x002d_Ansari-2010" TYPE="STUDY">Al-Ansari 2010</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%, 5%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 4 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mL or salbutamol 2.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 30 minutes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until 2 doses had been administered</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Florin-2014" TYPE="STUDY">Florin 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Within 90 minutes after albuterol administration</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Single dose</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2.5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2.25% racemic epinephrine 0.5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>If needed, the second dose was given during the 120-minute study period.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Up to 2 doses</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 0.15 mg/kg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 20 minutes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until 3 doses had been administered</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Jacobs-2014" TYPE="STUDY">Jacobs 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>7%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Racemic epinephrine 0.5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Study solution was given after initial screening and assessment.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Single dose (if the infant was admitted, the same solution was given every 6 h until discharge or 24 h after the admission).</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Khanal-2015" TYPE="STUDY">Khanal 2015</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Study solution was given at 0 and 30 minutes.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until 2 doses had been administered</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Emergency department physicians could order 2 additional doses every 20 minutes.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Up to 3 doses</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Study solution was given at 0 and 30 minutes.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until 2 doses had been administered</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="6" VALIGN="TOP"><P><B>Inpatient trials</B></P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Albuterol 0.25 mg/kg/day</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 times a day</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>5 days</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until fit for discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 0.25 mL (1.25 mg)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Mahesh-Kumar-2013" TYPE="STUDY">Mahesh Kumar 2013</LINK> </P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 0.15 mg/kg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until ready for discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Miraglia-Del-Giudice--2012" TYPE="STUDY">Miraglia Del Giudice 2012</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>? mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%, 7%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2.5 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 0.15 mg/kg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2 doses were given at 30-minute interval, followed by every 6 hours.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Albuterol was added in 37% of the treatments, and racemic epinephrine was added in 23% of the treatments by attending physicians.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 2 hours for 3 doses, followed by every 4 hours for 5 doses, and then every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 2.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 8 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 2 hours for 3 doses, followed by every 4 hours for 5 doses, and then every 6 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 8 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 2.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 4 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until ready for discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.0 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 doses were given at 1-hour intervals, followed by every 6 hours.</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 8 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Ratajczyk_x002d_Pekrul-2016" TYPE="STUDY">Ratajczyk-Pekrul 2016</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 0.15 mg/kg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 4 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Tal-2006" TYPE="STUDY">Tal 2006</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 1.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 8 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK> </P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%, 6%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Salbutamol 2.5 mg</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 8 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Tinsa-2014" TYPE="STUDY">Tinsa 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>5%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Epinephrine 2 mL</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Every 4 hours</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Until discharge</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-12-01 10:06:36 -0200" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2017-02-24 15:43:11 -0300" MODIFIED_BY="[Empty name]">Subgroup analyses on length of hospital stay among inpatients</TITLE><TABLE COLS="6" ROWS="18"><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM"><P><B>Subgroups</B></P></TH><TH ALIGN="CENTER" COLSPAN="5" VALIGN="BOTTOM"><P><B>Length of hospital stay (days)</B></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Trial (n)</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Participants (N)</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Effect size (MD, 95% CI)</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>P values</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Heterogeneity (I²)</P></TH></TR><TR><TH COLSPAN="6"><P>Virological investigation</P></TH></TR><TR><TD VALIGN="TOP"><P>Available</P><P>Not available</P></TD><TD VALIGN="TOP"><P>10</P><P>7</P></TD><TD VALIGN="TOP"><P>1179</P><P>688</P></TD><TD VALIGN="TOP"><P>-0.58 (-1.12 to -0.04)</P><P>-0.05 (-0.24 to 0.13)</P></TD><TD VALIGN="TOP"><P>0.03</P><P>0.60</P></TD><TD><P>84%</P><P>0%</P></TD></TR><TR><TH COLSPAN="6" VALIGN="BOTTOM"><P><B>Upper age limits for infants</B></P></TH></TR><TR><TD><P>12 months</P><P>18 to 24 months</P></TD><TD><P>6</P><P>11</P></TD><TD><P>609</P><P>1258</P></TD><TD><P>-0.37 (-0.79 to 0.04)</P><P>-0.41 (-0.86 to 0.03)</P></TD><TD><P>0.08</P><P>0.07</P></TD><TD><P>23%</P><P>86%</P></TD></TR><TR><TH COLSPAN="6"><P>Hypertonic saline solution plus bronchodilator</P></TH></TR><TR><TD VALIGN="TOP"><P>&#946;&#8322; agonist</P><P>Epinephrine</P><P>No</P></TD><TD VALIGN="TOP"><P>9</P><P>5</P><P>3</P></TD><TD VALIGN="TOP"><P>1049</P><P>356</P><P>462</P></TD><TD VALIGN="TOP"><P>-0.22 (-0.67 to 0.22)</P><P>-0.65 (-1.01 to -0.30)</P><P>-0.51 (-1.67 to 0.65)</P></TD><TD VALIGN="TOP"><P>0.32</P><P>P &lt; 0.001</P><P>0.39</P></TD><TD><P>81%</P><P>0%</P><P>79%</P></TD></TR><TR><TH COLSPAN="6"><P>Administration interval*</P></TH></TR><TR><TD VALIGN="TOP"><P>A</P><P>B</P></TD><TD VALIGN="TOP"><P>12</P><P>5</P></TD><TD VALIGN="TOP"><P>1375</P><P>492</P></TD><TD VALIGN="TOP"><P>-0.38 (-0.77 to 0.002)</P><P>-0.51 (-1.35 to 0.32)</P></TD><TD VALIGN="TOP"><P>0.05</P><P>0.22</P></TD><TD><P>75%</P><P>88%</P></TD></TR><TR><TH COLSPAN="6"><P>Hypertonic saline concentration</P></TH></TR><TR><TD VALIGN="TOP"><P>3%</P><P>&gt; 3%</P></TD><TD VALIGN="TOP"><P>14</P><P>3</P></TD><TD><P>1461</P><P>406</P></TD><TD><P>-0.49 (-0.86 to -0.13)</P><P>0.09 (-0.65 to 0.85)</P></TD><TD><P>0.01</P><P>0.79</P></TD><TD><P>52%</P><P>79%</P></TD></TR><TR><TH COLSPAN="6"><P>Length of stay in the control group</P></TH></TR><TR><TD><P>&lt; 3 days</P><P>&#8805; 3 days</P></TD><TD><P>4</P><P>13</P></TD><TD><P>594</P><P>1273</P></TD><TD><P>0.07 (-0.29 to 0.44)</P><P>-0.59 (-0.97 to -0.20)</P></TD><TD><P>0.69</P><P>0.003</P></TD><TD><P>59%</P><P>68%</P></TD></TR><TR><TH COLSPAN="6"><P>Risk of selection bias</P></TH></TR><TR><TD VALIGN="TOP"><P>Low</P><P>Unclear/high</P></TD><TD VALIGN="TOP"><P>11</P><P>6</P></TD><TD VALIGN="TOP"><P>1366</P><P>501</P></TD><TD VALIGN="TOP"><P>-0.37 (-0.81 to 0.06)</P><P>-0.51 (-1.02 to 0.004)</P></TD><TD VALIGN="TOP"><P>0.09</P><P>0.05</P></TD><TD><P>82%</P><P>64%</P></TD></TR><TR><TH COLSPAN="6"><P>Year of publication</P></TH></TR><TR><TD><P>Before 2013</P><P>2013 and thereafter</P></TD><TD><P>7</P><P>10</P></TD><TD><P>577</P><P>1290</P></TD><TD><P>-0.98 (-1.41 to -0.55)</P><P>0.02 (-0.15 to 0.20)</P></TD><TD><P>P &lt; 0.001</P><P>0.75</P></TD><TD><P>59%</P><P>3%</P></TD></TR></TABLE><FOOTNOTES><P>Abbreviations: CI: confidence interval; MD: mean difference<BR/>*A: every 4 to 6 hours; B: every 8 hours</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2017-12-01 10:24:42 -0200" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2017-05-04 04:46:24 -0300" MODIFIED_BY="[Empty name]">Sensitivity analyses: length of hospital stay among inpatients</TITLE><TABLE COLS="4" ROWS="7"><TR><TH ALIGN="CENTER" COLSPAN="4" VALIGN="BOTTOM"><P><B>Length of hospital stay</B></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Effect size<BR/>(RR, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P><B>Heterogeneity</B><BR/><B>(I²)</B></P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Trials excluded from analysis</P></TH><TH VALIGN="BOTTOM"><P><B>Reasons for exclusion</B></P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.51 (-0.91 to -0.11)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>82%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK>; <LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Open trials</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.49 (-0.83 to -0.15)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>75%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Mean and standard deviation were estimated from median and interquartile range.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.49 (-0.87 to -0.11)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>80%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-NCT01238848" TYPE="STUDY">NCT01238848</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Withdrawal rate &gt; 15% or data obtained from a part of study sample.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.45 (-0.78 to -0.12)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>80%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Did not use 0.9% saline as the control</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.22 (-0.48 to 0.05)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>50%</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK>; <LINK REF="STD-Ojha-2014" TYPE="STUDY">Ojha 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Very short (&lt; 2 days) or very long (&gt; 6 days) length of stay in the control group</P></TD></TR></TABLE><FOOTNOTES><P>Abbreviations: CI: confidence interval; RR: risk ratio</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2017-11-20 22:16:10 -0200" MODIFIED_BY="[Empty name]" NO="4"><TITLE MODIFIED="2017-05-04 04:44:39 -0300" MODIFIED_BY="[Empty name]">Subgroup analyses: hospitalisation rate among outpatients and emergency department patients</TITLE><TABLE COLS="6" ROWS="16"><TR><TH ROWSPAN="2" VALIGN="BOTTOM"><P><B>Subgroups</B></P></TH><TH ALIGN="CENTER" COLSPAN="5" VALIGN="BOTTOM"><P><B>Hospitalisation rate (%)</B></P></TH></TR><TR><TH VALIGN="BOTTOM"><P>Trial (n)</P></TH><TH VALIGN="BOTTOM"><P>Participants (N)</P></TH><TH VALIGN="BOTTOM"><P>Effect size<BR/>(RR, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P>P values</P></TH><TH VALIGN="BOTTOM"><P>Heterogeneity<BR/>(I²)</P></TH></TR><TR><TH COLSPAN="6" VALIGN="BOTTOM"><P>Virological investigation</P></TH></TR><TR><TD VALIGN="TOP"><P>Available</P><P>Not available</P></TD><TD VALIGN="TOP"><P>5</P><P>3</P></TD><TD VALIGN="TOP"><P>1392</P><P>331</P></TD><TD VALIGN="TOP"><P>0.81 (0.69 to 0.96)</P><P>1.04 (0.75 to 1·44)</P></TD><TD VALIGN="TOP"><P>0.01</P><P>0.81</P></TD><TD VALIGN="TOP"><P>21%</P><P>0%</P></TD></TR><TR><TH COLSPAN="6"><P><B>Upper age limits for infants</B></P></TH></TR><TR><TD><P>12 months</P><P>18 to 24 months</P></TD><TD><P>2</P><P>6</P></TD><TD><P>818</P><P>905</P></TD><TD><P>0.86 (0.64 to 1.15)</P><P>0.82 (0.66 to 1.01)</P></TD><TD><P>0.31</P><P>0.06</P></TD><TD><P>26%</P><P>9%</P></TD></TR><TR><TH COLSPAN="6"><P>Hypertonic saline solution plus bronchodilator*</P></TH></TR><TR><TD VALIGN="TOP"><P>&#946;&#8322; agonist</P><P>Epinephrine</P><P>No</P></TD><TD VALIGN="TOP"><P>3</P><P>3</P><P>3</P></TD><TD VALIGN="TOP"><P>257</P><P>224</P><P>1242</P></TD><TD VALIGN="TOP"><P>0.65 (0.28 to 1.55)</P><P>0.78 (0.54 to 1.12)</P><P>0.87 (0.68 to 1.11)</P></TD><TD VALIGN="TOP"><P>0.34</P><P>0.18</P><P>0.27</P></TD><TD VALIGN="TOP"><P>0%</P><P>0%</P><P>65%</P></TD></TR><TR><TH COLSPAN="6"><P>Administration interval**</P></TH></TR><TR><TD VALIGN="TOP"><P>A</P><P>B</P></TD><TD VALIGN="TOP"><P>3</P><P>5</P></TD><TD VALIGN="TOP"><P>209</P><P>1514</P></TD><TD VALIGN="TOP"><P>0.91 (0.67 to 1.23)</P><P>0.83 (0.70 to 0.98)</P></TD><TD VALIGN="TOP"><P>0.54</P><P>0.02</P></TD><TD VALIGN="TOP"><P>24%</P><P>11%</P></TD></TR><TR><TH COLSPAN="6"><P>Hypertonic saline concentration</P></TH></TR><TR><TD VALIGN="TOP"><P>3%</P><P>&gt; 3%</P></TD><TD VALIGN="TOP"><P>7</P><P>1</P></TD><TD VALIGN="TOP"><P>1622</P><P>101</P></TD><TD VALIGN="TOP"><P>0.85 (0.71 to 1.00)</P><P>0.86 (0.56 to 1.32)</P></TD><TD VALIGN="TOP"><P>0.05</P><P>0.50</P></TD><TD VALIGN="TOP"><P>20%</P><P>-</P></TD></TR><TR><TH COLSPAN="6"><P>Risk of selection bias</P></TH></TR><TR><TD VALIGN="TOP"><P>Low</P><P>Unclear/high</P></TD><TD VALIGN="TOP"><P>6</P><P>2</P></TD><TD VALIGN="TOP"><P>1454</P><P>269</P></TD><TD VALIGN="TOP"><P>0.85 (0.72 to 1.00)</P><P>0.66 (0.24 to 1.78)</P></TD><TD VALIGN="TOP"><P>0.06</P><P>0.42</P></TD><TD VALIGN="TOP"><P>29%</P><P>0%</P></TD></TR><TR><TH COLSPAN="6"><P>Year of publication</P></TH></TR><TR><TD VALIGN="TOP"><P>Before 2013</P><P>2013 and thereafter</P></TD><TD VALIGN="TOP"><P>4</P><P>4</P></TD><TD VALIGN="TOP"><P>380</P><P>1343</P></TD><TD VALIGN="TOP"><P>0.63 (0.37 to 1.06)</P><P>0.87 (0.72 to 1.05)</P></TD><TD VALIGN="TOP"><P>0.08</P><P>0.15</P></TD><TD VALIGN="TOP"><P>0%</P><P>48%</P></TD></TR></TABLE><FOOTNOTES><P>Abbreviations: CI: confidence interval; RR: risk ratio</P><P>*<LINK REF="STD-Anil-2010" TYPE="STUDY">Anil 2010</LINK> used two intervention groups: hypertonic saline plus salbutamol and hypertonic saline plus epinephrine.<BR/>**Regimen A: single dose; regimen B: multiple doses (&#8805; 2).</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2017-11-28 23:12:41 -0200" MODIFIED_BY="[Empty name]" NO="5"><TITLE MODIFIED="2017-11-28 23:12:41 -0200" MODIFIED_BY="[Empty name]">Narrative summary: adverse events of treatment reported in 11 trials</TITLE><TABLE COLS="3" ROWS="12"><TR><TH VALIGN="TOP"><P>Trials</P></TH><TH VALIGN="TOP"><P>Comparisions</P></TH><TH VALIGN="TOP"><P>Narrative summary</P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Everard-2014" TYPE="STUDY">Everard 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline (N = 142) versus standard care (N = 143)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>6 AEs were possibly related to saline treatment, including 1 SAE, bradycardia and desaturation, which resolved the following day. The remaining 5 non-SAEs were: bradycardia (self correcting), desaturation, coughing fit, and increased respiratory rate (all of which were resolved within 1 day); and a chest infection, which resolved after 6 days.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Flores-2016" TYPE="STUDY">Flores 2016</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline + salbutamol (N = 33) versus 0.9% saline + salbutamol (N = 35)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Exacerbation of coughing and excessive rhinorrhoea were more common in the 3% saline group (45.5% and 57.6%) than in the 0.9% saline group (20% and 31.4%). There was no significant difference in bronchial constriction and agitation between the 2 groups. Apnoea, cyanosis, saturation dips, tachycardia, and vomiting were not observed.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Grewal-2009" TYPE="STUDY">Grewal 2009</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline + epinephrine (N = 23) versus 0.9% saline + epinephrine (N = 23)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Adverse events were noted in 4 infants (vomiting 3; diarrhoea 1) in the hypertonic saline group. No additional bronchodilators were given to any enrolled infant during the study period.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-K_x00f6_se-2016" TYPE="STUDY">Köse 2016</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline + salbutamol (N = 35), 7% saline + salbutamol (N = 32) versus 0.9% saline + salbutamol (N = 35)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No AEs were reported in the 3% and 0.9% saline groups. In the 7% saline group, bronchospasm was observed in 2 infants, and exacerbation of coughing was observed in another 2 infants. Both bronchospasm and cough was observed during nebulisation in 1 infant.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Kuzik-2007" TYPE="STUDY">Kuzik 2007</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline (N = 47) versus 0.9% saline (N = 49)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No infants were withdrawn by the medical staff due to AEs, although 5 infants were withdrawn at parents&#8217; request due to perceived AEs, only 2 of which were from the hypertonic saline group (1 presented with vigorous crying and another with agitation).</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Li-2014" TYPE="STUDY">Li 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>5% saline (N = 40), 3% saline (N = 42) versus 0.9% saline (N = 42)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No AEs were observed in the 3% and 0.9% saline groups. 4 infants from the 5% saline group presented with paroxysmal cough during saline inhalation.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Luo-2011" TYPE="STUDY">Luo 2011</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline (N = 57) versus 0.9% saline (N = 55)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No infants were withdrawn by the medical staff due to AEs. Coughing and wheezing did not worsen during saline inhalation. Although 5 infants had hoarse voices, only 2 of these were from the hypertonic saline group, and the symptom disappeared after 3 to 4 days.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Pandit-2013" TYPE="STUDY">Pandit 2013</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline + epinephrine (N = 51) versus 0.9% saline + epinephrine (N = 49)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No AEs were observed in the 3% saline group. In the 0.9% saline group, 3 infants had vomiting, and 1 infant had diarrhoea.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Teunissen-2014" TYPE="STUDY">Teunissen 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3%, 6% saline + salbutamol (N = 167) versus 0.9% saline + salbutamol (N = 80)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>A substantial number of AEs (cough, bronchospasm, agitation, desaturation, etc.) were noted in all treatment groups. Except for cough, which occurred more significantly in the hypertonic saline groups (P = 0.03), no differences were found between groups. Withdrawals due to AEs did not differ between groups (4.3%, 6.1%, and 7.9% in the 3%, 6%, and 0.9% saline groups, respectively; P = 0.59).</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Wu-2014" TYPE="STUDY">Wu 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline (N = 211) versus 0.9% saline (N = 197)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 infants in the normal saline group and 4 infants in the hypertonic saline group withdrew owing to parent request. Of these parent requests, 1 in the normal saline group and 2 in the hypertonic saline group were attributed to worsening cough. For these 3 infants, pre-treatment and post-treatment vital signs and Respiratory Distress Assessment Instrument score were the same or improved, and no intervention or additional treatment was necessary.</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Angoulvant-2017" TYPE="STUDY">Angoulvant 2017</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3% saline (N = 385) versus 0.9% saline (N = 387)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No SAEs were reported. Mild AEs occurred 57 times among 50 infants: in 35 of 392 infants (8.9%) in the HS group versus 15 of 384 infants (3.9%) in the NS group (risk difference 5.0%, 95% confidence interval 1.6% to 8.4%; P = 0.005). Worsening of cough without respiratory distress was the most frequent AE, occurring in 26 infants (6.6%) in the HS group and 3 infants (0.8%) in the NS group. Bronchospasm occurred in 3 infants (0.8%) in the NS group.</P></TD></TR></TABLE><FOOTNOTES><P>Abbreviations:<BR/>AE: adverse event<BR/>HS: hypertonic saline<BR/>NS: normal saline<BR/>SAE: serious adverse event<BR/></P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2017-12-01 10:11:21 -0200" MODIFIED_BY="[Empty name]" NO="6"><TITLE MODIFIED="2017-11-21 01:52:54 -0200" MODIFIED_BY="[Empty name]">Comparative summary: main findings of 4 systematic reviews addressing efficacy and safety of nebulised hypertonic saline for infants with acute bronchiolitis</TITLE><TABLE COLS="8" ROWS="5"><TR><TH VALIGN="BOTTOM"><P>Review</P></TH><TH VALIGN="BOTTOM"><P>Trials included<BR/>(n)</P></TH><TH VALIGN="BOTTOM"><P>Participants<BR/>(N)</P></TH><TH VALIGN="BOTTOM"><P>Hospital length-of-stay reduction<BR/>(MD, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P>Clinical score reduction<BR/>(MD, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P>Hospitalisation rate reduction<BR/>(RR, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P>Re-admission rate reduction<BR/>(RR, 95% CI)</P></TH><TH VALIGN="BOTTOM"><P>Other findings</P></TH></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="REF-Chen-2014" TYPE="REFERENCE">Chen 2014</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>11</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>1070</P><P>(infants with previous wheeze excluded)</P><P/><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.96 (-1.38 to -0.54)</P><P>(6 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Day 1: -0.77 (-1.30 to -0.24)</P><P>Day 2: -0.85 (-1.30 to -0.39)</P><P>Day 3: -1.14 (-1.69 to -0.58)</P><P>(6 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0.59 (0.37 to 0.93)</P><P>(5 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>1.08 (0.68 to 1.73)</P><P>(3 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>None</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="REF-Badgett-2015" TYPE="REFERENCE">Badgett 2015</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>19</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2441</P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.42 (-0.72 to -0.11)</P><P>(19 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="REF-Maguire-2015" TYPE="REFERENCE">Maguire 2015</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>1922</P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.36 (-0.50 to -0.22)</P><P>(15 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-1.36 (-1.52 to -1.20)</P><P>(5 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P><P/><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="REF-Zhang-2015" TYPE="REFERENCE">Zhang 2015</LINK></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>24</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3209</P><P>(infants with previous wheeze excluded)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-0.51 (-0.91 to -0.11)</P><P>(14 trials)*</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Day 1: -0.99 (-1.48 to -0.50)</P><P>Day 2: -1.45 (-2.06 to -0.85)</P><P>Day 3: -1.44 (-1.78 to -1.11)</P><P>(5 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0.80 (0.67 to 0.96)</P><P>(7 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Re-admission to<BR/>hospital</P><P>1.45 (0.67 to 3.14)</P><P>(4 trials)</P><P>Re-admission to<BR/>emergency department</P><P>0.78 (0.46 to 1.32)</P><P>(5 trials)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No significant difference between the hypertonic saline group and the control group in terms of oxygen saturation, duration of oxygen supplementation, respiratory rate, heart rate, radiograph scores, and parental perception of improvement</P></TD></TR></TABLE><FOOTNOTES><P>Abbreviations: CI: confidence interval; MD: mean difference; RR: risk ratio</P><P>*<LINK REF="REF-Zhang-2015" TYPE="REFERENCE">Zhang 2015</LINK> included one unpublished inpatient trial (NCT01488448) that included infants with previous wheeze. In the erratum (<LINK REF="REF-Zhang-2016" TYPE="REFERENCE">Zhang 2016</LINK>), removal of this trial from the meta-analysis changed the results of hypertonic saline on length of hospital stay from MD -0.45 days (95% CI -0.82 to -0.08) to MD -0.51 days (95% CI -0.91 to -0.11).</P></FOOTNOTES></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-10-25 22:11:11 -0200" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2017-10-25 22:11:11 -0200" MODIFIED_BY="[Empty name]" NO="1"><NAME>Hypertonic saline versus normal saline (0.9%)</NAME><CONT_OUTCOME CHI2="76.46118413202687" CI_END="-0.07032251949150836" CI_START="-0.7548437267682299" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4125831231298691" ESTIMABLE="YES" I2="79.07434970877182" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2017-10-25 22:11:11 -0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="7.178836414212242E-10" P_Q="1.0" P_Z="0.018143931969636845" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="YEAR" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.36301583203091403" TOTALS="YES" TOTAL_1="994" TOTAL_2="873" UNITS="" WEIGHT="100.0" Z="2.3626676671733784"><NAME>Length of hospital stay (days)</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_DATA CI_END="-0.12845857385974757" CI_START="-1.8715414261402525" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" MODIFIED="2012-12-04 20:52:13 -0200" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="1.2" SD_2="1.9" SE="0.4446721638840611" STUDY_ID="STD-Mandelberg-2003" TOTAL_1="27" TOTAL_2="25" WEIGHT="5.438122746882247"/><CONT_DATA CI_END="0.05583835254106628" CI_START="-1.855838352541066" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.5" MODIFIED="2012-12-04 20:52:13 -0200" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="1.4" SD_2="1.7" SE="0.4876815901111434" STUDY_ID="STD-Tal-2006" TOTAL_1="21" TOTAL_2="20" WEIGHT="5.075188528578422"/><CONT_DATA CI_END="0.105230942402472" CI_START="-1.9052309424024718" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.5" MODIFIED="2017-05-09 15:03:56 -0300" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="1.9" SD_2="2.9" SE="0.5128823541307929" STUDY_ID="STD-Kuzik-2007" TOTAL_1="45" TOTAL_2="46" WEIGHT="4.8707833442921125"/><CONT_DATA CI_END="-0.8417522232600458" CI_START="-1.9582477767399549" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="7.4" MODIFIED="2017-10-25 22:11:02 -0200" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="1.2" SD_2="1.5" SE="0.2848255279909946" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="6.865882575412703"/><CONT_DATA CI_END="-1.1163234508871684" CI_START="-2.0836765491128326" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="6.4" MODIFIED="2017-10-25 22:11:05 -0200" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="1.2" SD_2="1.4" SE="0.24677828415624514" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="7.19347097442756"/><CONT_DATA CI_END="1.394581690297244" CI_START="-0.734581690297244" EFFECT_SIZE="0.33000000000000007" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.47" MODIFIED="2017-02-23 11:09:48 -0300" MODIFIED_BY="[Empty name]" ORDER="941" SD_1="2.7" SD_2="2.1" SE="0.5431639043852482" STUDY_ID="STD-NCT01238848" TOTAL_1="37" TOTAL_2="45" WEIGHT="4.634079299679847"/><CONT_DATA CI_END="-0.1459593742116151" CI_START="-1.2540406257883836" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.6" MODIFIED="2013-05-10 20:17:19 -0300" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="1.3" SD_2="1.6" SE="0.28267898296019006" STUDY_ID="STD-Miraglia-Del-Giudice--2012" TOTAL_1="52" TOTAL_2="54" WEIGHT="6.884765846401677"/><CONT_DATA CI_END="0.23435300586201313" CI_START="-1.494353005862013" EFFECT_SIZE="-0.6299999999999999" ESTIMABLE="YES" MEAN_1="2.25" MEAN_2="2.88" MODIFIED="2016-08-12 14:37:40 -0300" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="0.89" SD_2="1.76" SE="0.4410045351240733" STUDY_ID="STD-Mahesh-Kumar-2013" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.469808502982564"/><CONT_DATA CI_END="0.5512301593153789" CI_START="-0.8712301593153792" EFFECT_SIZE="-0.16000000000000014" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="4.08" MODIFIED="2016-08-12 11:41:08 -0300" MODIFIED_BY="[Empty name]" ORDER="51" SD_1="1.72" SD_2="1.9" SE="0.3628791982533719" STUDY_ID="STD-Pandit-2013" TOTAL_1="51" TOTAL_2="49" WEIGHT="6.164221534369135"/><CONT_DATA CI_END="0.21661546803491724" CI_START="-0.2366154680349177" EFFECT_SIZE="-0.010000000000000231" ESTIMABLE="YES" MEAN_1="2.65" MEAN_2="2.66" MODIFIED="2016-08-12 11:40:32 -0300" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="0.89" SD_2="0.93" SE="0.11562226133869365" STUDY_ID="STD-Sharma-2013" TOTAL_1="125" TOTAL_2="123" WEIGHT="8.101885420485562"/><CONT_DATA CI_END="1.0186879433363694" CI_START="0.10131205666362997" EFFECT_SIZE="0.5599999999999996" ESTIMABLE="YES" MEAN_1="3.03" MEAN_2="2.47" MODIFIED="2016-08-12 14:34:54 -0300" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="1.95" SD_2="1.6" SE="0.23402876121930893" STUDY_ID="STD-Teunissen-2014" TOTAL_1="167" TOTAL_2="80" WEIGHT="7.299018997944283"/><CONT_DATA CI_END="0.7357823243020136" CI_START="-0.6157823243020144" EFFECT_SIZE="0.05999999999999961" ESTIMABLE="YES" MEAN_1="3.76" MEAN_2="3.7" MODIFIED="2017-09-25 23:02:39 -0300" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="3.05" SD_2="2.82" SE="0.34479323581070814" STUDY_ID="STD-Everard-2014" TOTAL_1="142" TOTAL_2="149" WEIGHT="6.32793968530141"/><CONT_DATA CI_END="0.6784835210279889" CI_START="-2.4784835210279885" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="4.5" MODIFIED="2017-05-07 10:16:05 -0300" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="1.7" SD_2="3.8" SE="0.8053635339622898" STUDY_ID="STD-Tinsa-2014" TOTAL_1="31" TOTAL_2="26" WEIGHT="3.014376880597477"/><CONT_DATA CI_END="0.5967927699287847" CI_START="-0.4967927699287846" EFFECT_SIZE="0.050000000000000044" ESTIMABLE="YES" MEAN_1="1.87" MEAN_2="1.82" MODIFIED="2017-10-25 22:11:11 -0200" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="0.96" SD_2="1.18" SE="0.27898102936677216" STUDY_ID="STD-Ojha-2014" TOTAL_1="28" TOTAL_2="31" WEIGHT="6.917202570632107"/><CONT_DATA CI_END="1.3185339680725137" CI_START="-0.9185339680725133" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.7" MODIFIED="2017-03-03 16:38:20 -0300" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="2.4" SD_2="2.3" SE="0.5706910825379276" STUDY_ID="STD-Flores-2016" TOTAL_1="33" TOTAL_2="35" WEIGHT="4.427768903777283"/><CONT_DATA CI_END="0.8081106592412302" CI_START="-1.0481106592412304" EFFECT_SIZE="-0.1200000000000001" ESTIMABLE="YES" MEAN_1="3.08" MEAN_2="3.2" MODIFIED="2017-05-09 15:54:49 -0300" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="2.11" SD_2="2.35" SE="0.4735345478600876" STUDY_ID="STD-K_x00f6_se-2016" TOTAL_1="67" TOTAL_2="35" WEIGHT="5.192709471342474"/><CONT_DATA CI_END="0.6702169204225478" CI_START="-0.7702169204225474" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="3.06" MEAN_2="3.11" MODIFIED="2017-05-20 14:15:54 -0300" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="1.61" SD_2="1.63" SE="0.36746436470441635" STUDY_ID="STD-Ratajczyk_x002d_Pekrul-2016" TOTAL_1="41" TOTAL_2="37" WEIGHT="6.122774716893153"/></CONT_OUTCOME><DICH_OUTCOME CHI2="7.527476969668716" CI_END="0.9795432452572366" CI_START="0.7579565192480517" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8616560732845302" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="355" I2="7.007354147932123" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.00897638584382281" LOG_CI_START="-0.12035570728649729" LOG_EFFECT_SIZE="-0.06466604656516006" METHOD="MH" MODIFIED="2017-09-03 14:51:10 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.37609569979934776" P_Q="1.0" P_Z="0.022853045296791684" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002903520951366004" TOTALS="YES" TOTAL_1="870" TOTAL_2="853" WEIGHT="100.00000000000001" Z="2.2758824645118154"><NAME>Rate of hospitalisation</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><DICH_DATA CI_END="3.616879841726863" CI_START="0.11554614955887724" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5583340810751983" LOG_CI_START="-0.9372445223025239" LOG_EFFECT_SIZE="-0.1894552206136627" MODIFIED="2013-03-29 20:45:37 -0300" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.8785102748575585" STUDY_ID="STD-Sarrell-2002" TOTAL_1="33" TOTAL_2="32" VAR="0.771780303030303" WEIGHT="0.5525350743544879"/><DICH_DATA CI_END="1.1960825237768211" CI_START="0.3166154653411966" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.07776114485681722" LOG_CI_START="-0.4994678754866035" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2013-02-15 21:37:33 -0200" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.33906718387945844" STUDY_ID="STD-Grewal-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.1149665551839465" WEIGHT="3.631455907380166"/><DICH_DATA CI_END="15.482621494741561" CI_START="0.06287766651414614" EFFECT_SIZE="0.9866666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.189844496677011" LOG_CI_START="-1.201503583998459" LOG_EFFECT_SIZE="-0.005829543660723844" MODIFIED="2013-02-15 21:35:45 -0200" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.404689699952681" STUDY_ID="STD-Anil-2010" TOTAL_1="75" TOTAL_2="74" VAR="1.973153153153153" WEIGHT="0.21661321251269453"/><DICH_DATA CI_END="1.80128068021618" CI_START="0.21685959567007587" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2555813909824164" LOG_CI_START="-0.6638213562942659" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2013-02-15 21:41:29 -0200" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Ipek-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.2916666666666667" WEIGHT="1.4531001516011095"/><DICH_DATA CI_END="1.5527918576762318" CI_START="0.779241592502151" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.1911132450905372" LOG_CI_START="-0.10832787477408704" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-08-18 15:12:11 -0300" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.17589319606592915" STUDY_ID="STD-Florin-2014" TOTAL_1="31" TOTAL_2="31" VAR="0.030938416422287396" WEIGHT="12.648211583127857"/><DICH_DATA CI_END="1.3239898126704803" CI_START="0.5635386503557074" EFFECT_SIZE="0.8637820512820513" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.121884643473759" LOG_CI_START="-0.24907629246512955" LOG_EFFECT_SIZE="-0.06359582449568527" MODIFIED="2016-08-18 15:12:23 -0300" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.21790429005675124" STUDY_ID="STD-Jacobs-2014" TOTAL_1="52" TOTAL_2="49" VAR="0.04748227962513678" WEIGHT="8.495250236919828"/><DICH_DATA CI_END="0.8850263109731383" CI_START="0.5194125724578575" EFFECT_SIZE="0.6780072218460844" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="84" LOG_CI_END="-0.05304381795687141" LOG_CI_START="-0.28448754241755725" LOG_EFFECT_SIZE="-0.16876568018721436" MODIFIED="2016-08-18 15:12:34 -0300" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.13595118941312" STUDY_ID="STD-Wu-2014" TOTAL_1="211" TOTAL_2="197" VAR="0.018482725902842036" WEIGHT="20.01473129918108"/><DICH_DATA CI_END="1.0599882077146467" CI_START="0.7995399250541226" EFFECT_SIZE="0.9205992027774206" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="202" LOG_CI_END="0.02530103379972778" LOG_CI_START="-0.09715984486612624" LOG_EFFECT_SIZE="-0.03592940553319925" MODIFIED="2017-09-03 14:51:10 -0300" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.07193412631944858" STUDY_ID="STD-Angoulvant-2017" TOTAL_1="385" TOTAL_2="387" VAR="0.005174518529342385" WEIGHT="52.98810253492278"/></DICH_OUTCOME><CONT_OUTCOME CHI2="31.3000332314927" CI_END="-0.3579525487894127" CI_START="-1.1784026197761288" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7681775842827707" ESTIMABLE="YES" I2="74.44092170499438" I2_Q="81.59112480293788" ID="CMP-001.03" MODIFIED="2017-09-15 11:11:29 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.2423354833102085E-4" P_Q="0.004373645447218855" P_Z="2.4237816125785493E-4" Q="10.864324835659605" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.28569554493309374" TOTALS="YES" TOTAL_1="457" TOTAL_2="355" UNITS="" WEIGHT="100.0" Z="3.6701816531370373"><NAME>Clinical severity score (post-treatment) at day 1</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.0" CI_END="-0.6373183028801944" CI_START="-1.9226816971198044" DF="0" EFFECT_SIZE="-1.2799999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2013-02-17 17:49:16 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="9.478356604250066E-5" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="11.140782739469564" Z="3.903571412495976"><NAME>Outpatients</NAME><CONT_DATA CI_END="-0.6373183028801945" CI_START="-1.9226816971198042" EFFECT_SIZE="-1.2799999999999994" ESTIMABLE="YES" MEAN_1="4.36" MEAN_2="5.64" MODIFIED="2013-02-15 15:38:21 -0200" MODIFIED_BY="[Empty name]" ORDER="1099" SD_1="1.05" SD_2="1.54" SE="0.327904850389699" STUDY_ID="STD-Sarrell-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="11.140782739469564"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.3308379892902933" CI_START="-0.5108379892902939" DF="0" EFFECT_SIZE="-0.0900000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2013-03-29 22:44:32 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6751021441443947" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="56" WEIGHT="13.203012587813946" Z="0.4191559771162369"><NAME>Emergency department patients</NAME><CONT_DATA CI_END="0.33083798929029323" CI_START="-0.5108379892902939" EFFECT_SIZE="-0.0900000000000003" ESTIMABLE="YES" MEAN_1="3.88" MEAN_2="3.97" MODIFIED="2013-02-17 17:48:40 -0300" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="1.13" SD_2="1.4" SE="0.21471720532102115" STUDY_ID="STD-Al_x002d_Ansari-2010" TOTAL_1="115" TOTAL_2="56" WEIGHT="13.203012587813946"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="18.363052251829103" CI_END="-0.37656623142041623" CI_START="-1.2544306850740474" DF="6" EFFECT_SIZE="-0.8154984582472319" ESTIMABLE="YES" I2="67.32569336667682" ID="CMP-001.03.03" MODIFIED="2017-09-15 11:11:29 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.005386169513552197" P_Z="2.711119419895892E-4" STUDIES="7" TAU2="0.23210378105320756" TOTAL_1="309" TOTAL_2="267" WEIGHT="75.6562046727165" Z="3.6414451022826286"><NAME>Inpatients</NAME><CONT_DATA CI_END="0.713747090934156" CI_START="-0.9337470909341549" EFFECT_SIZE="-0.10999999999999943" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="7.81" MODIFIED="2012-12-04 20:53:18 -0200" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="1.54" SD_2="1.49" SE="0.4202868508971427" STUDY_ID="STD-Mandelberg-2003" TOTAL_1="27" TOTAL_2="25" WEIGHT="9.475232656665025"/><CONT_DATA CI_END="-0.1070271080746159" CI_START="-1.392972891925384" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="6.25" MEAN_2="7.0" MODIFIED="2012-12-04 20:53:18 -0200" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="1.1" SD_2="1.0" SE="0.3280534218980921" STUDY_ID="STD-Tal-2006" TOTAL_1="21" TOTAL_2="20" WEIGHT="11.138022241759355"/><CONT_DATA CI_END="-0.8926979488859821" CI_START="-2.1073020511140186" EFFECT_SIZE="-1.5000000000000004" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.9" MODIFIED="2012-12-04 20:53:12 -0200" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="1.2" SD_2="1.7" SE="0.30985367889631615" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="11.476790801363622"/><CONT_DATA CI_END="-1.0054516569303722" CI_START="-2.194548343069627" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="7.3" MODIFIED="2012-12-04 20:53:14 -0200" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="1.5" SD_2="1.7" SE="0.3033465654263797" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="11.598031183400835"/><CONT_DATA CI_END="-0.2459593742116165" CI_START="-1.354040625788385" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="8.8" MODIFIED="2013-05-10 20:21:52 -0300" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="1.3" SD_2="1.6" SE="0.28267898296019006" STUDY_ID="STD-Miraglia-Del-Giudice--2012" TOTAL_1="52" TOTAL_2="54" WEIGHT="11.982251926057476"/><CONT_DATA CI_END="0.43036839864592613" CI_START="-0.8303683986459247" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="4.6" MODIFIED="2016-11-26 20:27:16 -0200" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="1.2" SD_2="1.7" SE="0.3216224398091959" STUDY_ID="STD-K_x00f6_se-2016" TOTAL_1="69" TOTAL_2="35" WEIGHT="11.257608175892361"/><CONT_DATA CI_END="0.41134698687131566" CI_START="-1.4113469868713158" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="6.3" MODIFIED="2016-11-26 20:21:06 -0200" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="2.1" SD_2="1.7" SE="0.46498149662948113" STUDY_ID="STD-Flores-2016" TOTAL_1="33" TOTAL_2="35" WEIGHT="8.728267687577818"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="57.01526726648531" CI_END="-0.6510138734651152" CI_START="-1.9051415673273988" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.278077720396257" ESTIMABLE="YES" I2="87.7225867112356" I2_Q="89.40411999877661" ID="CMP-001.04" MODIFIED="2017-09-24 07:39:06 -0300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="5.936073854684309E-10" P_Q="7.966947721005369E-5" P_Z="6.475252861317823E-5" Q="18.875260948303314" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.6860206135794068" TOTALS="YES" TOTAL_1="384" TOTAL_2="319" UNITS="" WEIGHT="100.0" Z="3.9947866771129465"><NAME>Clinical severity score (post-treatment) at day 2</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.0" CI_END="-1.0679406481933773" CI_START="-2.932059351806622" DF="0" EFFECT_SIZE="-1.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2013-02-15 15:53:23 -0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.6031734685790373E-5" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="11.22154521261439" Z="4.205663471410981"><NAME>Outpatients</NAME><CONT_DATA CI_END="-1.0679406481933773" CI_START="-2.932059351806622" EFFECT_SIZE="-1.9999999999999996" ESTIMABLE="YES" MEAN_1="2.77" MEAN_2="4.77" MODIFIED="2013-02-15 15:53:23 -0200" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="1.4" SD_2="2.31" SE="0.47554922394420895" STUDY_ID="STD-Sarrell-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="11.22154521261439"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="0.08981573395873155" CI_START="-0.6298157339587316" DF="0" EFFECT_SIZE="-0.27" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2013-02-17 17:51:35 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14136529149615126" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="56" WEIGHT="14.222036833812547" Z="1.4707257795639066"><NAME>Emergency department patients</NAME><CONT_DATA CI_END="0.08981573395873155" CI_START="-0.6298157339587316" EFFECT_SIZE="-0.27" ESTIMABLE="YES" MEAN_1="3.85" MEAN_2="4.12" MODIFIED="2013-02-17 17:51:35 -0300" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="1.16" SD_2="1.11" SE="0.183582829478966" STUDY_ID="STD-Al_x002d_Ansari-2010" TOTAL_1="115" TOTAL_2="56" WEIGHT="14.222036833812547"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="20.431027238353632" CI_END="-0.8368521090309508" CI_START="-1.9450091926790742" DF="5" EFFECT_SIZE="-1.3909306508550126" ESTIMABLE="YES" I2="75.52741748288663" ID="CMP-001.04.03" MODIFIED="2017-09-24 07:39:06 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.001037077949153864" P_Z="8.645842199446391E-7" STUDIES="6" TAU2="0.34711283382098984" TOTAL_1="236" TOTAL_2="231" WEIGHT="74.55641795357306" Z="4.920194114888376"><NAME>Inpatients</NAME><CONT_DATA CI_END="0.3367467851633926" CI_START="-1.3567467851633923" EFFECT_SIZE="-0.5099999999999998" ESTIMABLE="YES" MEAN_1="6.41" MEAN_2="6.92" MODIFIED="2012-12-04 20:54:16 -0200" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="1.4" SD_2="1.62" SE="0.4320216043980517" STUDY_ID="STD-Mandelberg-2003" TOTAL_1="24" TOTAL_2="25" WEIGHT="11.729530818550153"/><CONT_DATA CI_END="-0.3811980722178332" CI_START="-1.8188019277821679" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="5.35" MEAN_2="6.45" MODIFIED="2013-02-15 15:54:49 -0200" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="1.3" SD_2="1.0" SE="0.366742416417845" STUDY_ID="STD-Tal-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.474922226768403"/><CONT_DATA CI_END="-1.0578101166012877" CI_START="-2.1421898833987116" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.8" MODIFIED="2012-12-04 20:54:11 -0200" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="1.1" SD_2="1.5" SE="0.27663257471843195" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="13.423358358246416"/><CONT_DATA CI_END="-1.9114333765584703" CI_START="-2.8885666234415304" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.9" MODIFIED="2012-12-04 20:54:13 -0200" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="1.1" SD_2="1.5" SE="0.2492732658841086" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="13.681513694703296"/><CONT_DATA CI_END="-0.8080687262102314" CI_START="-1.9919312737897674" EFFECT_SIZE="-1.3999999999999995" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.2" MODIFIED="2013-05-10 20:22:59 -0300" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="1.4" SD_2="1.7" SE="0.3020113014620913" STUDY_ID="STD-Miraglia-Del-Giudice--2012" TOTAL_1="52" TOTAL_2="54" WEIGHT="13.169733384210451"/><CONT_DATA CI_END="0.22542694458607304" CI_START="-2.025426944586072" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.8" MODIFIED="2016-11-26 20:22:08 -0200" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="2.3" SD_2="2.4" SE="0.574207971913411" STUDY_ID="STD-Flores-2016" TOTAL_1="33" TOTAL_2="34" WEIGHT="10.077359471094347"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="15.202622583022816" CI_END="-1.0369126544989702" CI_START="-1.8163981015089816" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.426655378003976" ESTIMABLE="YES" I2="60.53312533917428" I2_Q="74.92417487321046" ID="CMP-001.05" MODIFIED="2017-09-15 11:11:48 -0300" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.01873801487422677" P_Q="0.04582809676106847" P_Z="7.259371528354401E-13" Q="3.9879046649262944" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.13348445148080348" TOTALS="YES" TOTAL_1="250" TOTAL_2="249" UNITS="" WEIGHT="99.99999999999999" Z="7.174458920211905"><NAME>Clinical severity score (post-treatment) at day 3</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.0" CI_END="-1.4302900012293096" CI_START="-3.849709998770691" DF="0" EFFECT_SIZE="-2.64" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2013-07-21 21:05:38 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.891651205230742E-5" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="32" WEIGHT="7.686541973035905" Z="4.277310201985502"><NAME>Outpatients</NAME><CONT_DATA CI_END="-1.4302900012293096" CI_START="-3.849709998770691" EFFECT_SIZE="-2.64" ESTIMABLE="YES" MEAN_1="1.77" MEAN_2="4.41" MODIFIED="2013-02-15 15:58:46 -0200" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="2.4" SD_2="2.57" SE="0.6172103203491128" STUDY_ID="STD-Sarrell-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="7.686541973035905"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="11.599236682826472" CI_END="-0.9793413149394541" CI_START="-1.7220247921568592" DF="5" EFFECT_SIZE="-1.3506830535481567" ESTIMABLE="YES" I2="56.89371519245857" ID="CMP-001.05.02" MODIFIED="2017-09-15 11:11:48 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04071155906105628" P_Z="1.0111085118952373E-12" STUDIES="6" TAU2="0.10087006387866326" TOTAL_1="217" TOTAL_2="217" WEIGHT="92.31345802696408" Z="7.1289862254685215"><NAME>Inpatients</NAME><CONT_DATA CI_END="0.8275265701592689" CI_START="-1.3675265701592698" EFFECT_SIZE="-0.27000000000000046" ESTIMABLE="YES" MEAN_1="5.81" MEAN_2="6.08" MODIFIED="2012-12-04 20:54:58 -0200" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="1.68" SD_2="2.03" SE="0.5599728254276195" STUDY_ID="STD-Mandelberg-2003" TOTAL_1="21" TOTAL_2="23" WEIGHT="8.845040951659527"/><CONT_DATA CI_END="-0.050846870419172685" CI_START="-1.9891531295808265" EFFECT_SIZE="-1.0199999999999996" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="5.72" MODIFIED="2012-12-04 20:54:54 -0200" MODIFIED_BY="[Empty name]" ORDER="1106" SD_1="1.5" SD_2="1.0" SE="0.4944749685327807" STUDY_ID="STD-Tal-2006" TOTAL_1="13" TOTAL_2="14" WEIGHT="10.46115413197459"/><CONT_DATA CI_END="-1.1384673855018304" CI_START="-1.6615326144981695" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.9" MODIFIED="2012-12-04 20:54:49 -0200" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="0.5" SD_2="0.7" SE="0.13343745934165396" STUDY_ID="STD-Luo-2010" TOTAL_1="45" TOTAL_2="40" WEIGHT="26.13663098283227"/><CONT_DATA CI_END="-1.327037205987291" CI_START="-2.0729627940127084" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.1" MODIFIED="2012-12-04 20:54:58 -0200" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="0.9" SD_2="1.1" SE="0.19029063643750177" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="23.301874555410706"/><CONT_DATA CI_END="-1.2282421393558651" CI_START="-2.3717578606441343" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="7.6" MODIFIED="2013-05-10 20:23:52 -0300" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="1.4" SD_2="1.6" SE="0.2917185546030885" STUDY_ID="STD-Miraglia-Del-Giudice--2012" TOTAL_1="52" TOTAL_2="54" WEIGHT="18.090107564322704"/><CONT_DATA CI_END="1.403261377469771" CI_START="-1.6032613774697704" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="5.6" MODIFIED="2016-11-26 20:22:46 -0200" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="3.2" SD_2="2.7" SE="0.7669841840601688" STUDY_ID="STD-Flores-2016" TOTAL_1="29" TOTAL_2="31" WEIGHT="5.478649840764284"/></CONT_SUBGROUP></CONT_OUTCOME><DICH_OUTCOME CHI2="7.854892689637281" CI_END="1.2513483416120306" CI_START="0.47907601862476334" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7742680294395423" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="36.34540664576682" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.09737822238841422" LOG_CI_START="-0.31959556831865193" LOG_EFFECT_SIZE="-0.11110867296511882" METHOD="MH" MODIFIED="2017-04-05 03:41:52 -0300" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1644162676672083" P_Q="1.0" P_Z="0.29624429723247947" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.12574695822210918" TOTALS="YES" TOTAL_1="417" TOTAL_2="370" WEIGHT="99.99999999999999" Z="1.044521273207121"><NAME>Rate of re-admission</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><DICH_DATA CI_END="2.8218808405888063" CI_START="0.5556363280667281" EFFECT_SIZE="1.2521739130434784" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.4505386708756781" LOG_CI_START="-0.2552093673924021" LOG_EFFECT_SIZE="0.097664651741638" MODIFIED="2013-02-15 21:44:55 -0200" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.41455989118780234" STUDY_ID="STD-Al_x002d_Ansari-2010" TOTAL_1="115" TOTAL_2="56" VAR="0.1718599033816425" WEIGHT="20.1581085555223"/><DICH_DATA CI_END="2.1343117235374587" CI_START="0.4561241454915455" EFFECT_SIZE="0.9866666666666667" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3292578499175859" LOG_CI_START="-0.34091693723903366" LOG_EFFECT_SIZE="-0.005829543660723844" MODIFIED="2010-08-26 13:00:36 -0300" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.39366398739449737" STUDY_ID="STD-Anil-2010" TOTAL_1="75" TOTAL_2="74" VAR="0.15497133497133497" WEIGHT="21.370860284273174"/><DICH_DATA CI_END="2.085188127051878" CI_START="0.1873332170523535" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.3191452434127921" LOG_CI_START="-0.7273852087246417" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2017-02-28 10:00:17 -0300" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.6147371679948153" STUDY_ID="STD-Everard-2014" TOTAL_1="128" TOTAL_2="140" VAR="0.37790178571428573" WEIGHT="11.911459117694848"/><DICH_DATA CI_END="34.74842437981448" CI_START="0.49655310068808967" EFFECT_SIZE="4.153846153846154" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5409351168781944" LOG_CI_START="-0.3040343018459308" LOG_EFFECT_SIZE="0.6184504075161318" MODIFIED="2017-02-28 10:51:33 -0300" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.0837441693044647" STUDY_ID="STD-Florin-2014" TOTAL_1="26" TOTAL_2="27" VAR="1.1745014245014245" WEIGHT="4.6138810882507455"/><DICH_DATA CI_END="1.1960825237768211" CI_START="0.3166154653411966" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.07776114485681722" LOG_CI_START="-0.4994678754866035" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2017-02-28 10:47:09 -0300" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.33906718387945844" STUDY_ID="STD-Grewal-2009" TOTAL_1="23" TOTAL_2="23" VAR="0.1149665551839465" WEIGHT="24.92253691198795"/><DICH_DATA CI_END="0.8474844504389772" CI_START="0.13110696137676403" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.07186826144405466" LOG_CI_START="-0.8823742479952703" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2017-02-28 10:00:31 -0300" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.47609522856952335" STUDY_ID="STD-Khanal-2015" TOTAL_1="50" TOTAL_2="50" VAR="0.22666666666666668" WEIGHT="17.023154042270964"/></DICH_OUTCOME><CONT_OUTCOME CHI2="21.97936843444695" CI_END="-0.8378921528360126" CI_START="-1.5387554410854445" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1883237969607285" ESTIMABLE="YES" I2="77.25139366532571" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2013-04-22 21:18:21 -0300" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="5.28348901337794E-4" P_Q="0.7332632101864589" P_Z="3.005639698486356E-11" Q="0.6205012249038291" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.13272585683140847" TOTALS="YES" TOTAL_1="321" TOTAL_2="294" UNITS="" WEIGHT="100.0" Z="6.646294314636772"><NAME>Time for resolution of symptoms/signs</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.1303239289931083" CI_END="-0.8896355612246614" CI_START="-1.4259344866908077" DF="1" EFFECT_SIZE="-1.1577850239577345" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2013-04-22 21:13:25 -0300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7180964978033196" P_Z="2.6168799117426594E-17" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="98" WEIGHT="37.414590739125366" Z="8.46250790759881"><NAME>Wheezing</NAME><CONT_DATA CI_END="-0.687291268102376" CI_START="-1.5127087318976233" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.8" MODIFIED="2013-04-22 21:13:14 -0300" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="0.9" SD_2="1.1" SE="0.21056954880447679" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="18.054138339440005"/><CONT_DATA CI_END="-0.847248164436671" CI_START="-1.5527518355633285" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="4.8" MODIFIED="2013-04-22 21:13:25 -0300" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="0.9" SD_2="1.0" SE="0.17997873345928306" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="19.36045239968536"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.04414944741057546" CI_END="-0.6645087055496999" CI_START="-1.3494589475334038" DF="1" EFFECT_SIZE="-1.0069838265415518" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2013-04-22 21:15:02 -0300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8335759471177305" P_Z="8.267769994961255E-9" STUDIES="2" TAU2="0.0" TOTAL_1="107" TOTAL_2="98" WEIGHT="22.623619330021462" Z="5.762906301981354"><NAME>Cough</NAME><CONT_DATA CI_END="-0.6513841129028041" CI_START="-1.3486158870971958" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="6.3" MODIFIED="2013-04-22 21:14:07 -0300" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="0.8" SD_2="0.9" SE="0.1778685168947152" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="19.449400357079206"/><CONT_DATA CI_END="0.6327249977102225" CI_START="-3.032724997710223" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="5.5" MODIFIED="2013-04-22 21:15:02 -0300" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="7.0" SD_2="0.9" SE="0.9350809566739611" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="3.1742189729422554"/></CONT_SUBGROUP><CONT_SUBGROUP CHI2="18.26256310714335" CI_END="-0.32431235295390093" CI_START="-2.2842052391235432" DF="1" EFFECT_SIZE="-1.3042587960387222" ESTIMABLE="YES" I2="94.5243173472794" ID="CMP-001.07.03" MODIFIED="2013-04-22 21:15:28 -0300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.9245682289725785E-5" P_Z="0.009091019779015573" STUDIES="2" TAU2="0.4726215867363969" TOTAL_1="107" TOTAL_2="98" WEIGHT="39.96178993085317" Z="2.6086122203866218"><NAME>Pulmonary moist crackles</NAME><CONT_DATA CI_END="-0.4513841129028039" CI_START="-1.1486158870971956" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="6.2" MODIFIED="2013-04-22 21:14:33 -0300" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="0.8" SD_2="0.9" SE="0.1778685168947152" STUDY_ID="STD-Luo-2010" TOTAL_1="50" TOTAL_2="43" WEIGHT="19.449400357079206"/><CONT_DATA CI_END="-1.5019848032069696" CI_START="-2.09801519679303" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="4.4" MEAN_2="6.2" MODIFIED="2013-04-22 21:15:28 -0300" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="0.9" SD_2="0.7" SE="0.15205136377185302" STUDY_ID="STD-Luo-2011" TOTAL_1="57" TOTAL_2="55" WEIGHT="20.512389573773966"/></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.003446315027656653" CI_END="0.7479621920363071" CI_START="-0.9049550524203418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07849643019201735" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-04-23 00:57:55 -0300" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9531868560175596" P_Q="1.0" P_Z="0.8523224801361605" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="0.18615593322325166"><NAME>Radiological assessment score</NAME><GROUP_LABEL_1>Hypertonic saline</GROUP_LABEL_1><GROUP_LABEL_2>0.9% saline</GROUP_LABEL_2><GRAPH_LABEL_1>Favours hypertonic saline</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours 0.9% saline</GRAPH_LABEL_2><CONT_DATA CI_END="1.2102329646149983" CI_START="-1.3102329646149988" EFFECT_SIZE="-0.050000000000000266" ESTIMABLE="YES" MEAN_1="3.38" MEAN_2="3.43" MODIFIED="2013-04-22 21:26:39 -0300" MODIFIED_BY="[Empty name]" ORDER="36" SD_1="2.28" SD_2="2.35" SE="0.6429878174066235" STUDY_ID="STD-Mandelberg-2003" TOTAL_1="27" TOTAL_2="25" WEIGHT="43.00713961596563"/><CONT_DATA CI_END="0.9947397506551361" CI_START="-1.1947397506551363" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.6" MODIFIED="2013-04-22 21:26:50 -0300" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="2.2" SD_2="2.3" SE="0.5585509526145906" STUDY_ID="STD-Sarrell-2002" TOTAL_1="33" TOTAL_2="32" WEIGHT="56.992860384034365"/></CONT_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-12-05 04:08:45 -0200" MODIFIED_BY="Liz Dooley"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-11-21 03:16:43 -0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flow diagram.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-12-05 04:08:45 -0200" MODIFIED_BY="Liz Dooley" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Funnel plot.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2017-11-21 03:18:22 -0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Funnel plot of the weighted mean difference (WMD) of length of hospital stay (days) against its standard error. The circles represent risk estimates of each study, and the black vertical line represents the pooled effect estimate. Dashed lines represent pseudo-95% confidence limits. Egger test (P = 0.29) suggests no small-study effects.</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK/><APPENDICES MODIFIED="2017-11-21 03:25:38 -0200" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2017-03-29 00:05:43 -0300" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2010-06-09 02:27:21 -0300" MODIFIED_BY="[Empty name]">Previous search</TITLE><APPENDIX_BODY MODIFIED="2017-03-29 00:05:43 -0300" MODIFIED_BY="[Empty name]"><P>For the 2013 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 4, part of <I>The Cochrane Library</I>, www.thecochranelibrary.com (accessed 8 May 2013), which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE (May 2010 to April week 4, 2013), EMBASE (June 2010 to April 2013) and LILACS (June 2010 to May 2013). We broadened our search to include two further databases and searched CINAHL (1981 to May 2013) and Web of Science (1955 to May 2013). We used the search strategy detailed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> to search MEDLINE and CENTRAL. As there were so few search results we used no filter to identify randomised trials in MEDLINE. We adapted the search terms to search EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), CINAHL (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) and Web of Science (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).<BR/><BR/>For the 2010 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2010, Issue 2), which contains the Cochrane Acute Respiratory Infections Group Specialised Register, OLDMEDLINE (1951 to 1965), MEDLINE (1966 to May Week 4, 2010), EMBASE (1974 to June 2010) and LILACS (1985 to June 2010).</P><P>For the original search we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2007, Issue 4), which contains the Cochrane Acute Respiratory Infections Group Specialised Register, OLDMEDLINE (1951 to 1965), MEDLINE (1966 to November 2007), EMBASE (1974 to November 2007) and LILACS (November 2007).</P><P>For the original search and the 2010 update the following search terms were combined with the highly sensitive search strategy as recommended by The Cochrane Collaboration (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) to search MEDLINE. These terms were adapted to search CENTRAL, EMBASE and LILACS as required.</P><SUBSECTION><HEADING LEVEL="4">MEDLINE (OVID)</HEADING><P>1 exp Bronchiolitis/<BR/>2 bronchiolit$.mp.<BR/>3 exp Respiratory Syncytial Viruses/<BR/>4 exp Respiratory Syncytial Virus Infections/<BR/>5 (respiratory syncytial vir$ or RSV).mp.<BR/>6 exp Parainfluenza Virus 1, Human/<BR/>7 exp Parainfluenza Virus 2, Human/<BR/>8 exp Parainfluenza Virus 3, Human/<BR/>9 exp Respirovirus Infections/<BR/>10 exp Adenoviridae Infections/<BR/>11 exp Influenza, Human/<BR/>12 (parainfluenza or adenovirus$ or influenza).mp.<BR/>13 or/1-12<BR/>14 exp Saline Solution, Hypertonic/<BR/>15 hypertonic saline.mp.<BR/>16 exp Sodium Chloride/<BR/>17 saline.mp.<BR/>18 or/14-17<BR/>19 exp "Nebulizers and Vaporizers"/<BR/>20 (nebulis$ or nebuliz$).mp.<BR/>21 exp Administration, Inhalation/<BR/>22 inhal$.mp.<BR/>23 exp Aerosols/<BR/>24 aerosol$.mp.<BR/>25 or/19-24<BR/>26 13 and 18 and 25<BR/>27 from 26 keep 1-79<BR/><BR/>There were no language or publication restrictions.</P></SUBSECTION></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2017-03-29 00:05:43 -0300" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2017-03-16 22:36:13 -0300" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE><APPENDIX_BODY MODIFIED="2017-03-16 22:37:14 -0300" MODIFIED_BY="[Empty name]"><P>1 exp Bronchiolitis/<BR/>2 (bronchiolit* or wheez*).tw.<BR/>3 respiratory syncytial viruses/ or respiratory syncytial virus, human/<BR/>4 Respiratory Syncytial Virus Infections/<BR/>5 (respiratory syncytial virus* or rsv).tw.<BR/>6 parainfluenza virus 1, human/ or parainfluenza virus 3, human/<BR/>7 Parainfluenza Virus 2, Human/<BR/>8 Respirovirus Infections/<BR/>9 Adenovirus Infections, Human/<BR/>10 Rhinovirus/<BR/>11 Influenza, Human/<BR/>12 exp influenzavirus a/ or exp influenzavirus b/<BR/>13 (parainfluenza* or respirovirus* or adenovirus* or rhinovirus* or influenza*).tw.<BR/>14 or/1-13<BR/>15 Saline Solution, Hypertonic/<BR/>16 (hypertonic adj3 (saline or solution*)).tw.<BR/>17 Sodium Chloride/<BR/>18 (sodium chloride or saline).tw.<BR/>19 or/15-18<BR/>20 exp "Nebulizers and Vaporizers"/<BR/>21 (nebuli* or vapor* or vapour* or atomi*).tw.<BR/>22 Administration, Inhalation/<BR/>23 inhal*.tw.<BR/>24 Aerosols/<BR/>25 aerosol*.tw.<BR/>26 or/20-25<BR/>27 14 and 19 and 26</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2017-03-29 00:05:43 -0300" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2010-06-09 02:37:32 -0300" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE><APPENDIX_BODY MODIFIED="2011-02-01 02:09:39 -0200" MODIFIED_BY="[Empty name]"><P>24. #12 AND #16 AND #23<BR/>23. #17 OR #18 OR #19 OR #20 OR #21 OR #22<BR/>22. aerosol*:ab,ti<BR/>21. 'aerosol'/de<BR/>20. inhal*:ab,ti<BR/>19. 'inhalational drug administration'/de<BR/>18. nebuli*:ab,ti OR vapour*:ab,ti OR vapour*:ab,ti OR atomi*:ab,ti<BR/>17. 'nebulizer'/exp<BR/>16. #13 OR #14 OR #15<BR/>15. 'sodium chloride':ab,ti OR saline:ab,ti<BR/>14. (hypertonic NEAR/3 (saline OR solution*)):ab,ti<BR/>13. 'hypertonic solution'/de OR 'sodium chloride'/de<BR/>12. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11<BR/>11. parainfluenza*:ab,ti OR respirovirus*:ab,ti OR adenovirus*:ab,ti OR rhinovirus*:ab,ti OR<BR/>influenza*:ab,ti<BR/>10. 'influenza virus'/de OR 'influenza virus a'/exp OR 'influenza virus b'/de OR 'influenza'/exp<BR/>9. 'rhinovirus infection'/de<BR/>8. 'human adenovirus infection'/de<BR/>7. 'respirovirus infection'/de<BR/>6. 'parainfluenza virus 1'/de OR 'parainfluenza virus 2'/de OR 'parainfluenza virus 3'/de<BR/>5. 'respiratory syncytial virus':ab,ti OR 'respiratory syncytial viruses':ab,ti OR rsv:ab,ti<BR/>4. 'respiratory syncytial virus infection'/de<BR/>3. 'respiratory syncytial pneumovirus'/de<BR/>2. bronchiolit*:ab,ti<BR/>1. 'bronchiolitis'/exp</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-04" MODIFIED="2017-03-29 00:05:40 -0300" MODIFIED_BY="[Empty name]" NO="4"><TITLE MODIFIED="2010-06-09 02:41:30 -0300" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE><APPENDIX_BODY MODIFIED="2012-09-11 01:23:01 -0300" MODIFIED_BY="[Empty name]"><P>&gt; Search &gt; (MH:Bronchiolitis OR bronchiolit$ OR Bronquiolitis OR Bronquiolite OR MH:C08.127.446.135$ OR MH:C08.381.495.146.135$ OR MH:C08.730.099.135$ OR wheez$ OR MH:"Respiratory Syncytial Viruses" OR "Virus Sincitiales Respiratorios" OR "Vírus Sinciciais Respiratórios" OR "Respiratory Syncytial Virus, Human" OR "Respiratory Syncytial Virus Infections" OR "Infecciones por Virus Sincitial Respiratorio" OR "Infecções por Vírus Respiratório Sincicial" OR rsv "respiratory syncytial virus" OR "respiratory syncytial virus infection" OR "respiratory syncytial virus infections") AND (MH:"Saline Solution, Hypertonic" OR "Solución Salina Hipertónica" OR "Solução Salina Hipertônica" OR "Hypertonic Saline Solution" OR "Solución Hipertónica de Cloruro de Sodio" OR "Solução Salina Hipertônica" OR "Solução Hipertônica de Cloreto de Sódio" OR MH:"Sodium Chloride" OR "sodium chloride" OR "Cloruro de Sodio" OR "Cloreto de Sódio" OR salin$) AND (MH:"Nebulizers and Vaporizers" OR MH:E07.605$ OR atomi$ OR inhal$ OR vapor$ OR vapour$ OR nebuli$ OR Inala$ OR MH:Aerosols OR aerosol$ OR Aerossóis OR MH:"Administration, Inhalation" OR "Administración por Inhalación" OR "Administração por Inalação")</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-05" MODIFIED="2017-11-21 03:25:38 -0200" MODIFIED_BY="[Empty name]" NO="5"><TITLE MODIFIED="2017-11-21 03:25:38 -0200" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE><APPENDIX_BODY MODIFIED="2013-05-08 20:20:05 -0300" MODIFIED_BY="[Empty name]"><P>S22 S10 and S15 and S21 <BR/>S21 S16 or S17 or S18 or S19 or S20 <BR/>S20 TI (inhal* or aerosol*) OR AB (inhal* or aerosol*) <BR/>S19 (MH "Aerosols") <BR/>S18 (MH "Administration, Inhalation") <BR/>S17 TI (nebuli* or vapor* or vapour* or atomi*) OR AB (nebuli* or vapor* or vapour* or atomi*) <BR/>S16 (MH "Nebulizers and Vaporizers") <BR/>S15 S11 or S12 or S13 or S14 <BR/>S14 TI (sodium chloride or saline) OR AB (sodium chloride or saline) <BR/>S13 (MH "Sodium Chloride") <BR/>S12 TI (hypertonic N3 (salin* or solut*)) OR AB (hypertonic N3 (salin* or solut*)) <BR/>S11 (MH "Saline Solution, Hypertonic") <BR/>S10 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 <BR/>S9 TI (influenza* or flu) OR AB (influenza* or flu) <BR/>S8 (MH "Influenzavirus A+") OR (MH "Influenzavirus B+") <BR/>S7 (MH "Influenza") OR (MH "Influenza, Human") OR (MH "Influenza A H5N1") OR (MH "Influenza, Pandemic (H1N1) 2009") OR (MH "Influenza, Seasonal") <BR/>S6 TI (parainfluenza* or respirovirus* or adenovirus* or rhinovirus*) OR AB (parainfluenza* or respirovirus* or adenovirus* or rhinovirus*) <BR/>S5 TI (respiratory syncytial virus* or rsv) OR AB (respiratory syncytial virus* or rsv) <BR/>S4 (MH "Respiratory Syncytial Virus Infections") <BR/>S3 (MH "Respiratory Syncytial Viruses") <BR/>S2 TI (bronchiolit* or wheez*) OR AB (bronchiolit* or wheez*) <BR/>S1 (MH "Bronchiolitis+") </P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-06" MODIFIED="2017-03-29 00:05:32 -0300" MODIFIED_BY="[Empty name]" NO="6"><TITLE MODIFIED="2012-09-11 01:08:23 -0300" MODIFIED_BY="[Empty name]">Web of Science (Thomson Reuters) search strategy</TITLE><APPENDIX_BODY MODIFIED="2012-09-11 01:20:10 -0300" MODIFIED_BY="[Empty name]"><TABLE COLS="3" ROWS="5"><TR><TD VALIGN="TOP"><P># 3</P></TD><TD VALIGN="TOP"><P><B>93 </B></P></TD><TD VALIGN="TOP"><P>#2 AND #1</P><P><I>Databases=SCI-EXPANDED, CPCI-S Timespan=All Years</I></P><P><I>Lemmatization=On   </I></P></TD></TR><TR><TD COLSPAN="4"><P> </P></TD></TR><TR><TD VALIGN="TOP"><P># 2</P></TD><TD VALIGN="TOP"><P><B>1,322,438 </B></P></TD><TD VALIGN="TOP"><P>Topic=(random* or placebo* or ((single or double) NEAR/1 blind*) or allocat* or (clinical NEAR/1 trial*)) OR Title=(trial)</P><P><I>Databases=SCI-EXPANDED, CPCI-S Timespan=All Years</I></P><P><I>Lemmatization=On   </I></P></TD></TR><TR><TD COLSPAN="4"><P> </P></TD></TR><TR><TD VALIGN="TOP"><P># 1</P></TD><TD VALIGN="TOP"><P><B>173 </B></P></TD><TD VALIGN="TOP"><P>Topic=(bronchiolit* or wheez* or "respiratory syncytial virus" or "respiratory syncytial viruses" or rsv or parainfluenza* or "respirovirus infection" or "respirovirus infections" or rhinovirus* or adenovirus* or influenza*) AND Topic=((hypertonic NEAR/3 (salin* or solut*)) or "sodium chloride" or saline) AND Topic=(nebuli* or vapor* or vapour* or atomi* or inhal* or aerosol*)</P><P><I>Databases=SCI-EXPANDED, CPCI-S Timespan=All Years</I></P><P><I>Lemmatization=On   </I></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;25 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;28 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;10 records await classification&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;11 trials included in the 2013 update&lt;/p&gt;"/><FLOWCHARTBOX TEXT="&lt;p&gt;17 studies met inclusion criteria&lt;/p&gt;&lt;p&gt;10 records await classification&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="208"><FLOWCHARTBOX TEXT="&lt;p&gt;36 records assessed for eligibility&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;125 duplicates excluded = 239 records screened&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;2017 update:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;350 records identified through database searching&lt;/li&gt;&lt;li&gt;14 records identified from searches of trials registers&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Total = 364 records&lt;/p&gt;" WIDTH="253"/><OUT TEXT="&lt;p&gt;203 records excluded following assessment of title and abstract&lt;/p&gt;"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;9 full-text articles excluded:&lt;/p&gt;&lt;p&gt;Other comparisons: 4&lt;/p&gt;&lt;p&gt;Inclusion of participants with previous wheezing: 1&lt;/p&gt;&lt;p&gt;Suspected plagiarism: 2&lt;/p&gt;&lt;p&gt;Not a randomised controlled trial: 1&lt;/p&gt;&lt;p&gt;Abstract only: 1&lt;/p&gt;" WIDTH="230"/></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>